Neue Nachrichten von Immune Response - 500 Beiträge pro Seite

[Nussel]

Neue Nachricht von imnr:Thursday April 26, 6:57 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Granted U.S. Patent for the Use of Antibodies To Target T Cell Receptors to Treat Rheumatoid Arthritis
CARLSBAD, Calif., April 26 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it was awarded United States Patent Number 6,221,352 that covers claims relating to the use of antibodies to target specific T Cell Receptors (TCRs) to treat rheumatoid arthritis. Specifically, the new patent covers the administration of monoclonal antibodies, alone and/or coupled to cytotoxic or cytostatic agents, that selectively bind to and prevent the proliferation of T Cells that express either Vbeta 14 or Vbeta 17 TCRs. These Vbeta 14 and Vbeta 17 T Cells serve as good targets for treating rheumatoid arthritis because they are among the over-expressed pathogenic T Cells thought to cause the disease. The Company believes that selectively targeting these ``fingerprint`` TCRs may help reduce the population of pathogenic T Cells and prevent further tissue damage in people suffering from rheumatoid arthritis.

``Approaches utilizing monoclonal antibodies are emerging in the marketplace as new options for treating human diseases, including autoimmune diseases such as rheumatoid arthritis,`` said Richard M. Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``This patent allows us to utilize antibodies, either alone or coupled to chemotherapeutic or radioactive moieties, to target pathogenic T Cells for the treatment of rheumatoid arthritis. This is a valuable extension of our core technology on TCRs as therapeutic targets in autoimmune disease.``

On March 30, 2001, the Company announced the issuance of U.S. Patent Number 6,207,645, which covers vaccination of individuals with rheumatoid arthritis using DNA vaccines designed to synthesize the key Vbeta TCR peptides. The Company also announced on August 9, 2000, that it was issued U.S. Patent Number 6,090,387 for vaccinating individuals with rheumatoid arthritis using the specific Vbeta TCR peptides.

The Immune Response Corporation`s Vbeta TCR peptide vaccine, RAVAX(TM), has completed two Phase II clinical trials, exhibiting safety and a statistically significant treatment effect in individuals with rheumatoid arthritis. The Company has also carried out clinical trials using its core TCR peptide technology towards the development of investigational immune-based therapies to treat other autoimmune diseases, including multiple sclerosis and psoriasis.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether preclinical data can be replicated in clinical trials, whether if initiated clinical trials will be successfully concluded and whether a preventative vaccine will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X31554977

SOURCE: The Immune Response Corporation

Gruß

Nussel

[thebull 2]

heute wieder 100%???

gruss
tb 2

[willimaus]

Hoffe doch.
Kannst Du Dir erklären, warum von IMNR soviel Aktien
short sind. Ist ja enorm.

Gruß

[thebull 2]

@ willimaus(cooler name)hahaha
keine ahnung,aber ich halte es für möglich das wir im mai noch die
5 euro sehen können.
gruss
tb 2

[thebull 2]

die letzte news
Friday April 27, 7:01 am Eastern Time

Press Release

SOURCE: The Immune Response Corporation

The Immune Response Corporation Names Dr. Elias Nyberg as Vice President, Regulatory Affairs

SAN DIEGO, April 27 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that Elias Nyberg, DVM, BVSc(hons),
MACVS, MRCVS, MBA, has been named Vice President, Regulatory Affairs. Dr. Nyberg brings expertise in global regulatory affairs to the Company and has
been responsible for the successful launch of several pharmaceutical products during his career. Dr. Nyberg has extensive experience in regulatory affairs and quality
assurance. His expertise includes regulatory strategy, coordinating clinical trials and knowledge of FDA and European regulations and guidelines. While at INC
Research/PRA International Inc., Dr. Nyberg developed and assessed regulatory strategy for clients and managed the entire quality assurance process for the
company. Prior to joining INC Research/PRA International Inc., Dr. Nyberg was Worldwide Director of Regulatory Affairs for Astra Arcus AB. Previously Dr.
Nyberg served as Head of Technical Services and Regulatory Affairs for Pfizer Pharmaceuticals, Northern European Division, where he consecutively launched
three new products. Prior to Pfizer, Dr. Nyberg was Head of Technical Services and Regulatory Affairs and Director of Worldwide Global Anthelmintic Business
Development at Ciba-Geigy Animal Health, World Headquarters.

``The Immune Response Corporation has numerous innovative products focused on immune-based therapies,`` said Dr. Nyberg. ``I look forward to moving these
products toward the goal of achievement of commercial approval and into the marketplace.``

``We are very pleased to have Dr. Nyberg join our executive management team. His expertise in worldwide regulatory affairs, including pre-clinical, clinical, FDA,
and the European Agency for the Evaluation of Medicinal Products (EMEA) experience will be a key asset to the Company as we continue to develop our
products,`` said Dennis J. Carlo, Ph.D., President and Chief Executive Officer of The Immune Response Corporation.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell
responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene
therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific
release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company
information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether preclinical data can be replicated in clinical trials, whether if initiated clinical trials will be successfully concluded and whether a product will be
approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings,
including but not limited to its report on Form 10-K for the year ended December 31, 2000. The Company undertakes no obligation to publicly release the result of
any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

gruss
tb 2

[e.broker]

mir wären +1-2% täglich lieber, als ein einmaliges kursfeuerwerk

[thebull 2]

@ e.broker
hahaha,wie bist du denn drauf.es gibt zur zeit nur gute news.
überleg mal das potenzial das da drin steckt.das nach ca.100%
am tag gewinnmitnahmen folgen ist klar.ich bleib dabei.
mai 2001=5 euro.
gruss
tb 2

[FLOTSAM_AND_JETSAM_US]

die werfen ja alle paar Tage ne News raus

The Immune Response Corporation Announces Publication Of Data From a Previous Multiple Sclerosis Vaccine Study
Company`s BV6 TCR Peptide Vaccine Induces An Immune Response in 80% of Vaccinated MS Patients

CARLSBAD, Calif., April 30 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced the publication of data on their investigational T Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that it induced a specific response (stimulation index >5) in 80% of the patients treated. The objective of the Company`s TCR vaccine program is to induce an immune response that inactivates the T cells thought to be pathogenic in MS. The article appears in the May issue of the Journal of Neuroscience Research. Eight of ten patients given five 300 microgram injections of the TCR peptides emulsified in Incomplete Freund`s adjuvant (IFA) during the 48 week open label trial developed specific cell mediated responses as measured by both delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation assays (LPA). No responses against an irrelevant peptide were observed, and neurologic assessments, on average, remained stable during the trial.

``These data, from our Phase I MS trial completed in 1999, suggest that our BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as part of a combination peptide vaccine in our future MS trials,`` said Richard M. Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``Based on data from previous clinical trials and over 160 pathogenic T cell clones isolated from many different MS patients, we believe that if commercially approved our TCR therapeutic vaccine combining BV5, BV6 and BV13.1 could potentially be used to treat approximately 90% of the patients suffering from MS.``

Currently, the Company has a 60 patient Phase I/II TCR combination peptide vaccine study under way. The trial is being conducted at six centers located within the states of Washington and Oregon. The double blind, placebo-controlled trial will monitor safety, immunogenicity and clinical benefits.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

[e.broker]

Tuesday May 1, 9:15 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces the Conversion and Proposed Redemption of Its Outstanding Shares of Series F Convertible Preferred Stock
CARLSBAD, Calif., May 1 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that approximately 160.7 shares of the 200 shares of Series F Convertible Preferred Stock (Preferred Stock) which the Company issued in April of 1998 have been converted, pursuant to the terms of the Preferred Stock, into 4,208,924 shares of Common Stock of the Company. The balance of the outstanding 39.3 shares of Preferred Stock will be redeemed for $2,783,045. Upon completion of this transaction, the Company will have no issued and outstanding shares of Preferred Stock.

The Company also announced today that, for personal reasons, Elias Nyberg, DVM, BVSc(hons), MACVS, MRCVS, MBA, will not be joining the Company as Vice President, Regulatory Affairs. The Company intends to continue its search to fill this position.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

---------------------------------------------------------
Monday April 30, 7:05 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Publication Of Data From a Previous Multiple Sclerosis Vaccine Study
Company`s BV6 TCR Peptide Vaccine Induces An Immune Response in 80% of Vaccinated MS Patients
CARLSBAD, Calif., April 30 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced the publication of data on their investigational T Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that it induced a specific response (stimulation index >5) in 80% of the patients treated. The objective of the Company`s TCR vaccine program is to induce an immune response that inactivates the T cells thought to be pathogenic in MS. The article appears in the May issue of the Journal of Neuroscience Research. Eight of ten patients given five 300 microgram injections of the TCR peptides emulsified in Incomplete Freund`s adjuvant (IFA) during the 48 week open label trial developed specific cell mediated responses as measured by both delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation assays (LPA). No responses against an irrelevant peptide were observed, and neurologic assessments, on average, remained stable during the trial.

``These data, from our Phase I MS trial completed in 1999, suggest that our BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as part of a combination peptide vaccine in our future MS trials,`` said Richard M. Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``Based on data from previous clinical trials and over 160 pathogenic T cell clones isolated from many different MS patients, we believe that if commercially approved our TCR therapeutic vaccine combining BV5, BV6 and BV13.1 could potentially be used to treat approximately 90% of the patients suffering from MS.``

Currently, the Company has a 60 patient Phase I/II TCR combination peptide vaccine study under way. The trial is being conducted at six centers located within the states of Washington and Oregon. The double blind, placebo-controlled trial will monitor safety, immunogenicity and clinical benefits.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.

[thebull 2]

mai 2001=5 euro.4,90 sind sie schon.
gruss
tb 2

[Nussel]

IMMUNE RESPONSE CORP (IMNR)
Quarterly Report (SEC form 10-Q)
Item 2. Management`s Discussion and Analysis of Financial Conditions and Results of Operations
This discussion contains forward-looking statements concerning our operating results and timing of anticipated revenues and expenditures. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include those discussed under "Risk Factors". The following should be read in conjunction with the Condensed Consolidated Financial Statements and Notes thereto included elsewhere in this Form 10-Q. These forward-looking statements speak only as of the date hereof. We undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Summary

We are a biopharmaceutical company developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, we are developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

We have not been profitable since inception and had an accumulated deficit of $215.9 million as of March 31, 2001. To date, we have not recorded any revenues from the sale of products. Revenues recorded through March 31, 2001 were primarily received from contract research, licensing of technology, milestone achievement payments and investment income. We expect our operating losses to continue, as well as to have quarter-to-quarter fluctuations, some of which could be significant, due to


9
----------------------------------------------------------------------------------------------------------------------------

research, development and clinical trial activities. We cannot provide assurance that we will be able to generate sufficient product revenue to become profitable at all or on a sustained basis.

On April 28, 2001, we converted 160.7 shares of the Series F Stock for 4,208,924 shares of our common stock. On May 2, 2001, we redeemed 39.3 shares of the Series F Stock for cash of $2.8 million. As of May 2, 2001, we had no issued and outstanding shares of Series F Stock.

In December 1999, the SEC issued Staff Accounting Bulletin 101, or SAB No. 101, "Revenue Recognition in Financial Statements". We implemented SAB No. 101 in the fourth quarter of 2000 by adjusting the first, second and third quarters of our 2000 financial statements. Our statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000. Deferred revenue recognized, to reflect the application of the SAB No. 101 adjustment, was approximately $960,000 for the first quarter of 2000. The balance of $9.7 million of deferred revenue from this adjustment will be recognized as revenue over the expected development period, which is estimated to be through June 2003. See Note 4 to the Condensed Consolidated Financial Statements.

Results of Operations

We recorded revenues for the quarter ended March 2001 of $1.0 million as compared to $4.0 million for the same period in 2000. Revenues for 2001 were primarily attributed to deferred revenues recognized from the SAB 101 adjustment. The decrease in revenues in 2001 was the result of having received in 2000 the final $3.0 million quarterly payment under the agreement with Agouron Pharmaceuticals, Inc., a Pfizer Inc. company, or Pfizer. As a result, we expect no additional revenues, other than deferred revenues recognized from the SAB 101 adjustment, unless it is earned through existing corporate collaborations or new research and development agreements, if any. We have not received any revenues from the commercial sale of products and do not expect to derive revenue from the sale of products for the foreseeable future.

Our research and development expenditures of $5.3 million during the first quarter of 2001 increased from $5.1 million during the same period in 2000. The increase in research and development spending of $200,000 from 2000 to 2001 was due primarily to spending on the scale-up of the manufacturing process of REMUNE. With the current U.S. pivotal HIV clinical study being conducted and paid for by Pfizer, we expect future clinical study spending to remain consistent with this quarter unless we initiate new clinical studies in our other development programs. However, spending associated with our scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies could increase in the foreseeable future. Overall, we expect future research and development expenditures to remain somewhat level with the current quarter, but quarter to quarter fluctuations may occur due to the timing of expenditures. If we enter into additional collaborations, research and development expenditures would increase over current levels; but we cannot provide assurance that we will enter into any collaborations, that existing collaborations will not end, or that we will be able to obtain other financing needed to continue our research and development efforts.

General and administrative expenses for the first quarter of 2001 were $1.2 million as compared to $1.1 million for the same period in 2000. This increase in spending was primarily attributed to higher



professional fees for the current quarter. We expect quarterly general and administrative expenses for the remainder of 2001 to remain consistent with first quarter levels with possible increases due to higher professional fees.

Investment income, net, decreased to $644,000 for the quarter ended March 31, 2001 from $2.5 million during the same period in 2000. The decrease in investment income in 2001 compared to 2000 was due primarily to the sale of approximately $2.3 million of an equity security in 2000 as compared to the sale of approximately $156,000 of an equity security in 2001.

Other income of $732,000 for the quarter ended March 31, 2000 was attributable to the gain recognized from the sale of undeveloped property adjacent to our headquarters facility in Carlsbad, California for approximately $2.0 million

Liquidity and Capital Resources

Since our inception through March 31, 2001, we have financed our activities primarily from public and private sales of equity, funding from collaborations with corporate partners and investment income. At March 31, 2001, we had working capital of $13.9 million, including $21.2 million of cash, cash equivalents and marketable securities. This compares with working capital as of December 31, 2000 of $20.6 million, including $28.4 million of cash, cash equivalents and marketable securities. Working capital decreased as a result of the cost of operations of $5.9 million and purchase of equipment coming off lease of $686,000. In April and May 2001, all of the Series F Stock was converted and redeemed for shares of our common stock along with $2.8 million in cash.

We will need to raise additional funds to conduct research and development, preclinical studies and clinical trials necessary to bring potential products to market and to establish manufacturing and marketing capabilities. We anticipate that for the foreseeable future, the scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies will continue to represent a significant portion of our overall expenditures. Overall, future research and development expenditures are expected to increase slightly from current levels. However, future spending for research and development may see a greater increase if we enter into additional collaborations, but there can be no assurance that we will enter into any such collaborations. We anticipate additional capital improvements of approximately $3.0 million for 2001 related to the scale-up of the manufacturing process; some of which we anticipate will be funded with debt financing, if available. Other anticipated costs with respect to REMUNE, including investment in inventory, will depend on many factors including the results of clinical trials, the continuation of our collaboration with Pfizer and other factors which will influence our determination of the appropriate continued investment of our financial resources in this program.

Our future capital requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of preclinical studies and clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patent claims, competing technological and market developments, the cost of manufacturing scale-up and inventories, effective commercialization activities and arrangements and other factors not within our control. We intend to seek additional funding through additional research and development agreements with suitable corporate collaborators, extensions of existing corporate



collaborations and through public or private financings, if available. However, we cannot provide assurance that such collaboration arrangements or any public or private financings will be available on acceptable terms, if at all. If we raise funds through equity arrangements, further dilution to stockholders may result. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs, or take other measures to cut costs, which could have a material adverse effect on us. We estimate that our existing capital resources will be sufficient to fund our planned operations through 2001. We cannot provide assurance, however, that changes in our research and development plans or other changes affecting our operating expenses will not result in the expenditure of such resources before such time. In any event, we will need to raise substantial additional capital to fund our operations in future periods.



RISK FACTORS


You should carefully consider the risks described below before making an investment decision. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business.

If any of the following risks actually occur, our business could be adversely affected. In those cases, the trading price of our common stock could decline, and you may lose all or part of your investment.

Our Failure to Develop and Commercialize Products Successfully May Cause Us to Cease Operations

We have not completed the development of any products. Our failure to develop and commercialize products successfully may cause us to cease operations. Our potential therapies under development will require significant additional research and development efforts and regulatory approvals prior to potential commercialization.

The discontinuation of a previous Phase 3 trial of Remune in May 1999 due to lack of efficacy has had a material adverse effect on us. If our primary marketing partner, Pfizer, does not successfully complete the current pivotal trial of REMUNE, we may have to abandon REMUNE or seek additional funding.

Our other therapies and technologies are at earlier stages of development than Remune and may not be shown to be safe or efficacious or ever receive regulatory approval. Some of our technologies have not yet been tested in humans. Human testing of potential products based on these technologies may not be permitted by regulatory authorities. Even if human testing is permitted, the products based on these technologies may not be successfully developed or be shown to be safe and effective.

The results of our preclinical studies and clinical trials may not be indicative of future clinical trial results. A commitment of substantial resources to conduct time-consuming research, preclinical studies and clinical trials will be required if we are to develop any products. Delays in planned patient enrollment in our clinical trials may result in increased costs, program delays or both. None of our potential products may prove to be safe and effective in clinical trials. Food and Drug Administration, or FDA, or other regulatory approvals may not be obtained and even if successfully developed and approved, our products may not achieve market acceptance. Any products resulting from our programs may not be successfully developed or commercially available for a number of years, if at all.

Unacceptable toxicities or side effects may occur at any time in the course of human clinical trials or, if any products are successfully developed and approved for marketing, during commercial use of our products. The appearance of any unacceptable toxicities or side effects could interrupt, limit, delay or abort the development of any of our products or, if previously approved, necessitate their withdrawal from the market.

Our Additional Financing Requirements and Limited Access to Financing May Adversely Affect Our Ability to Develop Products

We will need to raise additional funds to conduct research and development, preclinical studies and clinical trials necessary to bring our potential products to market and to establish manufacturing and marketing capabilities. A failure to raise additional funds would require us to scale back or eliminate some or all of our research and development programs or license to third parties products or technologies that we would otherwise seek to develop ourselves. We estimate that our existing capital resources will be sufficient to fund our planned operations through 2001. We will need to obtain additional financial resources to fund operations beyond 2001.



Although we anticipate that development of REMUNE will continue to represent a significant portion of our overall expenditures, costs related to the development of REMUNE decreased in 2000. We believe costs relating to the development of REMUNE will remain constant in 2001 with the prior year. Other anticipated costs with respect to REMUNE will depend on many factors, in particular, our collaboration with Pfizer.

The timing and amount of our future capital requirements will depend on many factors, including:

o o

continued scientific progress in our research and development programs;

o

the scope and results of preclinical studies and clinical trials;

o

the time and costs involved in obtaining regulatory approvals;

o

the costs involved in filing, prosecuting and enforcing patent claims;

o

competing technological and market developments;

o

the cost of manufacturing scale-up;

o

effective commercialization activities and arrangements; and

o

other factors not within our control.

Our access to capital could be limited if we are not capable of continued progress in:
o o

our research and development programs;

o

our preclinical and clinical trials;

o

obtaining regulatory approvals; or

o

scaling up manufacturing.

It could also be limited by overall financial market conditions.
If Pfizer Terminates Its Collaboration With Us We May Have To Abandon REMUNE

According to its terms, our binding letter of intent with Pfizer may be terminated at will and at any time by Pfizer. If our agreement with Pfizer were terminated, that might require us to abandon REMUNE.

We May Be Unable to Enter Into Additional Collaborations or Maintain Existing Ones

We intend to seek additional collaborative arrangements to develop and commercialize our products. We may not be able to negotiate collaborative arrangements on favorable terms, or at all, in the future and our current or future collaborative arrangements may not be successful or continue. Under the 1998 Schering collaboration for gene delivery technology, Schering`s obligation to fund expired on December 31, 1999. Without funding arrangements, we may have to abandon some of our products under development.

Our Patents and Proprietary Technology May Not Provide Us With Any Benefit and the Patents and Proprietary Technology of Others May Prevent Us From Commercializing Products

A failure to obtain meaningful patent protection for our potential products and processes would greatly diminish the value of our potential products and processes.

In addition, whether or not our patents are issued, or issued with limited coverage, others may receive patents which contain claims applicable to our products. We are aware that AstraZeneca PLC has acquired the rights to a patent, which has been issued in Europe and other countries, that may



interfere with our ability to develop some of our technologies related to autoimmune disease if the patent is upheld after current opposition proceedings. This patent, and others that we are not aware of, may adversely affect our ability to develop and commercialize products.

The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. Therefore, the breadth of claims allowed in biotechnology and pharmaceutical patents cannot be predicted. We also rely upon unpatented trade secrets and know how, and others may independently develop substantially equivalent trade secrets or know how.

We also rely on protecting our proprietary technology in part through confidentiality agreements with our corporate collaborators, employees, consultants and certain contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or independently discovered by our competitors. Our products and processes may infringe, or be found to infringe on, patents not owned or controlled by us, such as the patent owned by AstraZeneca PLC. If relevant claims of third-party patents are upheld as valid and enforceable, we could be prevented from practicing the subject matter claimed in the patents, or would be required to obtain licenses or redesign our products or processes to avoid infringement. Licenses may not be available at all or on commercially reasonable terms and we may not be able to redesign our products or processes to avoid infringement. Litigation may be necessary to defend against claims of infringement, to enforce our patents or to protect trade secrets. Litigation could result in substantial costs and diversion of management efforts regardless of the results of the litigation. An adverse result in litigation could subject us to significant liabilities to third parties, require disputed rights to be licensed or require us to cease using certain technologies.

Our History of Operating Losses and Our Expectations of Continuing Losses May Hurt Our Ability to Continue Operations

As of March 31, 2001 we had a consolidated accumulated deficit of $215.9 million. We have not generated revenues from the commercialization of any product. We expect to incur substantial net operating losses over the next several years, which may imperil our ability to continue operations. We may not be able to generate sufficient product revenue to become profitable on a sustained basis, or at all.

The Lengthy Product Approval Process and Uncertainty of Government Regulatory Requirements May Delay or Prevent Us From Commercializing Products

Clinical testing, manufacture, promotion and sale of our products are subject to extensive regulation by numerous governmental authorities in the United States, principally the FDA, and corresponding state and foreign regulatory agencies. This regulation may delay or prevent us from commercializing products. Noncompliance with applicable requirements can result in, among other things, fines, injunctions, seizure of products, total or partial suspension of product marketing, failure of the government to grant premarket approval, withdrawal of marketing approvals and criminal prosecution.

The regulatory process for new therapeutic drug products, including the required preclinical studies and clinical testing, is lengthy and expensive. We may not receive necessary FDA clearances for any of our potential products in a timely manner, or at all. The length of the clinical trial process and the number of patients the FDA will require to be enrolled in the clinical trials in order to establish the safety and efficacy of our products is uncertain.

Even if additional clinical trials of REMUNE are successfully completed, the FDA may not approve REMUNE for commercial sale. We may encounter significant delays or excessive costs in our efforts to secure necessary approvals. Regulatory requirements are evolving and uncertain. Future United States or foreign legislative or administrative acts could also prevent or delay regulatory



approval of our products. We may not be able to obtain the necessary approvals for clinical trials, manufacturing or marketing of any of our products under development. Even if commercial regulatory approvals are obtained, they may include significant limitations on the indicated uses for which a product may be marketed.

In addition, a marketed product is subject to continual FDA review. Later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market, as well as possible civil or criminal sanctions.

Among the other requirements for regulatory approval is the requirement that prospective manufacturers conform to the FDA`s Good Manufacturing Practices, or GMP. In complying with the FDA`s GMP requirements, manufacturers must continue to expend time, money and effort in production, record keeping and quality control to assure that products meet applicable specifications and other requirements. Failure to comply with the FDA`s GMP requirements subjects manufacturers to possible FDA regulatory action. We or our contract manufacturers, if any, may not be able to maintain compliance with the FDA`s GMP requirements on a continuing basis. Failure to maintain compliance could have a material adverse effect on us.

The FDA has not designated expanded access protocols for REMUNE as "treatment" protocols. The FDA may not determine that REMUNE meets all of the FDA`s criteria for use of an investigational drug for treatment use. Even if REMUNE is allowed for treatment use, third party payers may not provide reimbursement for the costs of treatment with REMUNE.

The FDA may not consider REMUNE or any other of our products under development to be appropriate candidates for accelerated approval, expedited review or fast track designation.

Marketing any drug products outside of the United States will subject us to numerous and varying foreign regulatory requirements governing the design and conduct of human clinical trials and marketing approval. Approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory approval processes include all of the risks associated with obtaining FDA approval set forth above, and approval by the FDA does not ensure approval by the health authorities of any other country.

Technological Change and Competition May Render Our Potential Products Obsolete

The biotechnology industry continues to undergo rapid change and competition is intense and is expected to increase. Competitors may succeed in developing technologies and products that are more effective or affordable than any that we are developing or that would render our technology and products obsolete and noncompetitive. Many of our competitors have substantially greater experience, financial and technical resources and production, marketing and development capabilities than us. Accordingly, some of our competitors may succeed in obtaining regulatory approval for products more rapidly or effectively than us.

Our Lack of Commercial Manufacturing and Marketing Experience May Prevent Us from Successfully Commercializing Products

We have not manufactured any of our product candidates in commercial quantities. We may not successfully make the transition from manufacturing clinical trial quantities to commercial production quantities or be able to arrange for contract manufacturing and this could prevent us from commercializing products. Even if REMUNE is successfully developed and receives FDA approval, we have not demonstrated the capability to manufacture REMUNE in commercial quantities. Except for REMUNE, we have not demonstrated the ability to manufacture our treatments in large-scale clinical



quantities either. We rely on a third party for the final inactivation step of the REMUNE manufacturing process. If the existing manufacturing operations prove inadequate, there can be no assurance that any arrangement with a third party can be established on a timely basis or that we can establish other manufacturing capacity on a timely basis.

We have no experience in the sales, marketing and distribution of pharmaceutical products. Thus, our products may not be successfully commercialized even if they are developed and approved for commercialization.

The manufacturing process of our products involves a number of steps and requires compliance with stringent quality control specifications imposed by us and by the FDA. Moreover, our products can only be manufactured in a facility that has undergone a satisfactory inspection by the FDA. For these reasons, we would not be able quickly to replace our manufacturing capacity if we were unable to use our manufacturing facilities as a result of a fire, natural disaster (including an earthquake), equipment failure or other difficulty, or if such facilities are deemed not in compliance with the FDA`s GMP requirements and the non-compliance could not be rapidly rectified. Our inability or reduced capacity to manufacture our products would prevent us from successfully commercializing products.

We may enter into arrangements with contract manufacturing companies to expand our own production capacity in order to meet requirements for our products, or to attempt to improve manufacturing efficiency. If we choose to contract for manufacturing services and encounter delays or difficulties in establishing relationships with manufacturers to produce, package and distribute our finished products, clinical trials, market introduction and subsequent sales of the products would be delayed. Further, contract manufacturers must also operate in compliance with the FDA`s GMP requirements; failure to do so could result in, among other things, the disruption of product supplies. Our potential dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to develop and deliver products on a timely and competitive basis.

Adverse Determinations Concerning Product Pricing, Reimbursement and Related Matters Could Prevent Us from Successfully Commercializing Products

Our ability to earn sufficient revenue on our products will depend in part on the extent to which reimbursement for the costs of the products and related treatments will be available from government health administration authorities, private health coverage insurers, managed care organizations and other organizations. Failure to obtain appropriate reimbursement could prevent us from successfully commercializing products. Third party payors are increasingly challenging the price of medical products and services. If purchasers or users of our products are not able to obtain adequate reimbursement for the cost of using the products, they may forego or reduce their use. Significant uncertainty exists as to the reimbursement status of newly approved health care products and whether adequate third party coverage will be available.

Product Liability Exposure May Expose Us to Significant Liability

We face an inherent business risk of exposure to product liability and other claims in the event that the development or use of our technology or prospective products is alleged to have resulted in adverse effects. We may not avoid significant liability exposure. We may not have sufficient insurance coverage, and we may not be able to obtain sufficient coverage at a reasonable cost. An inability to obtain product liability insurance at acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our products. A product liability claim could hurt our financial performance. Even if we avoid liability exposure, significant costs could be incurred that could hurt our financial performance.



Hazardous Materials and Environmental Matters Could Expose Us to Significant Costs

We may be required to incur significant costs to comply with current or future environmental laws and regulations. Although we do not currently manufacture commercial quantities of our product candidates, we produce limited quantities of these products for our clinical trials. Our research and development and manufacturing processes involve the controlled storage, use and disposal of hazardous materials, biological hazardous materials and radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and some waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of an accident, we could be held liable for any damages that result, and any liability could exceed our resources. Our operations, business or assets may be materially and adversely affected by current or future environmental laws or regulations.

Subordination of Common Stock to Preferred Stock Could Hurt Common Stockholders

Our common stock is expressly subordinate to our Series F Stock, in the event of our liquidation, dissolution or winding up. If we were to cease operations and liquidate our assets, there may not be any remaining value available for distribution to the holders of common stock after providing for the Series F Stock liquidation preference. On April 28, 2001, we converted 160.7 shares of the Series F Stock into shares of our common stock. On May 2, 2001, we redeemed the remaining 39.3 shares of Series F Stock for cash. As of May 2, 2001, we had no issued and outstanding shares of Series F Stock.

You Could Suffer Substantial Dilution of Your Investment if Our Preferred Stock is Converted Into Common Stock or Certain Options or Warrants to Purchase Common Stock are Exercised

In 1998 we sold 200 shares of Series F Stock, in return for gross proceeds of $10 million. These shares of Series F Stock are currently convertible into at least 4.2 million shares of our common stock, which number is subject to increase if our common stock does not meet certain specified price trading levels. Additionally, on April 28, 2001 we will be required to redeem the Series F Stock in shares of our common stock. As of March 31, 2001 we had reserved 7.9 million shares of our common stock for potential issuance upon the exercise of stock options and warrants and payment of dividends on the Series F Stock. Issuance of any of these additional shares could substantially dilute your interest in our company.

On April 28, 2001, we partially converted the Series F Stock into 4,208,924 shares of our common stock and paid the final Series F Stock dividend. We redeemed the remaining shares of Series F Stock on May 2, 2001 for cash of $2.8 million, and there are no issued and outstanding shares of Series F Stock remaining. On April 17, 2001, 2,051,281 warrants to purchase common stock expired, unexercised.

Volatility Of Stock Price and Absence Of Dividends May Hurt Common Stockholders

The market price of our common stock, like that of the common stock of many other biopharmaceutical companies, has been and is likely to be highly volatile. Factors such as the following could have a significant adverse impact on the market price of our common stock:

o o

the results of preclinical studies and clinical trials by us, our collaborators or our competitors;

o

concern as to, or other evidence of, the safety or efficacy of our products or our competitors`
products;

o

announcements of technological innovations or new products by us or our competitors;

o

governmental regulatory actions;


o o

actual or anticipated changes in drug reimbursement policies;

o

developments with our collaborators;

o

developments concerning patent or other proprietary rights of ours or our competitors (including
litigation);

o

period-to-period fluctuations in our operating results;

o

changes in estimates of our performance by securities analysts;

o

market conditions for biopharmaceutical stocks in general; and

o

other factors not within our control.

We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future.
Changes to Financial Accounting Standards May Affect Our Reported Results of Operations

We prepare our financial statements to conform with generally accepted accounting principles, or GAAP. GAAP are subject to interpretation by the American Institute of Certified Public Accountants, the Securities and Exchange Commission and various bodies formed to interpret and create appropriate accounting policies. A change in those policies can have a significant effect on our reported results and may even affect our reporting of transactions completed before a change is announced. Accounting policies affecting many other aspects of our business, including rules relating to purchase and pooling-of-interests accounting for business combinations, employee stock option grants and revenue recognition have recently been revised or are under review. Changes to those rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. In December 1999, the SEC issued SAB No. 101, "Revenue Recognition in Financial Statements." We implemented SAB No. 101 in the fourth quarter of 2000 by adjusting the first, second and third quarters of our 2000 financial statements. Our statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000. Deferred revenue recognized, to reflect the application of the SAB No. 101 adjustment, was approximately $960,000 for each quarter of 2000. The balance of $9.7 million of deferred revenue from this adjustment will be recognized as revenue over the expected development period, which is estimated to be through June 2003. See Note 4 to the Condensed Consolidated Financial Statements.

In addition, our preparation of financial statements in accordance with GAAP requires that we make estimates and assumptions that affect the recorded amounts of assets and liabilities, disclosure of those assets and liabilities at the date of the financial statements and the recorded amounts of expenses during the reporting period. A change in the facts and circumstances surrounding those estimates could result in a change to our estimates and could impact our future operating results.

Our Certificate of Incorporation and Bylaws Include Provisions that Could Make Attempts by Stockholders to Change Management More Difficult

The approval of 662 /3 percent of our voting stock is required to approve certain transactions and to take certain stockholder actions, including the calling of special meetings of stockholders and the amendment of any of the anti-takeover provisions, such as those providing for a classified board of directors, contained in our certificate of incorporation. The practical effect of these provisions is to make attempts by stockholders to change management more difficult.



We May Experience Power Blackouts and Higher Electricity and Gas Prices as a Result of California`s Current Energy Crisis, Which Could Disrupt Our Operations and Increase Our Expenses

California is in the midst of an energy crisis that could disrupt our operations and increase our expenses. We rely on a major southern California public utility to supply power to our facilities in southern California. Due to problems associated with the deregulation of the power industry in California and shortages in wholesale electricity and gas supplies, customers have been faced with increased utility prices, power shortages and, in some cases, rolling blackouts. If blackouts interrupt our power supply, we may be temporarily unable to continue operations at our facilities. Any such interruption of operations at our facilities could delay research and development activities as well as delay our ability to develop or provide our clinical supplies or services, all of which could damage our reputation and result in potentially lost revenue, either of which could substantially harm our business and results of operations.

[thebull 2]

5 euro geknackt.hahaha
gruss
tb 2

[BII-Aktionär]

in Usa schon bei 4.58$!!!!

Mann, so einen riesen Gewinn hatte ich schon lange nicht mehr. (Einstandspreis: 1.80$)

Langsam wirds unheimlich... :-))

[BII-Aktionär]

in Usa schon bei 4.58$!!!!

Mann, so einen riesen Gewinn hatte ich schon lange nicht mehr. (Einstandspreis: 1.80$)

Langsam wirds unheimlich... :-))

[RCZ]

5,12 $

[BII-Aktionär]

Schlusskurs: 4.85$

Mann, bin ich froh, dass die Nasdaq geschlossen hat!
Ich kann diesen Krimi bald nicht mehr ertragen.. :-)

[BII-Aktionär]

Analyst Cites Upcoming Remune Data for Rise in Immune Response`s Stock Price

Dow Jones Newswires
PALO ALTO, Calif. -- Optimism for Immune Response Corp.`s Phase II clinical trial results of Remune, a therapeutic AIDS vaccine, pushed the biopharmaceutical concern`s shares sharply higher, an analyst said.

As of 4 p.m. EDT on the Nasdaq National Market, shares of Immune Response ( IMNR) jumped 65 cents, or 16%, to $4.85.

Darren Mac, an analyst at Gruntal & Co., said the Carlsbad, Calif., concern is expected to present its findings of a trial during the 6th European Conference on Experimental AIDS Research in Scotland June 23 through 26.

The pivotal study, which is being conducted in Spain, should wrap up by the end of the month, Mr. Mac said.

Investors tend to "increase their focus" on clinical trials once a date is set to release results, he said.

In a 10-Q filed Thursday with the SEC, Immune Response reported first-quarter research and development spending of $5.3 million, up from $5.1 million in the year-earlier quarter because of "the scale-up of the manufacturing process of Remune."

Since hitting a low of $1.35 on April 16, Immune Response`s share price has risen sharply after the company announced in April 23 a publication of a paper in HIV Medicine that was viewed as favorable to Remune.

Immune Response officials didn`t immediately return calls seeking comment.

Immune Response is developing Remune in combination with Agouron Pharmaceuticals Inc., a La Jolla, Calif., subsidiary of Pfizer Inc. (PFE).

Immune nachbörslich wieder über 5$ !!!

[oski]

IMNR ein super Wert weiter so

[Heul]

Derzeit an der Nasdaq schon wieder um 20 % gestiegen, trotz keiner neuen Nachrichten. Den Ordergrößen nach 2000/1000 Stücke sind hier keine Privatpersonen am Werke. Vielleicht sehen wir ja den alten Kurs wieder vom März 2000.

[Ironollar]

ich Depp hab nur 450 Stück gekauft für 3 Euro.

[BII-Aktionär]

Ich depp.... das kann man immer schreiben...

Ich hätte auch mehr kaufen sollen..

Aber bin mit meinen 2000 Stk. zu 1.80$ ganz zufrieden... :-)) Wollte noch nachkaufen zu 1.63 aber es kam nicht mehr dazu... das nennt man pech. Aber was solls: ich bin glücklich!!! :_)))))

[RCZ]

ich habe die Hälfte verkauft...
die andere läuft noch weiter

[oski]

soooooooooooooooooo schööööööööööön

[Heul]

Nachbörslich schon wieder bei 6.30 USD - entspricht ca. 7.10 Euro. Die Umsätze sind auch ganz schön.......

[oski]

Wieso? Fällt die Aktie so Extrem?????

[Kursfuzzi]

Zittrige Hände, was sonst.
Mußte allerdings auch mal kommen.
Hoffe daß heute damit der Weg nach oben bereitet wurde.
Fuzzi

[Donkosak]

Hallo Bios

Die Aktie lief doch in der letzten Zeit nicht schlecht.Ich warte schon lange auf den Einstieg (3,0-4,0)Aber mit bedauern mußte ich sehen (nicht für Euch ) das die Aktie nur steigt.Also der Kurssturz heute ist nur logisch

Euer Donkosak-Grischka

[BII-Aktionär]

Wow! Heute 2`100 Dollars verloren! :-))
Macht nix. Ich denke, das ist eine gesunde Korrektur. Bleib drinnen bis die
News von Spanien kommen...

[BII-Aktionär]

Morgen kaufe ich nach. Egal was kommt! Ich bin glücklich, dass wir nicht auf Tagestiefst (4.62) geschlossen haben.
Ich hoffe aber, dass die Aktie bald wieder die 5-dollar-marke zurückerobern kann. Das ist wichtig.

Obwohl ich für meine Verhältnisse schon zu viel Geld in dieser Aktie habe, bin ich zum Entschluss gekommen, noch mehr zu investieren. Das hat folgende Gründe:
Ich denke jetzt da an die Studie in Spanien, die schon seit einiger Zeit läuft und auch an die AIDS-Konferenz in Schottland. Meine Ueberlegung: Warum hat Immune Response
den Termin für die Veröffentlichung der Studie auf Ende Mai/Anfang Juni gewählt? Die Aids-Konferenz in Schottland findet Ende Juni statt. Dort wird die Studie dann präsentiert.
Also, ich glaube nicht, dass die Studie negativ ausfallen wird und diese dann an der Konferenz präsentiert wird. Das ergibt ja keinen Sinn. Der Termin der Veröffentlichung wurde
absichtlich auf Ende Mai/anfang Juni gewählt. Was meint Ihr? Zuerst die Veröffentlichung der nackten Tatsachen, dann die hübsche Präsentation der natürlich positiven Studie an der
Konferenz. Warum sollte Immune an dieser Konferenz teilnehmen, wenn sie eh nix zum Sagen hätten? Darum: DIE STUDIE MUSS POSITIV SEIN!

Und dann gehts natürlich wieder ab. Die Investoren werden wieder in Kaufpanik geraten und emotional reagieren, d.h. es werden wahrscheinlich wieder Uebertreibungen nach oben entstehen.
Lieber wär mir natürlich auch nur 3% an einem Tag als 30%. Das kann mit der Zeit nicht gutgehen, irgendwann muss ja mal der Einbruch kommen. Also, Kursfuzzi, wenn du immer noch 2000Euro
zum "Versauen" hast, würde ich diese in den nächsten Tagen anlegen, vielleicht schon morgen. Ich mach es auf jeden Fall! Ich war noch nie so bullish auf eine Aktie. Aber eben: muss jeder
selber wissen, ich will niemanden ins Verderben bringen. Ich bin halt ein aggressiver Investor.



Hey, das mit dem Chart war echt lustig! Der bringt das Anlegerverhalten von vielen Leuten genau auf den Punkt! (Manchmal hab ichs auch so gemacht :-))

[kieI]

aus dem rb board kopiert
hört sich doch sehr gut an
gruß
kiel

Good news in the clinics!
There are several open labeled studies going on in the us right now using remmune in research centers/Hiv clinics. From the people I`ve spoken with (who have had clinical experience with this product) I have heard encouraging results. These same people also recommend trimeris and gilead, as they also have some good HIV products in the pipe. It doesn`t mean nothing till you have a paper with p values and percentages, but I would just sit back and hold your shares for a while. The failed trial was tainted by the introduction of a very efficacious class of antiretroviral drug into the patient population(protease inhibitors). The addition of this new class of drugs was not designed into the study so the results were very distorted and therefore the statistical analysis got gummed up. Have faith in the company, the Gruntle report from last week was very positive as well.

[Donkosak]

Hallo Bios

Hier was Neues(wird den Kurs wahrscheinlich nicht beeinflussen)

Multiple Sclerosis
CDR2 BV6S2/6S5 Peptide Vaccine Safe And Immunogenic




2001 MAY 16 - (NewsRx.com) -- by N.R. Saltmarsh, staff medical writer - Eight of 10 patients with multiple sclerosis (MS) developed peptide-specific immune responses after being immunized with a T-cell receptor (TCR) V(beta) vaccine, reported researchers with Immune Response Corporation.

E.E. Morgan and colleagues described earlier studies showing that MS patients overexpressed activated T cells from specific TCR V(beta) families, including BV6S2/S5, and that peptide vaccines to the overexpressed V(beta) 8.2 TCR can prevent myelin basic protein (MBP)-induced disease in rats.

In this study, the researchers immunized 10 MS patients with 300 (micro)g of BV6S2/6S5 peptide emulsified in incomplete Freund`s adjuvant. Their results were published in the May 2001 issue of the Journal of Neuroscience Research.

No serious adverse effects were reported during the 48-week trial, and eight of the 10 subjects showed cell-mediated immunity to the immunizing peptide ("Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis," J Neurosci Res May 1, 2001;64(3):298-301).

"These results demonstrate that immunization with TCR BV6S2/6S5 peptide vaccine in MS patients is safe and immunogenic, and support a larger double-blind placebo-controlled trial to determine the clinical efficacy of this approach," concluded Morgan and coworkers.

For further information regarding this study contact Richard M. Bartholomew, Immune Response Corp., 5935 Darwin Court, Carlsbad, CA 92008, USA. E-mail: [e-mail].

Key points reported in this study include:

• Earlier research showed that patients with MS overexpress activated T cells from specific TCR V(beta) families, including BV6S2/S5 and that peptide vaccines to V(beta) 8.2 TCR can prevent MBP-induced disease in animals

• Eight of 10 MS patients immunized with BV6S2/6S5 peptide vaccine developed immunity to the immunizing peptide, and none had adverse effects

• Immunization with TCR BV6S2/6S5 peptide vaccine in MS patients is safe and immunogenic

Euer Donkosak-Grischka

[Wombel_III]

Hi Leute,

oh mann. Weiter obne hat schon jemand den Ausdruck "zittrige Hände" verwendet. Dem kann ich nur zusti mmen. Ich habe mich auch schon gefragt, wann die technische Korrektur kommt. Also: jetzt nicht ärgern, sonder nach vorne sehen. die Steigerungszahlen von 20% und mehr, die IMNR in den letzten Wochen fast jeden Tag hingelegt hat waren ja nicht auf Dauer durchzuhalten.

Ich denke, dass sie jetzt etwas korrigiert und dann schön langsam nach oben geht. Wobei die Konferenz in Schottland natürlich auch einen enormen Schub geben kann (Ich denke eigentlich auch, dass positive Impulse und BErichte kommen!).

Also Kollegen: Abwarten und Tee trinken und in einem Jahr richtig freuen.

by
Wombel

[BII-Aktionär]

@Kiel:

Du bist im Ragingbull-Board aktiv, stimmts?
Dort hast du dich gefragt, ob es wahr ist, ob Immune Response in Spanien überhaupt an dieser Studie dran ist.
Dann kam so ein doofer Kommentar von einem Ami, der eine
uralte Nachricht von Immune reinstellte, in dieser Nachricht stand eben das von der Studie in Spanien. Aber die Nachricht stammt aus dem jahr 2000! Daraufhin meinte einer, das mit der spanischen Studie wäre ja längst schon alter Keks. Stimmt aber nicht, die Studie lief während mehreren Monaten/Jahren und erst jetzt kommen die ENDRESULTATE!

Auch Nachzulesen unter: Nasdaq.com IMNR eingeben und dann unter "Company-News" nachlesen.

[Kursfuzzi]

Hallo allseits,
sehe laut www.eltee.de oder com (vergessen, daß die "ZITTERHÄNDE" scheinbar ausverkauft sind. Die Shellpakete kommen jedenfalls nicht mehr in diesem Umfang und so schnell.
Zur Zeit stehen und 5 Dollar "nur" 3500 zu 4,80 im Shell/Ask dann erst wieder bei über 5 Dollar.
Scheinbar sind alle aufgekauft. Wenn so bleibt ziehts nach oben.
BII- ja, habe meine 2000€ verbraten, was sonst, wie üblich ein bischen zu früh.
Aber hoffe auf Deine guten Nachrichten, dann spielt das keine große Rolle.
Der Chart von e.broker ist echt geil, und trifft den Nagel auf den Kopf. Jedenfalls bei mir.
Übrigens ich bin auch schon wieder aufgestanden nur um zu sehen, deshalb auch meine Glaube an dein posting.
Glück ab
Fuzzi
Nachgesehen, damit nicht falsche Tatsachen.
3500 im Ask mit 4,8 dann erst wieder weit über 5 Dollar.
Leider hat der Kaufwille auch ein bischen nachgelassen. Wird nicht mehr so schnell und zu jedem preis geordert. Vielleicht kommts noch.

[Heul]

Neue News soeben bekommen:

Immunization With an HIV-1 Immunogen (REMUNE(TM)) Appears To Induce Allo-Responses and HIV-1 Specific Responses

Data Presented at the Federation of Clinical Immunology Societies (FOCIS)
1st Annual Meeting in Boston, Massachusetts May 4-7, 2001

CARLSBAD, Calif., May 21 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today data from preliminary interim clinical results
from an ongoing Phase II trial indicating that treatment with REMUNE(TM)
(HIV-1 Immunogen), an investigational product, appears to induce both allo and
HIV specific cell mediated immune responses. Allo (allo-geneic) immune
responses are directed to Human Leukocyte Antigens (HLA) and are associated
with development of both CD4+ T helper and CD8+ Cytotoxic T cell (CTL) immune
responses. Recently other researchers have proposed allo-antigen immunization
as an additional strategy for HIV-1 vaccination. Professor Eduardo Fernandez-
Cruz, M.D., Ph.D., Head of the Department of Clinical Immunology at the
University General Hospital "Gregorio Maranon" in Madrid, Spain and Principal
Investigator in the study STIR 2102 trial of REMUNE in Spain, presented data
at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting
in Boston, Massachusetts (published in Clinical Immunology, Volume 99, April
2001).
The data analyzed a subset of 66 HIV-infected patients from a double
blind, adjuvant controlled, randomized Phase II trial of REMUNE (STIR 2102)
conducted in Spain. The 243 patient trial is designed to evaluate the
effectiveness of REMUNE in conjunction with antiretroviral drugs on viral load
and CD4 cells, which are the primary endpoints. The trial is being conducted
at 13 clinical centers throughout Spain and is scheduled to end in the second
quarter of 2001.
Patients treated with REMUNE plus antiretrovirals appeared to exhibit both
humoral (allo-antibodies) and cell mediated (CD4+ T helper and CD8+ Cytotoxic
T cell) allo-immune responses. In the REMUNE treated group, 74% (25/34) of
the patients exhibited anti-HLA antibodies (an allo-immune response), compared
to only 25% (8/32) of the patients who received placebo (p<0.0001).
Additionally, the REMUNE treated group demonstrated significantly higher
T helper and Cytotoxic CD8+ T cell responses to allo-antigens compared to the
placebo group (p<0.05). "Allo-antigens presented together with HIV-1 antigens
in a single vaccine may potentially further stimulate the generation of HIV
specific immune responses," said Professor Fernandez-Cruz. "REMUNE treated
patients who elicited allo-antibodies demonstrated higher HIV-1 specific
immune responses than patients without allo-antibodies."
"These data are the first to indicate that treatment with a therapeutic
vaccine, REMUNE, can enhance allo-immune responses along with HIV specific
immune responses," said Professor Fernandez-Cruz. "Allo and HIV specific
immune responses are lost early in HIV-1 disease and the ability to restore
them may be important for control of HIV-1."
Previously (13th International AIDS Conference in Durban, South Africa,
See Press Release, July 13, 2000), Professor Cruz had presented data from the
same study that REMUNE treated subjects appeared to have enhanced HIV specific
T helper and functionally active CD8+ T cells also known as "killer cells"
which are capable of killing cells infected with HIV.
"Although several previous trials have indicated that REMUNE induces HIV-
specific immune responses, this is the first time that we have seen
stimulation of allo-responses as well," Professor Fernandez-Cruz noted. "If
the ability to restore allo-responses does in fact relate to the ability to
generate and potentiate anti-HIV immune responses, then treatment with REMUNE
may offer a `two-mechanism attack` against the virus by stimulating both HIV-
specific and allo-immune responses."
REMUNE is currently the subject of several clinical trials, including a
Phase II trial being conducted in Spain and a Phase III trial sponsored by the
Company`s partner Agouron Pharmaceuticals, Inc. (a Pfizer company) to evaluate
REMUNE`s effect on viral load when administered in combination with potent
antiviral drug therapy. Impact on viral load is now a measure of efficacy
that is accepted by the Food and Drug Administration.

The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News
On-Call fax service. For a menu of available news releases or to retrieve a
specific release made by The Immune Response Corporation, please call
800-758-5804, extension 434675. Please retain these numbers for future
reference. Company information can also be located on the Internet Web Site:
http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether preclinical data can be replicated in
clinical trials, whether if initiated clinical trials will be successfully
concluded and whether a preventative vaccine will be approved for marketing or
be successfully commercialized. Those factors are discussed more thoroughly
in The Immune Response Corporation`s SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 2000 and subsequent
Form 10-Q. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X85336592

SOURCE Immune Response Corporation







Web site: http://www.imnr.com


Company News On-Call: http://www.prnewswire.com/comp/434675.htmlor fax, 800-758-5804, ext. 434675


CONTACT: Investors, Kathy Lane, 760-771-2236, or Media, LauraHansen, Ph.D., 858-860-0266, both of The Immune ResponseCorporation

[BII-Aktionär]

Endlich... Das ist die Meldung worauf wir warten oder?
Aber was heisst das denn? Hatte keine Zeit, die Meldung ausführlich zu lesen. aber es klingt doch positiv, oder?

Muss jetzt dringend arbeiten gehen (shit, komme zu spät, nur wegen der Meldung)

Vorbörslich immune aber "nur" bei 5.20$. Ist doch keine Hammermeldung. Oder sehe ich das falsch....??

[grast]

das meeting war vom 04. - 07. Mai in boston.
und wie wir alle wissen , sprang imnr da schon an.
wir warten also weiter auf spanien und usa studien
mit freundlichen grüßen.

[BII-Aktionär]

Ach so,
Ja, jetzt im Nachhinein hab ichs auch gesehen. Ich hab mir einen Print gemacht und in der Firma angeschaut (Heute war nicht viel los, hatte genügend zeit) :-))

Na, dann warten wir halt.

Dann wars nur eine Reaktion auf die sehr sehr positive Nasdaq-Eröffnung. Richtige News warens ja keine.

[Kipferl]

hallo hier ist die meldung auf deutsch von yahoo



Dienstag 22. Mai 2001, 11:10 Uhr
Positive Testergebnisse von Immune Response



Die Immune Response (Frankfurt: 879428.F - Nachrichten) Corporation veröffentlicht die vorl Ergebnisse einer klinischen Testphase II mit REMUNE(TM).

Das Medikament scheint sowohl bei Allo-Zellen als auch bei HIV-Zellen die Immunreaktionen zu
verbessern.

Allo Immunreaktionen werden mit der Bildung von CD4+ T-Helferzellen und CD8+ Cytotoxic T-Zellen
(CTL) in Verbindung gebracht.

Die Aktien stiegen an der Nasdaq um 15,45 Dollar und schlossen bei 5,83 Dollar.





grüsse



K.

[Kursfuzzi]

Danke Kipferl,
(Brötchen??)
Endlich mal ein Übersetzter, der an leute mit schlechtem englisch denkt. (Habs zwar vorgestern schon gelesen, aber jetzt weis ichs wenigstens genau)
Geht ganz gut ab heute.
Schöne hohe Bids!!!
Glück ab

[honko1]

Hoppla...
nur noch 100%, dann hab ich meinen Einstiegskurs wieder!

Glückwunsch an diejenigen, die günstiger gekauft haben ;D

[BII-Aktionär]

Gleiches Spiel wie seit wochen: Bei Börseneröffnung gehts mit hohen Umsätzen rauf, dann mit niedrigeren Umsätzen Konsolidierung und gegen Schluss wieder ein bisschen rauf.

Dieses Schema habe ich nun schon öfters bemerkt. Dieser Titel ist im Moment wahnsinnig berechenbar.

@kursfuzzi: ich setze morgen wirklich einen Stopploss bei etwa 5 Dollar. Scheint die beste Möglichkeit zu sein, wieder ein bisschen ruhig zu schlafen. Ich schlafe seit ein paar wochen wirklich nur noch 3 - 4 stunden pro nacht, manchmal mach ich sogar durch und gehe direkt arbeiten. Idiotisch sowas, aber ich kann nix dafür..

Uebrigens: bis jetzt hab ich meine (zugegebenermassen schwachen) Nerven behalten und besitze noch alle aktien :-))

Aber nachgekauft wie ich es mal um 4.5 dollar vor hatte, habe ich nicht. War nicht mehr fähig dazu (rein psychisch :-))

Schätze wir schliessen heute, falls es zu keinen Zwischenfällen kommt, bei ca. 6.35$

[BII-Aktionär]

Was ist denn jetzt wieder los? :-)))

denke, ich habe mich ein bisschen verschätzt!

jetzt schon bei 6.80$! + 16%!

Mann, was für ein Tag!

[Donkosak]

Guten Morgen

Weils so schön war nochmal MS:

NewsRx Bioscience & Medicine Update Back To: Compilation



--------------------------------------------------------------------------------


Multiple Sclerosis
Peptide Vaccine Induces Immune Response In 80% Of Trial Patients




2001 MAY 23 - (NewsRx.com) -- The Immune Response Corp. (IMNR) has published data on its investigational T-Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that it induced a specific response (stimulation index >5) in 80% of the patients treated.

The objective of the company`s TCR vaccine program is to induce an immune response that inactivates the T cells thought to be pathogenic in MS. The article appears in the May 2001 issue of the Journal of Neuroscience Research.

Eight of 10 patients given five 300-(micro)gram injections of the TCR peptides emulsified in Incomplete Freund`s Adjuvant (IFA) during the 48-week, open-label trial developed specific cell mediated responses as measured by both delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation assays (LPA). No responses against an irrelevant peptide were observed, and neurologic assessments, on average, remained stable during the trial.

"These data, from our Phase I MS trial completed in 1999, suggest that our BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as part of a combination peptide vaccine in our future MS trials," said Richard M. Bartholomew, PhD, Immune Response. "Based on data from previous clinical trials and over 160 pathogenic T-cell clones isolated from many different MS patients, we believe that if commercially approved, our TCR therapeutic vaccine combining BV5, BV6, and BV13.1 could potentially be used to treat approximately 90% of the patients suffering from MS."

Currently, the company has a 60-patient, Phase I/II TCR combination peptide vaccine study under way. The trial is being conducted at six centers located within the states of Washington and Oregon. The double-blind, placebo-controlled trial will monitor safety, immunogenicity, and clinical benefits.

Euer Donkosak-Grischka

[honko1]

Mal ganz dumm gebabelfischt: (nur noch - 90%)

Peptid Impfstoff Der Multiplen Sklerose Verursacht Immune Antwort In 80% Der ProbePatienten

MAI 2001 23 - (NewsRx.com) -- die immune Response Corp. (IMNR) hat Daten bezüglich seines Untersuchungs Peptidimpfstoffs des T-Cellempfängers (TCR) für Vertretung der Multiplen Sklerose (MS) veröffentlicht, daß sie eine Besondere Antwort verursacht (Anregungindex > 5) in 80% der behandelten Patienten. Das Lernziel des vaccine Programms der company`s TCR ist, eine immune Antwort zu verursachen, die den t-Zellen Gedanken inaktiviert, um im MS pathogen zu sein, das, der Artikel in der Ausgabe Mais 2001 des Journals der Neurologieforschung erscheint. Acht von 10 Patient geben fünf 300-(micro)gram Einspritzung von d TCR Peptid emulgieren in unvollständig Freund`s Hilfe (IFA) während d 48-week, open-label Probe- entwickeln spezifisch Zelle vermitteln Antwort wie messen durch verzögern-Art überempfindlich (DTH) Haut Test und Lymphozyte Verbreitung Probe (LPA). kein Antwort gegen ein irrelevant Peptid sein beobachten, und neurologisch Einschätzung, auf Durchschnitt, bleiben beständig während d Versuch. " diese Daten, von unserem MSVERSUCH der Phase I, der 1999 durchgeführt wird, schlagen vor, daß unser Peptid BV6 bei MSPATIENTEN in hohem Grade immunisierend ist, und schließen seine Einbeziehung als Teil eines Kombination Peptidimpfstoffs in unseren zukünftigen MSVERSUCHEN, " aus, sagte Richard M. Bartholomew, PhD, immune Response. " gründete auf Daten von den vorhergehenden klinischen Versuchen und über 160 klont pathogene T-Zelle lokalisiert von vielen unterschiedlichen MSPATIENTEN, glauben wir, daß, wenn sie kommerziell genehmigt werden, unser therapeutischer Impfstoff TCR, der BV5 kombinieren, BV6 und BV13.1 möglicherweise verwendet werden konnten, um 90% der Patienten ungefähr zu behandeln, die leiden unter MS. ", Aktuell hat die Firma ein 60-patient, vaccine Studie des Peptids Kombination der Phase I/II TCR unterwegs. Der Versuch wird in sechs Mitte geleitet, die innerhalb der Zustände Washington und Oregon gelegen sind. Der double-blind, Placebo-kontrollierte Versuch überwacht Sicherheit, Immunisierungsfähigkeit und klinischen Nutzen.

[IgnacetheBroker]

Durchsnittliche Analysten einschaetzung: 1.0 (Strong buy!)
Durchschnittliches Kursziel: 14.0
Langfristig: Bullisch
Mittelfristig: Bullisch
Kurzfristig: Bullisch
Widerstand: 8.2
Unterstuetzung: 5.69
Breakout: 7.38
Beta: 1.27
Kapital: 104 Millionen
Einnahmen: 7.40 Millionen
Buch Wert: 0.64

Boah was fuer Daten!!! Sowas hab ich nicht oft gesehen!!!

Ist ein Biotech Unternehmen: sie entwickeln spezielle T-Zellen (Das sind die wichtigsten Zellen in unserem Immunsystem. Sie sind die Chefs der anderen Immunzellen die jeweils nach verschiedenen Krankheiten auch verschieden sind. Die T-Zellen erkennen immer die Krankheit und geben den zustaendigen Zellen die die Krankheit bekaempfen, ein Signal. Bei Aids ist es aber so, dass die T-Zelle die Krankheit nicht richtig erkennt, weil sich die ganze Erscheinungs Art und Aussehen des Virus aendert.) Die haben jetzt aber geschafft, diese T-Zellen so zu modifizieren, dass sie nicht durcheinander kommen und mit dem Virus fertig werden, jedoch nur vor der Infektion, es hilft nichts wenn man bereits infiziert, ist aber ja schon mal was? Und das letztere kommt ja vielleicht auch irgendwann in der nahen Zukunft.

Bei der Aktie sind ueber 100% moeglich, aber ernst, nicht Zockermaessig!!!

Have your fun!

ItheBroker

[Babytrade]

So, heute haben wir den Widerstand von 8,2 schon mal getestet. Was meint ihr, wie sich imnr in den nächsten Tagen entwickeln wird? Schaffen wir den Durchbruch?

[Kursfuzzi]

Wir haben hier 8,2€ getestet.
Das ist vollkommen unwichtig.
Wichtig ist bei IMNR nur Amiland, und da werden wir sehen was heute passiert.
Natürlich hoffe ich wie alle, daß es hoch geht.
Aber ein bischen ausruhen, ausharren bei ca. 7 Dollar ist auch nicht schlecht.
NUR DAS INTERRESSE UND HANDELSVOLUMEN IST MEINER MEINUNG NACH SEHR SEHR WICHTIG!!
Eine Etappenweise Konsolidierung kann nur gut sein.
Kraft sammeln für den weiteren Gipfelsturm und so.
Die Schweiz wirds wissen, da gibts doch Gipfel en Masse oder nicht?
Ein HOHER Gipfel wird nie in einem Anlauf genommen.
Glück ab
Fuzzi

[IgnacetheBroker]

Ausruhen? neeeee! Es wird stetig steigen!!! Bis etwa 14 Dollar in Amiland.

ItheBroker

[BII-Aktionär]

@Kursfuzzi,

die schweiz weiss es... :-))

Ich denke auch, dass kleinere Pausen notwendig sind. Konsolidierungen könnte man zu Nachkäufen nutzen, falls man unterinvestiert ist. Bäume wachsen nicht in den Himmel... Ich kann/möchte das mit Immune nicht mehr machen. Die schwierigste Hürde wird jetzt wirklich Ende Mai/anfang Juni sein, wenn die News kommen. Ich persönlich denke da an Anfang Juni. Was wir jetzt sehen ist nur die Vorfreude/Hoffnung vieler Anleger. Es könnte gutgehen, und bei positiver News schiesst die Aktie über 10 dollar. es könnte aber auch daneben gehen...darum habe ich einen stopploss gesetzt. und zu anderen Bios: Nein, Kursfuzzi, ich bin KEIN Bio-Kenner und kann zu denen nichts sagen. Ich habe nur in einem us-board viel über Orchid gelesen und ein bisschen den Kurs verfolgt. Denke im Moment gehts allen bios sehr gut!

so, muss jetzt leider wieder bei sehr schönem Wetter schlafen gehen, habe Nachtdienst. Viel spass noch..

[honko1]

@IgnacetheBroker
deine Meinung ist vor allem kurzfristig gesehen sehr gefährlich.
Du sprichst von von 100% Chanche, die gibt es mit sicherheit, jedoch sollte Berücksichtigt werden, dass der Wert innerhalb eines Monats schon fst 500% gelaufen ist. Da ist viel Platz für ne Korrektur...

Ich bin seit ca. 1,5 Jahren in diesem Wert investiert. Mein Durchschnitt liegt so bei 13 Euro/Aktie.

Es gab schon mal Aussagen, dass die Phase 3 in einem Test kurz vor dem Abschluss (so vor einem Jahr) steht, und dann die Zulassung als Medikament beantragt werden kann!

Allerdings hat man dann erstmal nichts mehr davon gehört!!!

Später hiess es dann so inetwa: durch Fehler im Test, wäre das Ergebnis nicht brauchbar, d.h. 2 Jahre fürn Arsch...

Wo wir bei Kurszielen sind:
Die Firma sagt selber, dass es nicht sicher ist, ob jemals ein Produkt Markreif wird.
(steht glaube ich immer als "Disclaimer" unter den Quartalszahlen)

Wenn REMUNE gegen AIDS funktioniert, dann sind 100% wohl nen Witz...
Sollte wieder ein Test versaut werden, oder das Ergebnis nicht soooo Überzeugend sein, dann sind -80% wohl wieder ziemlich schnell erreicht!

Sollte REMUNE erfolgreich als Medikament eingeführt werden, dann dann wird es auf 3 Jahressicht wohl Kurse über 100$ geben. Sollten wieder Fehler in den Tests unterlaufen, oder die Ergebnisse nicht so toll sein, dann wird die Firma die nächsten Jahre nicht überleben...

Ohne jetzt auf absolute buchhalterische Genauigkeit zu achten:
erfreulich ist, dass die "Burnrate" von 12 Mio 1/2000 auf 5 Mio 1/2001 reduziet werden konnte. Wenn ihr euch mal die Produktpipline (Technologies) auf http://www.imnr.com anseht, dann ist klar, dass innerhalb der rechnerischen Lebenszeit des Unternehmens von ca. 2 Jahren nur das HIV Produkt fertig werden kann.
Sollte also nochmal irgend ein Fehler unterlaufen ist Schicht im Schacht, oder es müssten wesentliche Lizenzen verkauft werden, was den Unternehmenswert enorm schmälern würde...

mal ne einfache Rechnung:
$39,017 / $4,9 = 7,95 Quartale Lebensdauer
da wird die Zeit für die Zulassung und die Markeinführung auf jeden Fall eng...

mal schauen

p.s.: Da die Stimmung im Moment sooo positiv ist, wollte ich auch mal auf Gefahren hinweisen...

[Kursfuzzi]

Danke Honko1,
vernünftig geschrieben.
Eindeutig zu sehen nach Deinem Schreiben hopp oder topp.
Werde Stopploss setzen knapp über Einstand.
Hoffen darf man ja.
mfg
Fuzzi

[hierlima]

Neueste Nachrichten von Immune response

The Immune Response Corporation Announces Additional Published Data Further Suggest Treatment With REMUNE(TM) May Stimulate CD8+ T Cell `Killer` Function Against HIV
CARLSBAD, Calif., May 29 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today the publication of data from a 15-patient,
open-label research study suggesting that treatment with REMUNE(TM)
(HIV-1 Immunogen) may increase the frequency of CD8+ T cells, which are
capable of killing virus-infected cells through molecules, called perforin, in
chronically HIV-infected patients concurrently treated with antiviral drug
therapy. Perforin expression is characteristic of activated CD8+ T cells that
can directly kill HIV-infected cells. The study appears in the May 2001 issue
of the Journal of Clinical and Experimental Immunology.
The published study involved 11 chronically HIV-infected patients taking
antiviral drug therapy with CD4 counts between 305 and 1,969 cc/mm(3) and
viral loads below 400 copies/ml at baseline. Patients received an
intramuscular injection of REMUNE at day 1 and at weeks 12, 24 and 36. Four
non-randomized HIV-infected patients who were not treated with REMUNE were
analyzed for comparison. All patients in both groups exhibited a low
frequency of CD8+ T cells expressing perforin prior to treatment.
When tested for the ability to respond to HIV and p24 (HIV protein)
antigens, the immune systems of patients treated with REMUNE appeared to
exhibit a significant increase in activated, perforin-expressing CD8+ T cell
responses compared to baseline. The increase in perforin-expressing CD8+ T
cell responses was apparent at week 24 against HIV (p=0.001) and p24 antigens
(p=0.009) and was maintained at week 36 (p<0.0001 and 0.005, respectively).
As observed in previous studies, the immune systems of patients treated
with REMUNE exhibited a statistically significant increase in
lymphoproliferative responses (LPRs) to HIV (p<0.05) when cells were examined
in vitro. LPRs, a common measure of CD4+ T helper cell activity, were also
found to correlate to the frequency of perforin-expressing CD8+ T cells when
stimulated with HIV (r=0.57, p=0.008).
"These results are consistent with interim data from a double-blind,
placebo-controlled study in Spain (Study 2101) where increased CD8+ T cell
activity (CTL`s) was observed after immunization with REMUNE (13th
International AIDS Conference in Durban, South Africa -- see Company`s Press
Release dated July 13, 2000)," explained Ronald Moss, M.D., Vice President,
Scientific and Medical Affairs at The Immune Response Corporation. "Recent
studies by other investigators have indicated that reduced expression of
perforin in CD8+ T cells may be related to the inability to control HIV. In
this study, we observed a significant increase in perforin expression from the
CD8+ T cells after treatment with REMUNE, indicating that these T cells were
`active` and may be able to attack HIV."
"Several previous studies have indicated that REMUNE appears to
significantly enhance CD4+ T helper cell activity, and these new data suggest
that restoration of CD4+ T helper immune responses may augment the ability of
CD8+ T cells to attack virus infected cells through the perforin pathway,"
said Dr. Moss. "These results are in accordance with what other researchers
have observed regarding the complex interactions between CD4+ T helper cells
and CD8+ T cells. Ongoing trials are being conducted with REMUNE to determine
whether or not vaccine-induced immune responses correlate with antiviral
effects."
REMUNE is currently the subject of several clinical trials, including a
Phase II trial being conducted in Spain and a Phase III trial sponsored by the
Company`s partner Agouron Pharmaceuticals, Inc. (a Pfizer company) to evaluate
REMUNE`s effect on viral load when administered in combination with potent
antiviral drug therapy. Impact on viral load is now a measure of efficacy
that is accepted by the Food and Drug Administration.

The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.

NOTE: News releases are available through PR Newswire Company News On-Call
fax service. For a menu of available news releases or to retrieve a specific
release made by The Immune Response Corporation, please call 800-758-5804,
extension 434675. Please retain these numbers for future reference. Company
information can also be located on the Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether preclinical data can be replicated in
clinical trials, whether if initiated clinical trials will be successfully
concluded and whether REMUNE will be approved for marketing or be successfully
commercialized. Those factors are discussed more thoroughly in The Immune
Response Corporation`s SEC filings, including but not limited to its report on
Form 10-K for the year ended December 31, 2000 and subsequent Form 10-Q. The
Company undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements which may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X47564975

SOURCE The Immune Response Corporation






Web site: http://www.imnr.com


Company News On-Call: http://www.prnewswire.com/comp/434675.htmlor fax, 800-758-5804, ext. 434675


CONTACT: investors, Kathy Lane, 760-771-2236, or media, LauraHansen, Ph.D., 858-860-0266, both of The Immune ResponseCorporation

[BII-Aktionär]

Wie ich mir schon dachte, heute war die Zeit der News.

Sind das nun gute news? glaube schon oder?
kann es jemand übersetzen? ist mir zu kompliziert.

Habe noch eine stunde zeit um zu überlegen, ob ich mir die optionen zulegen soll :-)

[BII-Aktionär]

OH mann! Das sind anscheinend SUPER-NEWS!!!

Muss grad nachkaufen. und meine optionen muss ich auch reinhauen!!

vorbörslich schon hohe umsätze bei 6.5$!!

[Heul]

Vorbörsliche Kurse unter www.island.com = IMNR eingeben - dann klappt es. Der Kurs zieht gerade an, auch bei uns schon bei 7,80 Euro.
mfG

[BII-Aktionär]

kann euch deutsche jetzt aber wirklich nicht verstehen: in frankfurt kann man die dinger noch für 7.40 euro haben während in usa vorbörslich bei 6.75$!

Das sind ja Schnäppchenpreise in Deutschland!
Hat es noch niemand gemerkt?
Heute müsste die aktie auf über 8 Euro hochschiessen..

[BII-Aktionär]

Das einzige, was mir sorgen bereitet: Warum nur 15 Personen bei dem Test???

Ist das überhaupt aussagekräftig?
aber den investoren scheints zu gefallen, momentan wenigstens...

sollte der test nicht an hunderten von personen durchgeführt werden? ich bin ein bisschen verwirrt...

aber auf die Ramblas gehe ich auf alle fälle und die Chicas verwöhne ich auch.. :-)

[Heul]

@BII
Ich glaube, objektiv kann das Testergebnis nur ein Mediziner beurteilen, aber im Moment scheint die Sache den Anlegern ja zu gefallen. Mir jedenfalls....

[BII-Aktionär]

Achtung!
Habe gerade rausgefunden, dass diese Studie aus Puerto Rico stammt und eben nur bei 15 personen stattgefunden hat.

Die grosse, Spanien-Studien-Resultate kommen erst noch. Das ist aber schon mal ein Hoffnungsschimmer, da diese Resultate ja durchwegs positiv sind.

Also, es handelt sich nicht um die Spanien-Studie! Abwarten ist immer noch angesagt.

ich erwarte heute aber trotzdem kurse von mehr als 7 dollar..

[kookie]

...und was machen wir jetzt? Nachkaufen, wegschmeissen oder doch noch hoffen?
-----------
Heftige Kursverluste im vorbörslichen Handel mussten dagegen die Aktien von Immune Response wegstecken, nachdem das Unternehmen mitteilte, dass es Probleme bei seinem HIV-Medikament "Remune" gebe. Das Gremium "Data Safety Monitoring Board" hat bei einem Test keine wesentlichen Wirkungen des Medikaments festgestellt. Kurz vor Handelsbeginn halbierte sich die Aktie im vorbörslichen Handel nahezu und kostete zuletzt 2,75 USD.

[BII-Aktionär]

Der Lustige Text noch auf Deutsch:

Die Immune Response (Frankfurt: 879428.F - Nachrichten) Corp. veröffentlichte, dass ein Medikament zur Bekämpfung der Immunkrankheit HIV erfüllte in einem klinischen Test nicht die Erwartungen.
Remune soll die körpereigenen Abwehrstoffe, die T-Zellen anregen, Antikörper gegen HIV zu produzieren. Der HIV-Virus verursacht AIDS.

Bei Tests zeigte das Präparat Remune bei seinen Patienten keine wesentlichen Unterschiede zur Kotrollgruppe. In der Phase II gab es eine Untergruppe von Patienten mit einem stärkeren Immun-System. Bei diesen Patienten zeigte das Medikament eine positive Wirkung. Die Test-Auswerter empfehlen weitere Studien mit diesen Patienten.

Die Aktien fielen an der Nasdaq um 59,18 Prozent und notieren aktuell bei 2,00 Dollar.

[Lima2000]

Ich interpretiere mal laienhaft:
Bei der Testgruppe,deren Immunsystem stark angekratzt ist,
wirkt Remune nicht(wie solls auch)
Bei der Gruppe mit noch intaktem Immunsystem scheint sich die
gewünschte Reaktion einzustellen.Das heisst,im Frühstadium einer
HIV Erkennung wäre hier ein probates Mittel zur Hand,oder?

Mal sehen ob sich noch was bewegt,vor allem mit dem Kurs,
vielleicht kommt noch der grosse AHA Effekt.

Einen Grippevirus überlebt ein angeschlagener älterer Mensch
mit schwachem Immunsysten auch nicht.Wie soll plötzlich ein
Medikament eine AIDS Infektion stoppen können.(Probantengruppe,
die eine fortgeschrittene HIV Infektion haben)

Ok,mir fehlt natürlich der Sachverstand .Ich hoffe alles wird gut,
für die Kranken und für uns Aktionäre.
Lima

[Oom]

Wie war!!"Auch Aktionäre sind Kranke"! Nur will es keiner wahrhaben.
Wer die letzten Handelstage genau verfolgt hat,der konnte eigentlich das
"Spanische Ergebnis" durch hohe Einzelverkäufe an der NAS schon
ahnen. Spätestens ab 29.5. haben Inseiter verkauft? Wir "Kleinen" wurden
wieder im Schlaf überrascht,und es gabkeine Chance ,noch rechtzeitig
auszusteigen. So geschehen bei der "Ossifirma Intershop" usw,usw.
Aber die Ami`s bestrafen eh immer sehr hart,und man sollte dieser Firma
noch eine Chance lassen.Es wird eben wieder dauern wie bei allen
ehemals guten Titeln ,like CMGI,Softbank,Ariba ,Cisco ect.
Einen kleinen Zukauf gab es schon wieder,und man sollte es als ein
positives Zeichen sehen. IMNR / ah Trading 2,17$.
Montag gehts wieder im 20° Winkel stetig nach seitwärts.
Happy Weakend

[prof19]

Ich Trottel hatte 700 IMNR bei 2,6 E nachgekauft auf 1000 Stück und bin leider schon bei 3,7 E wieder ausgestiegen. Danach habe ich mich tierisch aufgeregt über die entgangenen Gewinne. Aber nun ist die Welt ja wieder im Lot (es fiel senkrecht wie ein Lot).

Aber auch mir ist aufgefallen, daß es schon vorher gebröckelt ist. Irgendjemand weiß es halt schon vorher. Ich habe mir daher vorgenommen, solche ersten Warnzeichen in Zukunft ernster zu nehmen. Wenn ich andererseits die gesamte Aktivität der Firma anschaue, so sehe ich auch noch Licht am Ende des Tunnels. Ob dieses nun 2 oder 3 oder mehr USD wert ist, kann ich nicht so recht beurteilen. IMNR ist eine Entwicklerfirma und hat noch einen weiten Weg vor sich. Der Kurs ist volatil, je nachdem, wie diese uralten Studien in Spanien mal wieder bewertet werden. Vielleicht sollte man IMNR als einen von vielen Hoffnungswerten im Biotech-Bereich mal in sein Depot nehmen bzw. halten.

Kurzfristig erwarte ich einen Rebound auf 2,5 bis 3 USD. Irgend welche Investoren müssen ja die vielen Mio Aktien zu diesen tiefen Kursen aufgekauft haben. Ich nehme an, daß es sich dabei um starke Hände handelt, die langfristig die Titel einsammeln, wenn sie preiswert sind.

der Prof

[modelm]

werde morgen imnr kaufen, nach einer solchen bewegung sind ein paar prozent technische erholung drin !!!

[Kursfuzzi]

@Prof,
Sicher irgendwer muß die Stücke ja geordert und gekauft haben.
Nur "Deppen"? Order mit 10 000 zu 2,5 Dollar!! Oder ein Zocker? dann hat er ganz schön eingemufft!
Ich denke, daß ich jetzt ganz schön im Minus bin, und dann eben mal warte.
Ob Totalverlust oder dümpeln, spielt jetzt keine große Rolle mehr.
Vielleicht wird ja noch was.
BII-Aktionär, kennst Du das Sprichwort "wie gewonnen so zerronnen" ?
Wir waren halt ein bischen zu gierig! wie immer bei 5 wollten wir 10 und bei 10 wollten wir 100.
Nun stehen wir da im kurzen Hemd.
Was solls, werde erst mal ein paar Monate Pause machen und an den alten Kostolany denken. In 2 Jahren schau ich dann nach.
Und wehe ich bin nicht reich!!

[BII-Aktionär]

habe meine shares verkauft, glaube ich. Meine Bank ist eben zu langsam und ausserdem ist bei uns heute feiertag. und wenn nicht, auch nicht schlimm: sehe gerade, dass sich immune erholt. dann verkauf ich eben morgen. aber ich will die dinger weghaben. die story ist gelaufen. suche eine andere Perle. hat ja genug davon :-)

logisch waren wir zu gierig. aber meine Gier war berechtigt. ich wusste ja, dass es steil runtergehen würde, wenn die studie negativ ist. aber ich wusste auch, dass die Aktie über 10 dollar gehen würde bei positiver studie. Die Chancen standen gut. Ich bin zufrieden mit meinem Investment. Das einzige das ich vermisse, ist, dass ich nicht 800 stk. zu 6 dollar verkauft habe. war nahe dran aber eben... man kann nicht alles haben, später hätte ich mich dann aufgeregt, wenn die aktie über 10 gegangen wäre...mann ist eigentlich nie zufrieden. ich hab mich jetzt mit meinem minimalen realgewinn und mit meinem riesigen Buchverlust abgefunden.

Lustig: Gestern in der grössten Sonntagszeitung der schweiz (Wie bild am Sonntag) hat ein Finanzberater (der Ex unserer Ex-Miss-Schweiz, Patricia Fässler) Immune zum Kauf empfohlen! Das Interview war wohl VOR dem Schwarzen freitag! LOL

Grüsse

[Lima2000]

Hi BII Aktionär,
was ist los mit Dir??
dachte eigentlich,Du bist schon am Freitag raus mit Deinen 2000 Stück.
Also es hilft jetzt alles lamentieren nichts - wenn und hätte ich...
Du weisst doch:die Börse gibt aber Sie nimmt auch.
Wenn ich mein Depot anschaue,könnt ich gerade auch kotzen.
-55%,da macht IMRP den Kohl mit -60% auch nicht fett.Was solls,
duchstehen,die Zeiten werden sich bessern -allerdings auf längere Zeit glaub ich.
Geniesse die Chicas espanioles y katalanes y latinas .

Komisch , Immune response in Amiland - 9% , bei und +4%

[Oom]

Hi Leute,
das Papier ist jetzt fest in der Hand der "Kleinstaktionäre" aus der Bronx &
suroundings.IMNR wechselt den Besitzer 100 stückweise! Der Drive bei
Institutionellen ist raus,allerdings auch beim Verkauf?.Nur schade daßich
erst bei über 7 Euro eingestigen bin (Nach 5 wöchtenlicher Beobachtung).
Das wäre der 3. Totalabturz in diesem Jahr nach march first und e-toys,
allerdings nicht so verlustreich bei IMNR.Ich frage mich immer noch wer die 3-4 Analysten (die Einzigen!) sind,die das Papier bis vor 2
Handelstagen noch auf strong buy hatten. Sicher Firmeneigene? Nun ist
aber bei mir der Mut, solche "Billigheimer" noch einmal anzurühren aufden
Tiefststand gekommen. Man wird immer wieder von Ausenseitern gefragt,
warum man nicht beizeiten ausgestiegen ist,denn spätestens bei der ver-
korksten Präsidentenwahl mußte es doch ein"erfahrener Zocker" zumin-
dest geahnt haben was da kommt; aber man war ja verwöhnt (oder geb-
blendet?) von dem tollen Jahr davor,daß man nicht merkte,jeden 2-3.Tag
minus1-3% zu machen.Nun bin zumindest ich in meiner 18 Monatsbilanz
von +55% auf -70%gerutscht!(Zuletzt Dank REMUNE). Verschleudert
wird nichts,eher verkaufe ich meinen TT.
Wünsche eine positive Woche(wenn Uncle Sam so will).
Greetings from the Expatriot

[wolf cub]

Nun heißt es Zähne zusammenbeißen und warten, bis irgendwann wieder eine neue Testphase eingeläutet wird. Schade, gerade IMNR mochte ich so- ist mir nach langen Tradinphasen sehr ans Trader-Herz gewachsen- nun hat mich diese Liebe ganz schön arm gemacht- aber wie heißt es so schön: so wie in guten als auch in schlechten Zeiten. Irgendwie schaffe ich es nicht, meinen Bestand zu verkaufen- wenn IMNR tatsächlich in einer Testphase erfolgreich sein wird und ich nicht dabei bin, wohl aber vorher einen heavy Verlust realisiert hatte- ich würde verrückt werden. So groß ist mein Bestand ja nicht- ich werde halt abwarten.

Grüße
wolf cub

[BII-Aktionär]

@Lima,

ich weiss noch nicht ob ich verkauft habe, weil meine bank noch keine bestätigung geschickt hat. aber ich habe meine shares am freitag für 2 dollars aufgegeben, sollten gegangen sein, da der kurs von 1.85 - 2.20 schwankte. zu 99.99% sind die weg.

ich habe immune aufgegeben, da die Hoffnung für eine Zulassung von Remune sehr stark geschrumpft ist. die fa. hat noch für ca. 1 jahr cash und in dieser Zeit sollte eine Zulassung erfolgen sonst...

leider müssen jetzt zusätliche Studien erfolgen. im grunde genommen wirkt ja remune, aber nur bei patienten mit stärkerem Immunsystem. Und für solche Patienten haben wir viele andere Medikamente. Also die Top-Story ist vorbei. Immerhin habe ich ja keinen Verlust gemacht, da ich vor 1 1/2 monaten zu 1.80 reinging und jetzt zu 2 dollar verkauft habe, mit einem schönen Währungsgewinn (Dollar stieg von 1.72 auf 1.79, in CHF). Natürlich ist es nur ein kleiner Trost, da ich vor 2 Wochen über 10`000$ Reingewinn gehabt hätte. Jetzt sinds halt nur noch 500$. Das ist hart. aber das leben geht weiter und ich sehe vorwärts.. :-)

Und was die Weiber angeht....sicher gehe ich in 1 1/2 Wochen nach Barcelona zu den Chicas! Mann, das ist Tradition bei mir und das werde ich auch weiterführen! :-))))

[Die Stimme]

das macht mich krank, warum kann ich nicht wenigstens alleine der depp sein, da würd mir die rolle besser gefallen, aber alle habe sich verspekt mit der sche. aktie, und wir (lemminge) sind mal wieder auf die schnauze gefallen
jetzt heißts warten ob der dreck genauso tot ist wie seinerzeit die met@box, da bin ich zum glück noch mit minus 10% rausgeflutscht, obwohl die 19% + von heute wieder motten holen wird.
und jeder weiß ja was mit uns passiert wenn wir zu nah ans licht kommen, wir werden hinters licht geführt und bruzeln

[BII-Aktionär]

Ich will ja niemanden den Mut nehmen. Sieht vielleicht auch so aus, als ob ich die Firma mies machen will, da ich nun draussen bin, aber es ist wirklich nicht so:

Heute habe ich eine HAMMERMELDUNG vernommen:

Im Schweizer Fernsehen (Tele 24) haben sie heute in den Kurznachrichten folgendes gebracht:

Ein Professor in Genf hat anscheinend die Lösung gegen AIDS gefunden!!!!
Er hat einen Wirkstoff entwickelt, der 2000 mal stärker ist als bisherige Medikamente.
Es hat auch geheissen, dass AIDS mit diesem Wirkstoff wahrscheinlich ein für allemal
BESIEGT WERDEN KOENNTE!

Stellt euch das mal vor! Das wären super News für alle Aids-Kranken! Ich würde es allen gönnen.
Leider würde das den Firmen Imnr und Vaxgen aber nicht gut bekommen.

Ich konnte den Namen des Professors noch nicht in Erfahrung bringen, hoffe, morgen steht alles in der
Zeitung. Sobald ich mehr weiss, komme ich wieder. Aber wahrscheinlich geht das sowieso um die Welt, falls es wirklich KEINE ENTE ist.

Bitte zereisst mich nicht, falls das nicht stimmt, aber ich sage wirklich nur das, was in den Nachrichten kam. Komischerweise hab ich das
bisher nur auf diesem kleinen Sender gehört. Mal schaun, was noch kommt..

[BII-Aktionär]

Habe die Wiederholung der Nachrichten nochmals angeschaut. Traute meinen Ohren selber nicht.
es ist eben schon 0430 uhr und ich bin müde :-)

Der neue Wirkstoff ist sogar 2 MIO. mal stärker als AZT!!!

Der Durchbruch in der AIDS-FORSCHUNG!

Komischerweise hat der Nachrichtensprecher dies nur nebenbei bemerkt, als ob dies nichts besonderes wäre.
Nur etwa 30 sekunden war ihm diese Nachricht wert. Sehr komisch...

[BII-Aktionär]

Heute in der Zeitung:

"Neue Hoffnung im Kampf gegen Aids: Ein Genfer Pharmazie-Professor hat eine
hoch wirksame Verbindung im Kampf gegen das Aidsvirus entdeckt: Das Molekül
NU1320 soll zwei Millionen mal wirksamer sein als der bisher angewandte
Hemmstoff AZT. die Anfang Jahr patentierte Verbindung ist Gegenstand eines
Lizenzvertrages zwischen der Universität Genf und dem französischen Labor
Mayoly Spindler, teilte die Uni Genf gestern mit. Ziel ist die Entwicklung
eines neuen Medikamentes."

[BII-Aktionär]

Wenn dieses Medikament irgendwann mal verkauft wird, könnte man sich die Frage stellen: wer wird das ding produzieren/vertreiben? Dieses Labor, ist es an der Börse kotiert?

Leider hat der Wirkstoff noch erhebliche Nebenwirkungen, aber das muss nicht unbedingt ein Riesen-Hinderniss sein.

Natürlich kann es Jahre dauern, bis da was kommt. aber wenn...dann sehe ich schwarz für immune, vaxgen...etc.

[puhvogel]

Mir ist nicht klar, was IMNR mit VXGN zu tun hat.
Ok, beides Biotechunternehmen, die am NASDAQ gelistet sind und haben irgendwas mit AIDS zu tun , aber sonst .....

[Donkosak]

Hallo an Alle die glauben es geht nur um AIDS/HIV


Ich bekomme leider diese kleine nette Übersicht der Produkte von IMNR nicht hier rein. Wir haben noch zu bieten MS/RA/Cancer/Psoriasis etc.Und weitere Studien werden folgen zu den anderen Produkten.Also ganz langsam mit der Verurteilung einer Aktie nur weil eine Studie nicht ganz so lief.Würde mich mal interessieren ob die Studie neu aufgerollt wird oder ganz vergessen wird.
Geht einfach selber auf die IMNR-Seite rauf und schaut es Euch an

Euer Donkosak-Grischka

[BII-Aktionär]

Du vergisst aber, dass diese Produkte in einem frühen Test-Stadium sind. Es vergehen Jahre/Jahrzehnte bis ein Medikament zugelassen wird. (Wenn überhaupt).

Das Hauptprodukt Remune ist in Stadium 3. MS-Medikament in Stadium 2.

Leider hat immune nur noch für ca. 1 Jahr Cash. Das ist das grösste Problem! Immune muss sich irgendwas einfallen lassen (Kredite, Hochzeiten etc.)

[Donkosak]

an Bll-Aktionär

Selbstverständlich sind die Substanzen in frühen klinischen Studien aber die Börse spiegelt immer die Zukunft wieder und nicht das Sein oder gar das Gestern.Wenn Du erst
einsteigst wenn ein Produkt die Zulassung erhalten hat dann wirst Du nicht mehr viel Geld mit der Fa. verdienen.(So sehe ich das oder hast Du schon mal eine Fa gesehen die nach Zulassung noch ewig gestiegen ist /nur kurz)

Euer Donkosak-Grischka

PS:mit dem Geld das kann gut möglich sein aber bei der Produktfülle sollte es wohl kein Problem sein.(ist ja nicht eine Hinterhof-Fa. mit einem Produkt)

[BII-Aktionär]

Handelt sich um ein Abkommen mit der Uni Genf und dem französischen Labor Mayoly Spindler.

Leider ist Mayoly Spindler NICHT an der Börse notiert. oder vielleicht heisst es besser "NOCH NICHT".

[BII-Aktionär]

@donkosak

im grunde genommen hast du recht, dass der momentane wert der aktie die zukunft wiederspiegelt.

Bei immune müsste der kurs im falle einer zulassung von Remune aber bei 15 dollar oder mehr sein. Der momentane Kurs spiegelt die Unsicherheit dieses Medikamentes wieder. Die Chancen für eine Zulassung sind nun sehr minim. MS-Medikament kommt frühestens in 2 - 3 Jahren, von den anderen Produkten ganz zu schweigen. Immune wollte mit den durchaus grossen Erlösen aus Remune die anderen Medikamententests finanzieren. Das wird wohl nicht mehr möglich sein. Das heisst, sie müssen sich nach anderen Finanzspritzen umsehen. Theoretisch könnte der Kurs auch bei 1$ rumdümpeln, man erinnere sich vor diesem Mai, als der Kurs bei 1.8$ rumdümpelte, kein mensch mehr von dieser Aktie sprach, dann die Herausnahme aus dem S&P, und der Absturz bis auf 1.35$. UND NUN HABEN WIR WIEDER SOGAR EINE SCHLECHTERE AUSGANGSLAGE! Das ist problematisch...

Immune Response wurde 1986 gegründet und seither wurden noch nie Gewinne geschrieben! Immune bekam zwar Meilensteinzahlungen (à 5 mio $) von Aguron und Pfizer, aber es wird sich weisen, ob die beiden firmen immune immer noch finanziell unter die arme greifen wollen.

[Die Stimme]

noch 34% im minus, jetzt wirds langsam zeit, vielleicht hält ja der aufwärtstrend von heute orgen, das wird aber dauern

[FLOTSAM_AND_JETSAM_US]

indirekte News zu IMNR

June 15, 2001 07:00

Clinical Data of REMUNE as Long Term Immune Based Therapy of HIV Patients Announced by Trinity Medical Group USA
Jump to first matched term

RANCHO SANTA MARGARITA, Calif., June 15 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) announced today the presentation of clinical data of HIV positive patients who have undergone treatment using its Immune Based REMUNE product. The presentation concludes that long term REMUNE treatment is safe and resulted in increased CD4 and CD8 T cell count and body weight. These patients were not receiving any other form of antiviral therapy.

The data were presented at the Eleventh Symposium of HIV Infection, held in Toulon, France.

"The data suggest that nearly two thirds (65.91%) of infected patients could benefit from REMUNE as the sole treatment for HIV. The response to Immune Based Therapy (IBT), such as REMUNE, appears to depend upon the state of a person`s immune system; if the immune system has not degraded below a certain level, for example as measured by CD4 and viral load, the probability of benefit from IBT increases. On the other hand, if a person`s immune system is below a threshold level, the appropriate course of action may be the judicious use of other antiviral drugs, in addition to IBT. This suggested course of treatment is vitally important in areas of the world where antiviral drugs are not easily obtainable and rationing is required," says Dr. Vina Churdboonchart, President of Trinity Medical Group USA, Inc.

Conventional antiviral therapy in the U.S. and Europe may cost $10,000 to $20,000 annually. In countries such as Thailand, where the average income is on the order of several thousand dollars per year, conventional antiviral therapy is out of reach for many. IBT, such as REMUNE, is expected to be much more affordable. The course of treatment using REMUNE consists of a quarterly injection with no adverse side effects; such a regimen should be well tolerated and simpler to administer.

The original study group consisted of 297 HIV positive patients. The results of study after 40 weeks, which included a placebo control group, was previously announced by the Company in October of 2000 and published in the journal Clinical and Diagnostic Laboratory Immunology in September of 2000. The entire study group was placed on IBT after week 40 and the study continued in unblinded fashion. At 132 weeks, 223 patients remained in the study with REMUNE as the sole antiviral treatment. The data suggest the study group can be subdivided into responder and non-responder classes, as measured by CD4 and CD8 cell count increases or decreases, respectively. The responder group consisted of 147 patients or 65.91% of the total. CD4 and CD8 cell counts for the responder class increased an average of 164 and 543 cell counts per micro liter, respectively, after 132 weeks.

The studies of REMUNE conducted by Trinity USA and its affiliates in Thailand are currently the only ones in which no other antiviral drug is used by the patients. In studies of REMUNE conducted in the U.S. and Europe, the concomitant use of REMUNE and other antivirals may have contributed to lack of significant findings of efficacy for REMUNE in the early stages of those studies. "Monotherapy using REMUNE may become a practical solution in developing nations. Our studies continue to show promise at an earlier time frame perhaps due to our study conditions of monotherapy. Our studies are zeroing in on a precise course of treatment for the majority of patients," says Dr. James Namnath, CEO of Trinity Medical Group USA, Inc.

TRINITY MEDICAL GROUP USA ALSO ANNOUNCES LISTING OF COMMON SHARES ON NASD
OVER THE COUNTER BULLETIN BOARD
Trinity Medical Group USA is also pleased to announce that its common
shares of stock are now listed for trading on the Over the Counter Bulletin
Board under the ticker symbol TMGU. On some information systems, current
quotes may be retrieved using the TMGU or TMGU.OB ticker symbols.
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether additional clinical trials will be
successfully concluded and whether REMUNE will be approved for marketing or be
successfully commercialized.
Trinity Medical Group USA, Inc. is a developmental stage company. The
Company`s common stock is currently listed on the Over the Counter Bulletin
Board under the symbol TMGU. The Company`s first product in development is an
Immune Based Therapy for the treatment of Human Immunodeficiency Virus (HIV)
that has completed Phase II clinical trials and is undergoing further study in
Thailand. REMUNE is a product licensed from The Immune Response Corporation
of Carlsbad, California (Nasdaq: IMNR). REMUNE is a trademark of The Immune
Response Corporation.

CONTACT: Trinity Medical Group USA, Inc. investor relations, 303-369-7128, or [e-mail]; Web site: http://www.trinitymg.com.

[Kursfuzzi]

Bitte, wenn möglich ganz kurze Übersetzung!?
Danke

[FLOTSAM_AND_JETSAM_US]

Tmgu hat klinische Versuche auf Basis der ReImmune Therapie (IMNR)
durchgeführt. Ergebnis: Langzeitanwendung ist ist als sicher anzusehen.
Aber leider erst klinische Tests

[Kursfuzzi]

DANKE!!!!
Besser als nichts, jedenfalls kann damit wieder ein bisserl gehofft werden, nach dieser vernichtenden Spanien-Studie.
Und Langzeit!!
Langzeit ist immer gut fürs Geld, solange kein wirklich wiksames Mittel da ist.

[Heul]

Bemerkt von euch niemand, dass die News von heute morgen gar nicht so schlecht aufgenommen werden.

Sind schon für 2.10 Dollar gehandelt. Schön anzusehen unter Island.com.

[Heul]

Sind schon bei 2.40 Dollar. Und steigen und steigen.

[Kursfuzzi]

wie schööööööön,
leider muß die 2 te Hälfte noch viiiiiel steigen bis wieder am Geld.
Erste Hälfte zum Glück wieder leicht im Plus.
Hab die "Dinger" noch alle.
Erst dem Abwärtskurs hinterhergelaufen und dann aufgegeben und behalten.
Zum Glück????
Wir werden sehen.
Hallo BII-Aktionär:
Alle verkauft??
Oder Order nicht ausgführt? Währe jetzt wieder schön.
Oder schon auf bei den Senioritas in Barcelona?
Noch was: Hab mich gestern gewundert, wie so ein "Depp" 12000 Shares zu über 2€ kaufen konnte. Mal wieder einer mehr gewusst, nur ein paar Stunden zu früh!!!
Was für ein satter Gewinn, wenn er den tiefstkurs erwischt hätte.
mfg
Fuzzi

[oski]

Kursfuzzi
Hallo kannst du etwa den Schlusskurs abschätzen danke

[wolf cub]

ICH GLAUB ES NICHT!!!
Hatte gegen meine sonstige Strategie nochmals nachgekauft (normalerweise hätte ich nach so einem Kursrückgang keinen Pfennig mehr investiert)weil ich einfach die Chance bei Immune response für unglaublich hoch erachte- so hoch, das ich das hier auch hohe Risiko des Totalverlustes bereit bin zu tragen.
Schön, heute mal etwas im grünen Bereich zu sehen

[Kursfuzzi]

Oski,
leider bin ich kein Prophet.
Ich kann nur auf Island.com die Bits und Ask anschauen.
Im Moment stehen 2,30 Dollar Kurs.
Über 2 Dollar stehen schön viele und hohe Bids, sodaß ich annehme, daß es nicht unter die Marke von 2 Dollar geht.
1)Es ist Wochenende, und Zitterhände gibt es genug, die kurz vor Schluß noch schnell zu jedem Preis verkaufen wollen!!!
2) Der Kurs wird absichtlich nach unten gedrückt, weil ein paar Große noch nachlegen wollen.
3) Ich währe auserdem Vorsichtig, die Firma die die Nachricht rausgebracht hat TMGU.OB ist ne kleine Klitsche mit einer Marktkapitalisierung von 22 Mio. Dollar, ABER ERST NACHDEM HEUTE 1800 SHARES gehandelt wurden, zu 2 Dollar was einer Steigerung von 33% entspricht. Davor also nur so 15 MIio MKPT!!!!!
Im Moment läufts. Das ist das allerwichtigste. Das Vertrauen ist scheinbar wieder etwas zurück gekommen.
Hoffe auf 2,3-2,4 Dollar Schlußkurs.
Immune hat aber in der guten Zeit vor 2 Wochen im Späthandel oft noch deutlich zugelegt, war ne Eigenart von dehnen.
Na und ganz zum Schluß noch: Schätze mal einer die Amis ein. Ist fast nicht möglich. In 5 Minuten rauf und in 5 Minuten runter.
OK??
Meine ganz private Meinung: Sieht verdammt gut aus im Moment, hoffe auf 2,40 Dollar +- 5%

[wolf cub]

Wird in Berlin und Frankfurt weiter hochgetaxt.
Die nächste Woche wird auf jeden Fall spannend

[Kursfuzzi]

Jetzt drehen Sie durch!!!!!!!!!!!!
2,55 Dollar Kurs und 1000er Bids mit 2,58 Dollar, kaum ASK unter 3 Dollar!!!!!!!!!!!!
Wow wow, hoffentlich hälts.
Ist noch ne neue Nachricht gekommen??? Oder warum innerhalb der letzten Minuten dieser Schub?
Fuzzi
Doch 2,6-2,7 Dollar Schluß?

[wolf cub]

Nächste Woche bei 4-5 $-langsam kommt die Kaufpanik

[Heul]

Die spinnen die Amis,
habe heute morgen zu 1.91 gekauft und nun zu 2.80 verkauft, nachdem das "Eisen" zu heiß war. Jetzt war ich 30 min weg und was ist, na ja wenigstens kann ich nun ruhig schlafen.
Schönes WE...

[Kursfuzzi]

Hab ich vor 30 Min. Bids bei 2 Dollar gepostet?
Ja hab ich, jetzt stehen wir bei 2,5 - 2,8 Dollar mit jede Menge Bids.
Ask unter 3,1 Dollar keine!!
Oski ich gebs auf.
Die Amis sind mir über.
Aber schöööööön, weiter so.

[Heul]

Die Spinnen die Amis, wie wenn die Kaufpanik ausgebrochen wäre. 3.20 USD.????

[Heul]

Jetzt drehen die völlig durch. 3.50 USD

[oski]

Wie gehts weiter ??????

[wolf cub]

denke zwischen 4-5 Konsolidierung, zwischen 7-8 dann stärkere Gewinnmitnahmen

[BII-Aktionär]

Oje,oje,,,
hab die firma schon aufgegeben.
Heute kam dann diese news und der kurs stieg sehr langsam. gab einen kaufauftrag bei 1.90$. Ich idiot, hätte lieber 2.05 eingegeben, denn der kurs explodierte zu schnell, als dass ich noch kaufen konnte.

Habe vor 2 wochen alle verkauft zu 2 dollars. :-(

und nach barcelona ging ich auch nicht, jetzt war mir der flug zu teuer, keine schnäppchenpreise mehr, nur im frühling und im herbst...na,ja.

soviel pech wie ich in letzter zeit hatte...

und jetzt kann ich nicht nachkaufen, weil ich kein ami bin...schöne sch...und der kurs läuft mir davon: schon 3.5$. nächste woche schau ich weiter. hoffentlich bekomm ich noch ein paar. das ist wirklich wieder kaufpanik. aber konsolidierungen gibts immer...dann schlage ich wieder zu...

[kidloco]

Die Börse, speziell die Amis, sind echt verrückt.

Stand nicht fast exakt das Gleiche wie in der aktuellen schon in der vorherigen Studie, auf diese der Kurs sich gedrittelt hat?
(Nachweisbare Wirkung bei Pat. mit weniger geschwächtem Immunsystem). Ich glaube schon.

Unterschied war lediglich, daß man damals die negativen Aspekte (keine Wirkung bei Pat. mit stark angegriffenem Immunsystem) sehen wollte.

Oder täusche ich mich?

Mir ist das Ganze jedenfalls etwas suspekt.

MfG
kidloco

[wolf cub]

Die Frage ist doch, ob der Kursrückgang nicht übertrieben panisch gewesen ist. Denke, im Bereich AIDS Forschung einen Mini Schritt nach vorne gekommen zu sein sollte doch eine
gewisse Honorierung erhalten- letztendlich ist es ein Mini Schritt in Richtung Durchbruch.
Mal schaun, wie die Woche verläuft, kleinere Konsolidierungen werden mich noch nicht rausschütteln, sollten wir zwischen 7-8 € allerdings ankommen, werde ich mich mit engem stopploss absichern

[Kursfuzzi]

Hei BII
Ich hab meine Dinger noch, aber nur weil ich den Verlust nicht fressen wollte.
Glück?? Ich hab wie Kidloco ein bischen Bedenken. Mein englisch ist allerdings zu schlecht um genau zu übersetzen und die Feinheiten herauszufinden.
Was solls, im Moment läufts.
Diesmal hau ich aber nen Stopp beim Einstandkurs rein, das kannst Du mir glauben.
Nochmals mach ich die Sch.... nicht mit.
Läufste rum wie bekloppt.
Toi toi, dass Du die richte Konsolidierung erwischst.
Fuzzi

[kidloco]

Bin gerade dabei, mir beide Studien nochmal genau durchzulesen. Sicher ist die aktuelle Studie eine Honorierung wert. (Da sie die Phantasie anregt)
Ich stelle mir aber hauptsächlich die Frage, inwieweit es sich bei dem heutigen Anstieg um ein STROHFEUER handelt.

Schon in der vorgerigen Studie wurde attestiert, daß Remune bei Pat. mit weniger geschwächtem Immunsystem Wirkung zeigt.

Also insofern nichts wirklich neues.

Das ganze ist deshalb eher unter psychologischen Aspekten zu sehen, deshalb auch meine bedenken bzgl. Strohfeuer. Es könnte auch eine gewisse Klüngelei mit Trinity im Spiel sein.
However, einen Teil meiner Anteile werde ich auf jeden Fall behalten.

Good luck!

MfG
kidloco

[kidloco]

Aktuell:

+ 157%

[oski]

Wie gehts Montag weiter$$$$$

[kidloco]

Meine Güte, ich glaube IMNR hat mir heute fast das Leben gerettet.

Hatte ca. 12.000 shares (zuletzt ständig nachgekauft, Durchschnittskurs ca. 2,29 Euro, wobei allerdings schon ein Verlust aus vorherigen Verkäufen von über 25.000 DM zu Buche stand)

War schon nahe dran aus dem Fenster zu springen.

War mir eine Lehre, so eine Harakiri Aktion starte ich in nächster Zeit hoffentlich nicht mehr.

Ich glaube heute bekomm ich das Lächeln nicht mehr aus dem Gesicht

Good luck to all.

MfG
kidloco

[Algol]

Weiß jemand, wie man an nachbörsliche Kurse in den USA kommt?
Thanks,Algol

[BII-Aktionär]

@algol:

www.nasdaq.com dann "IMNR" eingeben, imnr anklicken und unter Extented trading siehst du die nachbörslichen tradings.

allerdings jetzt wieder zurückgekommen.

Momentan bei 3.52$ nachbörslich.
ich erwarte tiefere Kurse am Montag. Es werden bestimmt ein paar gewinne mitnehmen.

Die Frage ist nur, wenn ich nicht recht habe, wäre es eigentlich von Vorteil, diesmal in Frankfurt zu ordern. 1. ist mir der Dollar zu hoch und 2. wenn imnr am Montag in den usa doch wieder abgeht, hätten wir in europa den Vorteil vorher schon zu handeln...
bin in einer Zwickmühle...
ich weiss nicht so recht, was ich von der neuen NEws halten soll. Beim Sender CNBC wurde es allerdings positiv aufgenommen. Aber Gewinnmitnahmen bis 2.80$ sind auch schon in der Runde...

ich glaub, falls ihr deutschen nicht zuviel verlangt, kaufe ich euch ein paar ab am montag. :-))
Bitte,bitte, gebt mir ein paar... :-)

[Kursfuzzi]

Danke Kidlocco, fürs nochmalige übersetzen.
Wie ich schon weiter unten im tread bemerkte ist die Firma die die Nachricht rausbrachte am OTC gelistet. Habs Kürzel vergessen.
Ist nur ziemlich klein. Als ich nachsah waren ganze 1800 Shares gehandelt worden zu 2 USD. MKTP = 21 Mio USD. davor 14 Mio USD.
Klein muß allerdings ja nicht gleichbedeutend mit schlecht sein!!!!
Viele kleine Firmen sind gut und innovativ.

Für den anderen: Kurse USA nachbörslich unter www.island.com oder www.eltee.com weiter Kurse, dann Archipelago, dort kannste Bid Ask verfolgen.

[kidloco]

Nix für ungut Kursfuzzi, da hatten wir bzgl. Trinity den gleichen Gedanken (hab Deine Anmerkung erst in Nachhinein gelesen)

MfG
kidloco

[wolf cub]

ich glaube nicht, daß wir Montag einen erheblichen Kursrückgang sehen- sicher, einige werden Gewinne mitnehmen, dafür gibt es aber wiederum auch viele, die noch unbedingt reinwollen (wer hat nicht den letzten schnellen Anstieg noch vor Augen).
Ich denke, wir werden uns um die 3,8$ einpendeln und dann einen neuen Anlauf nehmen. Wie gesagt, zwischen 7-8 € werden sehr viele ihr Ziel erreicht haben- bei diesem Kurs würde die Phantasie für weitere Kursgewinne ersteinmal fehlen- es sei denn, es kommen noch positive Anaystenkommentare.

[Lima2000]

Falls Remune wirkt könnte es ja bei allen Autoimmune Erkrankungen
eingesetzt werden.Hier schlummert gewaltiges Potential.

[wolf cub]

Pfizer will market Remune once approved the

Company and Agouron Pharmaceuticals, Inc., a wholly-owned
subsidiary of Pfizer Inc., or Pfizer, entered into a
binding agreement under which the Company agreed to exclusively license
to Pfizer certain rights relating to REMUNE, its immune-based therapy
under development for the treatment of HIV infection.
Under the terms of the agreement, the Company will exclusively
manufacture commercial supplies of REMUNE, and Pfizer will have
exclusive rights to market REMUNE in North America, Europe, Japan and
certain other countries, if regulatory approvals are received. As a result of
this agreement, the Company may potentially receive in the aggregate up to
$77 million, including license and
milestone payments of $45 million, payments to support research and
development of $18 million and $14 million for the purchase of the
Company`s common stock, priced at a premium
to the market, subject to certain rights of termination by Pfizer. In addition,
the two companies will share all profits from the commercialization of
REMUNE on a 50/50 basis if
REMUNE
is successfully developed and receives the necessary regulatory
approvals.



(Voluntary Disclosure: Position- Long; LT Rating- Strong Buy)





Stand heute im Ragging bull Board- alter Hut oder gab es diese Abmachung schon vorher???

[oski]

wolf cub
Kannst es auf Deutsch übersetzen danke

[BII-Aktionär]

Das mit der Abmachung mit Pfizer IST ein alter Hut! Immune bekommt die Hälfte der Einnahmen im falle einer Zulassung von Remune. Meilensteinzahlungen etc.

[oski]

Wie sieht den die Zukunft aus

[wolf cub]

@oski, es geht um die Vereinbarungen zwischen Pizer und Immune Response- Pfizer unterstützt und würde bei erfolgreicher Produktentwicklung des HIV Medikamentes durch Immune Response exklusive Vermarktungsrechte erhalten.


@ Bll-Aktionär- Danke! Stimmt schon nichts wirklich neues, aber ich hatte diesen Bericht vorher nicht gelesen-

[e.broker]

hallo zusammen,
samstag 2:24uhr nacht, ich checke grade die tagesgewinner von freitag und fall fast vom stuhl
ich freu mich, das wir scheinbar nochmal mit nem blauen auge davongekommen sind.
ich bin jetzt 1 1/2 jahre in imnr investiert und hatte sie nach der meldung von anfang juni eigentlich schon abgeschrieben, aber so kanns gehn
ich wünsch allen viel glück mit imnr und drück die daumen.
@kursfuzzi
nich www.eltee.com sondern www.eltee.de

[wolf cub]

Das die Gewinne zwischen Pfizer und IMNR zu 50/50 aufgeteilt werden - sollte eine positive Entwicklung entstehen- ist neu! Die nimmt erst einmal die Bedenken, daß Pfizer IMNR fallen läßt, denn anscheinend sind sie sehr optimistisch.

[Kursfuzzi]

Grüß Euch,
schön, daß jeder versucht sein Wissen normal zu posten.
Mir gefällt, daß Pfizer mit im Boot ist.
Schon besser wie diese kleine Firma Trinity Kürzel TMGU.OB obwohl ich nichts schlechtes darüber sagen will.
Können 1-2 verdammt kluge Köpfe dort haben, die in so einem Fall alles reisen.
Der Absturz macht halt misstrauisch und werde es auch bleiben.
Mit dem eltee.com tut mir leid, war keine Absicht. Kommt daher, daß im neuen AOL nach www.e Eingabe sofort die ganze Adresse kommt.
Ist bequem, aber wie ihr seht verblödet der Mensch auch recht schnell.
schönen Sonntag und toi toi toi
MfG
Fuzzi
PS
TMGU.OB Info von finance.yahoo.com und tmgu.ob und Detailed und Profile
Handelsvolumen am Freitag = 17.700 Stück
Schlußkurs 3 USD ergibt eine MKTP von 33,8 Mio USD
High lag bei 3,8 USD
Shares gesamt = 11,3 Mio Float = 3,2 Mio
EBITDA = -2,37 Mio USD
Home Page www.trinitymg.com
macht euch selbst ein Bild davon

[BII-Aktionär]

@Kursfuzzi:

Hast du schon mal was von Magna-Lab gehört? Auch an der Nasdaq gehandelt unter dem Kürzel Magla. Kurs bei 0.48$. Könnte am Montag niedriger eröffnen. Ist in der Medizinaltechnik tätig (Herzinfarkte). Hat in den letzten 2 Monaten 2 (!) FDA-Zulassungen bekommen, doch der Kurs ist "nur" von 0.3$ auf 0.5 gesprungen. Also ich steig ein, bei solchen Sachen hab ich immer ein feines Näschen. Vorallem gefällt mir, dass in Europa kein Mensch über diese Fa. schreibt (in den Boards unbekannt). Und in den Usa ist die Firma auch nicht gerade DER Gesprächsstoff.

Der CEO von Magla spricht von einem Billionen-Markt! Na,ja, wer hört schon auf den CEO? :-)

Höchstkurs war vor ein paar Jahren über 6 dollar. Da war aber von einem Produkt weit und breit nichts zu sehen. (Aehnlich wie bei Immune Response). Doch jetzt haben sie die Zulassungen definitiv und ab nächstes Jahr soll die Produktion steigen. Mein Englisch ist auch nicht gerade perfekt, es soll ein Gerät o.ä. sein um perfekte Bilder vom Herzen zu erstellen. Aber häng mich nicht auf, wenns nicht stimmt. :-) Es gefällt mir eben auch, dass es dir Firma seit 1991 gibt, noch nie Gewinne geschrieben haben (da ohne Produkt), aber die Verluste waren auch nicht sehr hoch, letzter Quartalsbericht, Verlust: 0.01$ per Share. Und da ja jetzt 2 Produkte in der Pipline stehen, könnte es ja jetzt losgehen...

Also ich bin wirklich kein Pusher, hab ja auch noch keine Aktien, aber ich denke, das könnte abgehen...

Mal schaun..

[Bombenleger]

@ BII-Aktionär,

werde einen extra-thread für Magna-Lab einrichten.Ist eine sehr interessante Aktie

[BII-Aktionär]

Danke Bombenleger! (Hübscher Name)

Es gibt nämlich keinen einzigen Thread von Magna-Lab (nicht verwechseln mit Magna-Pacific)

Werde deinen neu eröffneten Thread verfolgen und mitposten.

[Kursfuzzi]

@BII-Aktionär,
Hab noch nie was von dieser Firma gehört.
Allerdings ein neuer Tread dazu vorhanden.
Werde Ihn gleich lesen.
Näschen ist immer gut.
Häng mich nicht auf, noch besser. Musste jedenfalls herzhaft lachen.
Jeder kann und soll seine freie Meinung schreiben. Ist doch ok so. Voll in Ordnung, jeder kann sehen, daß Du für die Aktie im Moment eingenommen bist, aber eben nicht mit letzter Sicherheit (wer hat die schon) bzw. noch Info-Lücken da sind.
Werde mir sowieso versuchen Infos dazu einzuholen und meine eigen Meinung dazu zu bilden. Werds Dir zukommen lassen,
so wie ich das dann denke und sehe.
Ist sicher nicht ALLES, aber immer ehrlich, das was ich weis oder meine.
MfG
Fuzzi

[wolf cub]

Immune Response, Trinity Rise on Remune Drug Study (Update2)
By Karen Fessler


Carlsbad, California, June 15 (Bloomberg) -- Immune Response Corp. shares more than doubled after the company said new data from a study of its experimental AIDS drug, Remune, in Thailand could support efforts to win approval of the drug in that country.

Shares of the biotechnology company rose $2.43 to $4. Shares of Trinity Medical Group USA Inc., which licenses the drug in Thailand, doubled to $3 from $1.50.

Trinity Medical plans to file an application with Thailand`s Ministry of Public Health within weeks, said Chief Executive James Namnath. Approval of the drug, which is designed to boost the immune systems of patients with HIV, would give both companies their first drug on the market.

``We feel we have sufficient grounds to file an application,`` Namnath said.

Immune Response is developing the drug in the U.S. with Pfizer Inc.`s Agouron. Agouron couldn`t immediately be reached for comment.

The study showed that about two-thirds of 223 patients who had taken the drug for 132 weeks had a significant increase in the number of CD4 and CD8 T-cells in their blood, which may signal immune system strength.

The study tested Remune alone, without other antiviral drugs. Showing that Remune can work well by itself in developing countries such as Thailand is important because patients in those countries typically have inadequate access to standard antiviral drugs, said Ron Moss, vice president of medical and scientific affairs at Immune Response.

Moss said the Thai data could also help support trials of the drug in the U.S.

The results come two weeks after Immune Response said an independent analysis of another study of Remune showed that the drug didn`t meet the trial`s main goal of reducing the amount of virus in the bloodstream. Since that data was announced, the stock had fallen about 68 percent, excluding today`s rise.

In that study, Remune was investigated in combination with standard HIV treatment. Reducing the amount of virus in the blood has been linked to longer life for HIV-infected patients. The data from that study indicated that Remune might have cut the amount of virus in a small group of patients who had strong immune systems.

Trinity said that its study suggests that patients` response to the drug may also depend on the condition of their immune systems. The likelihood that the drug will work increases with patients who have stronger immune systems, it said.

``We`re beginning to see that this type of therapy will be most beneficial in healthier, earlier-stage patients and the Thai data supports that,`` Moss said.

[Marmay200]

Hallo zusammen, mein erster versuch. Was wollen uns die vorhergehenden worte sagen, kann das eventuell jemand übersetzen???
Mfg Marmay200

[BII-Aktionär]

Ist nichts berauschendes, hat mit Remune auch nichts zu tun. Neues Medikament...
gene therapy, huIL-10 Immune Response preclinical data.(Brief Article)

06/18/2001
R & D Focus Drug News
Copyright 2001 Gale Group Inc. All rights reserved. COPYRIGHT 2001 IMS
World Publications Ltd.

Immune Response is developing a gene therapy, using a nonviral method
to deliver the gene for human interleukin-10 (huIL-10), as a potential
treatment of transplant rejection. Preclinical data showed that
transfected donor rat livers expressed

huIL-10, which was detectable at 1 ng/mL in the recipient rat serum,
24 h post-transplantation. Seven days post-transplantation, transfected
donor liver grafts expressing huIL-10 maintained normal graft size
whereas untreated donor liver grafts doubled in


size due to an infiltration of neutrophils. The treated liver graft
had a reduced number of infiltrating lymphocytes and less tissue damage.
The levels of the liver enzymes, glutamic pyruvic transaminase (GPT) and
glutamic oxaloacetic transaminase (GOT),

were comparable in treated and untreated rats. Preclinical evaluation
of the therapy is moving into pig models, R&D focus was informed by a
company representative at the 4th Annual Meeting of the American Society
for Gene Therapy, 30 May - 3 June 2001,

Seattle, USA.

gene therapy, huIL-10, gene therapy, transplant rejection,

L4A, Immunosuppressive Agents, Immune Response, preclinical-data,

new-drug

[oski]

wann wird IMNR bei 4$ wieder landen ??????????????

[Kursfuzzi]

Ich denke bald.
Bin ganz zufrieden mit 3,38 USD Kurs im Moment.
War zu erwarten, daß IMNR heute zurück kommt. Die Frage war nur wieviel. Hat sich wacker gehalten. Ich denke morgen könnte es schon wieder aufwärts gehen.
Denk mal nach: von 1,65 auf 4 USD an einem Tag. Da sind einige dabei die im großen gekauft haben und jetzt wieder aussteigen. ist doch normal.
Wenn ich zocken könnte, hätte ich heute zu 4,5 verkauft und bei 3,9 wieder gekauft. Aber das ist nicht so mein Bier, das hin und her gekaufe. Macht auch nur die Banken fett.
Ich steige ein oder aus, fertig.
toi toi
Fuzzi

[Lima2000]

4€ sind erreicht,sieht doch ganz gut aus.

[smarty7]

Heute +27% in den USA! Falls die 4$ geknackt werden, ist charttechnisch der Weg frei bis 6,5$

MfG smarty7

[oski]

Wieso jetzt diese Euphorie ? Kann der Absturz wieder kommen?
Danke Börsianer

[smarty7]

Hier nochmal ein Ausschnitt aus der Unternehmensmeldung vom 15.06. :

Conventional antiviral therapy in the U.S. and Europe may cost $10,000 to $20,000
annually. In countries such as Thailand, where the average income is on the order of
several thousand dollars per year, conventional antiviral therapy is out of reach for
many. IBT, such as REMUNE, is expected to be much more affordable. The course of
treatment using REMUNE consists of a quarterly injection with no adverse side effects;
such a regimen should be well tolerated and simpler to administer.
.................................

The studies of REMUNE conducted by TrinityUSA and its affiliates in Thailand are
currently the only ones in which no other antiviral drug is used by the patients. In studies
of REMUNE conducted in the U.S. and Europe, the concomitant use of REMUNE and
other antivirals may have contributed to lack of significant findings of efficacy for
REMUNE in the early stages of those studies. "Monotherapy using REMUNE may
become a practical solution in developing nations. Our studies continue to show
promise at an earlier time frame perhaps due to our study conditions of monotherapy.
Our studies are zeroing in on a precise course of treatment for the majority of patients,"
says Dr. James Namnath, CEO of Trinity Medical Group USA, Inc

Wichtige Schlußfolgerungen hieraus sind:

1. Erste erfolgreiche Studie mit REMUNE als einzigem Mittel !
2. Die Anwendung von REMUNE ist wesentlich kostengünstiger als herkömmliche Antiviral-Therapien.
3. Die Anwendung von REMUNE ist wesentlich angenehmer für den Patienten als bisher bekannte
Therapieformen.

Auch wenn vieles schon vorher bekannt war, Ich denke, die Kombination der Ergebnisse bringt die Phantasie für die Aktie!

[oski]

smarty7
IMNR wird die Firma noch eins drauf legen oder war das ein
tropfen ? Wie sieht es mit dem geld aus , reicht es zum überleben der kurs schwankt hin und her Gruss an alle euer
oski

[BII-Aktionär]

Cash nur noch 7 Monate!

(zum Glück hat immune mit Pfizer und Aquron zwei starke Partner)

[oski]

Bll
Lohnt es ein weiteres Investement und wann könnte der
nächste Schleudergang folgen richtung Himmel

[Donkosak]

Hallo an Alle

@Bll:Voher hast Du eigentlich immer die Liquiditätszahlen des Unternehmens?
Und warum ändern die sich so schnell.Gerade waren es noch 12 Monate und nun nur noch 7 M.Wie geht denn das?Kann mir kaum vorstellen das das so ein hin und her ist,oder?

Übrigens toll der Anstieg der letzten Woche.Damit kommen dann also doch die anderen Produkte noch zum Zuge.(wenn Pfizer ein Auge zudrückt wovon auszugehen ist

Bis dann Euer Donkosak-Grischka

[oski]

Hallo Börsianer wie siehts bei euch aus nächste Woche ??
gebt ihr noch einen drauf ??

[wolf cub]

Wenn nicht in der nächsten Woche News kommen, wird sich meiner Ansicht nach der Kurs etwas unterhalb des jetzigen stabilisieren. Mit den nächsten Adhoc - soweit positiv natürlich- werden wir uns weiter nach oben angeln. Sollte sich z.B. ein weiterer Invetor an Immune Response aufgrund der Thailand-Studien beteiligen (Thailand ist ein unglaublich großer Absatzmarkt), würde ich Kurse um die 16 für realistisch erachten.
Kommen überhaupt keine Neuigkeiten in der nächsten Zeit- nun ja, dann sehen wir wahrscheinlich wieder Kurse um die 2.

[BII-Aktionär]

@Donkosak:

12 Monate waren eine erste Schätzung von mir. Von 7 Monaten gehen die Amis jetzt aus. Wird wahrscheinlich etwa dazwischen sein. Aber das Geld reicht sicher nicht mehr über ein Jahr. Spannend wird, was Pfizer und Aguron jetzt machen. Falls kein Geld mehr zufliesst (d.h. keine Zulassungen) dann gute Nacht. Ich bin nicht mehr so gross eingestiegen, überlege mir aber, ob ich auf dem Niveau um die 3 dollar nochmals zukaufen sollte, da dieses Wochenende die Studie von Spanien in Schottland vorgestellt wird. Nächste Woche kommen bestimmt News raus, d.h. genauere Angaben zu dieser Studie und Aussichten.

Ich rechne doch noch mit einer Zulassung zumindest in Thailand. Aber meine Gefühle sind da leider ein bisschen gemischt. Gross steige ich nicht mehr ein, hab eh nicht mehr viel Geld :-))

[Donkosak]

Hallo an Alle

@Billanke Dir für die schnelle Antwort.Meine Frage war etwas ketzerisch formuliert.(Sorry so bin ich halt) Mein Einstiegskurs ist nach meiner Verbilligung 3,4€.Genau das was ich damals auch gepostet hatte.(wollte zwischen 3 und 4 einsteigen bei meinem Zielkurs von 10 ist der Faktor dann fast 3)Gehe davon aus das nicht die 16 aber immerhin vielleicht die 10 € erreicht werden.Wie schon gepostet die Fa. hat mehr zu bieten als nur HIV. Das mit den finanziellen Mitteln ist hingegen nicht ganz ohne Risiko.Einsteigen würde ich nur mit einer kleinen Position und das vielleicht wenn der Kurs die 3 Dollar wieder sieht was nicht unwahrscheinlich ist.Bei guten Nachrichten sind hingegen schnell die 7 bis 8 wieder drin.

Auf die Woche Euer Donkosak-Grischka

PS:ich lege nicht mehr nach

[Joscht]

Hi,
neu ist für mich, daß das Ding keinen Boden findet.

[Bombenleger]

Ich kann nur abraten in IMNR zu investieren.Remune hat bisher
keinen Erfolg gebracht und wird es auch nicht.Ich halte eine
Zulassung in Nordamerika und Europa für ausgeschlossen zumal einige
andere Firmen möglicherweise bessere Medikamente in der Pipeline haben.
Auch die Finanzanlage ist als schwierig zu betrachten.Das Geld
reicht nicht mehr lange.

[Donkosak]

Sehr gespalten die Meinungen.Bin mal gespannt was kommen wird.

Auf den Yahooseiten spricht man von Montag oder Dienstag.

Bis dann Donkosak

[BII-Aktionär]

@Bombenleger:

habe auch nicht mehr das always-super-gefühl, das ich mal bei immune hatte. hab jetzt MAGNA-LAB gekauft, leider geht der Kurs langsam aber sicher gegen süden. aber das kommt schon noch, sobald die ersten Produkte abgesetzt sind. :-)

und ein anderer heisser Kanditat habe ich auch noch im Visier: TMRO (Termo-Elastic-Technologies), jetzt bei 0.17$. Da greif ich auch noch zu. lohnt sich, die firma genauer zu betrachten, sind alles Juden in der Geschäftsleitung, die wissen, wie`s Business läuft. LOL. (Achtung: IST Keine Diskriminierung, sondern als Kompliment gemeint!)

[oski]

Bll
kannst du mir noch mehr über deine heissen Tips erzählen???

[BII-Aktionär]

.

[BII-Aktionär]

falsche taste.. :-)

@oski, was meinst du denn jetzt genau? TMRO oder Magna-Lab?

[oski]

Bll
beides Die lieben Juden wissen wie man Geld ortet
und bei IMNR könnte es sich lohnen

[BII-Aktionär]

@oski,

dann musst du mal im TMRO und im Magna-Lab Thread posten, da werde ich dir die fragen beantworten, wenn ich kann...

[oski]

Hallo Börsianer jetzt wirds spannend es wird klappen

[shy steven]

was ist los?

Erst rennen alle dem SWR3-Boersenman hinterher, und jetzt beachtet keiner seinen stop-loss bei 1,50....

Ich bin enttäuscht....

[shy steven]

sorry, falsche Baustelle...

ich dachte, ich wäre bei IQ Power....

[BII-Aktionär]

@Kursfuzzi,

hast du Magna-lab (Magla) gekauft? War ein guter deal. Innert 2 Tagen von 0.42 auf 0.56 (+ 30%). Erwarte über 1$ innert Jahresfrist..

[oski]

WAAAAAAAAAAAAAAAAANNNNNNNNNNNNNNNNNN????????????????????????????????????????????????????????????????????????????????????

[BII-Aktionär]

@oski:

etwa 2 tage bevor ich das geschrieben habe (ca. 23. Juni).
Jetzt halt wieder runtergekommen auf 0.48. aber keine Panik: bei kleinen umsätzen. Gesunde Konsolidierung wie bei Immune jetzt.

[Kursfuzzi]

@BII-Aktionär,
entschuldige, mach im Moment auf Kostolany,
Exodus und C1 haben mich geschafft. Mann o Mann
Ich buddel mich jetzt ein.
Magla hab ich leider nicht gekauft.
Den kleinen flüssigen Rest hab ich in PPHM angelegt.
Bei 2,1€ Einstieg und jetzt bei 2,9-3€ auch nicht schlecht.
Hoffe hier auf mehr.
Jedenfalls sind die Umsätze bei PPHM im Moment sehr gut.
Auch ein paar gute News. Scheint sich zu entwickeln.
Ich hab schon so viele kleine Firmen, auch Fonx ja, die haben mir meine erstes Magengeschwür und dann guten Gewinn gebracht.
Denke bei Magla.Ob sind immer noch Einstiegschancen da.
Toi toi
Fuzzi
(ganz schön down und klamm, schit exds)
Entschuldige mußte einfach mal raus.

[BII-Aktionär]

@kursfuzzi:

wieso macht dir Commerce one sorgen? die haben sich ja innert wenigen tagen von 3.2$ auf 6 dollar erholt! kann doch nicht so schlimm sein oder? C1 hatte ich auch im auge bei 3.7. jetzt will ich aber nicht mehr einsteigen, habe andere sachen im köcher. ausserdem hab ich bei immune aufgerüstet.. :-)

[BII-Aktionär]

@nochmals Kursfuzzi;

was ist eigentlich exodus? Bei dem Namen muss man sich ja nicht wundern, dass da etwas schiefläuft (kleiner scherz ;:-))

Morgen Feiertag in den USA, na dann: gute Nacht und träumt süss.

Immune 4.83 (+ 6.6%). Nicht schlecht Herr Specht..

[BII-Aktionär]

story ist vorbei...shit.

zum glück hab ich noch magna-labs gekauft. schon bei 0.58$! :-)

mit immune hab ich mir jetzt bös die finger verbrannt...

[oski]

Bll
Leider verloren aber es geht weiter Magna ist es noch Zeit einzusteigen hast du eine begründung und bei
imnr wie geht es weiter

[BII-Aktionär]

@oski:

also bei magna-lab hab ich keinen schimmer warum die bei der miserablen Nasdaq-verfassung steigen. ich bin jedenfalls seit 0.47 an bord. ich weiss nicht was da los ist. ich bin jedenfalls positiv gestimmt. News gibts keine.

@immune:
Pfizer weiss etwas was wir nicht wissen, nächste woche werden resultate in argentinien gezeigt. sieht nicht gut aus. ich jedenfalls steige am montag aus. zum glück geht der kurs wieder leicht nach oben, ich würd sagen rein technisch bedingt, da auch die volumen dünner werden. ich habe kein vertrauen mehr in die firma. könnte sein, dass trotzdem noch eine Thailand-Zulassung kommt, aber an eine US- und Europa-Zulassung glaube ich nicht mehr. Warum steigt Pfizer aus? pfizer glaubt auch nicht mehr an eine zulassung. Höchstens der Thailand-Markt könnte kommen. Das wichtigste: Immune braucht dringend Geld, und jetzt bekommen sie keines mehr von Pfizer. das ist eine Katastrophe! Entweder es werden mehr Aktien ausgegeben (Verwässerung) oder immune wird aufgekauft. Immune braucht dringend einen neuen Partner!! ich habe keine nerven mehr; deshalb geh ich raus.
wenigstens sind die amis noch zuversichtlich:

This is a pretty ugly period once again and in the spirit of providing some much needed glimmer of light, I present the hypothetical conversation below... no investment decisions should be made based on any of this info... is that enough caveats?

======================
Spoke to company this morning and this is what I was told:

News came as surprise last night

Company remains optimistic over financing, suggesting several alternatives have already been presented

No reason was given by AG/PFE for departure

Some comments/speculation that all of the former REMUNE champions at AG/WLA have since departed, perhaps contributed

Company remains confident of completing it`s mission to bring REMUNE to market

Cruz will be presenting Spain data in Argentina next week on Thursday and will be accompanied by Carlo & Moss

Comment was "Look at what is presented on Thursday and THEN tell me if you think PFE made the right decision" ...this was said with a good amount of emotion

At this point it is difficult to put a positive spin on todays news... actually impossible

[oski]

Bll
Danke für deine Auskunft du bist sehr Informativ
Caly ist hoffentlich ein guter Wert werde aufrüsten
Gruss Oski

[Forum]

Immune ist doch keine Ein-Produkt-AG !

[oski]

Forum
Morgen weist du was neues über IMNR

[Forum]

@oski

Das stell mir mal ins Postfach !

Danke !!

[BII-Aktionär]

@Forum: DOCH! Immune IST eine Einproduktfirma! Immune hat für 7 Monate Cash (12 Mio-Dollar). Remune war gedacht als Cash-Bringer für die Entwicklung der anderen Medikamente. Remune ist als einziges in Phase III. Alle anderen Medikamente sind in Phase II oder I. Es würde Jahre dauern, bis diese Medikamente zugelassen würden.

Hier noch ein interessanter artikel in der NY-Times:


Lack of Financing May End Trial of an AIDS Vaccine

By ANDREW POLLACK





OS ANGELES, July 8 — Jonas Salk died in 1995, but executives say his spirit lives at the Immune Response Corporation. The company was started by Dr. Salk to conquer AIDS with a vaccine, just as he had done for polio.

But Dr. Salk`s final quest is in danger of failing. After more than a decade of testing, Immune Response has not produced convincing evidence that its AIDS vaccine, known as Remune, helps patients.

And on Friday, the pharmaceutical company Pfizer Inc. delivered a possibly crippling blow, saying that it was pulling out of its partnership with Immune Response to develop Remune after it had reviewed results from a clinical trial.

The decision could mean an end to the clinical trial Pfizer was conducting, a trial that represented the best hope of proving that the drug works.

Immune Response will take over the trial, but it was unclear how it will pay for it. The company has only about $12 million in cash, executives said on Friday, enough for six months. Immune Response is close to raising more money, these executives said, but Pfizer`s no-confidence vote could make potential investors balk.

"This came out of the blue," said Dr. Ronald B. Moss, Immune Response`s vice president for medical and scientific affairs. Mr. Moss said he was puzzled by Pfizer`s move because data will be presented on Wednesday at an AIDS conference in Argentina that will suggest that Remune can be effective.

Pfizer had already paid $47 million to Immune Response and could have paid up to $30 million more. It appears Pfizer was less committed to the drug than Agouron Pharmaceuticals, the biotechnology company that initially signed the deal with Immune Response in 1998. Agouron was later acquired by Warner-Lambert, which in turn was bought by Pfizer.

Shares of Immune Response plunged 44 percent on Friday, down $2.01, to $2.58.

"I don`t know where they go from here," said John T. McCamant, editor of the Medical Technology Stock Letter in Berkeley, Calif. Remune was "old technology," Mr. McCamant said, that had been surpassed by other approaches to AIDS vaccines.....

[BII-Aktionär]

So newer trials looked to see whether Remune can suppress levels of the virus in the blood. But the company announced on June 1 that a trial in Spain found Remune no better than the placebo. The company argues that the vaccine worked in a subset of patients with stronger immune systems, and it will present data on this in Argentina. Some doctors testing Remune say further trials are warranted but, with Pfizer`s pullback, might not happen.

"A potentially good vaccine may not be adequately tested, and it deserves to be," said Dr. Eric S. Rosenberg, an instructor at Harvard Medical School. Dr. Fred T. Valentine, a professor of medicine at New York University, said Pfizer was "very foolish" to abandon the drug.

Still, even if reaches the market, it is clear that Remune will be just one drug in an arsenal and will not have the effect the polio vaccine had.

Dr. Carlo, a pharmaceutical industry executive who help start Immune Response, seems to care deeply about making Remune Dr. Salk`s final legacy. In the corporate lobby hangs a lithograph given to Dr. Carlo by Dr. Salk and his wife, Francoise Gilot, the artist who painted it. There are inspirational sayings from Dr. Salk hanging on the walls, like one calling for people to "optimize and not compromise."

Recently, a killed polio vaccine has come back into use in the United States because the live virus vaccine presents a tiny risk of giving people the disease. Dr. Carlo sees that as a vindication of Dr. Salk`s approach and predicts similar vindication for Remune.

Dr. Carlo said that when the company was started, Dr. Salk told him, "If we`re right, they`ll never forgive you for being right."

He added, "They never forgave Jonas, even till the day he died...

[BII-Aktionär]

sorry, dieser Text gehört an 2. stelle:

But Immune Response executives insisted they were near the goal line and would not give up. After all, they said, Dr. Salk never did.

"If Jonas felt he was right, he did not accept no for an answer," Dr. Dennis J. Carlo, the company`s chief executive, said in an interview last month at Immune Response`s headquarters in Carlsbad, Calif. Dr. Carlo was traveling to Argentina on Friday and could not be reached for comment.

While Dr. Salk was a hero to the public, he was often derided by fellow scientists. Many said his polio vaccine, based on a killed virus, would never work. Then, after it was shown to work in 1955, they said he had done mere "kitchen chemistry," not creative science. They pointed to the fact that the Salk vaccine was supplanted a few years later by the Sabin oral vaccine, which used a live but weakened virus. Many scientists also resented the acclaim that Dr. Salk received, accusing him of grandstanding.

Similar controversy has surrounded Immune Response ever since Dr. Salk, already in his 70`s, came out of retirement to start the company in 1987.

Many scientists said that Dr. Salk`s AIDS vaccine, also based on a killed virus, would not work. Remune was not intended to prevent disease, as most vaccines do, but stimulate the patient`s immune system to keep the virus in check after the patient was infected. To do this, Dr. Salk argued, the vaccine should stimulate not antibodies, as most vaccines do, but T-cells, which kill cells infected with a virus.

Stimulating T-cells and using vaccines for therapy rather than prevention are widely accepted concepts. But many scientists doubt that a killed virus vaccine is the best way to achieve those goals. While some studies have indicated Remune does provoke an immune response, it has not been shown that this helps patients. And Dr. Salk and his company have been accused of exaggerating Remune`s effectiveness.

The Food and Drug Administration warned the company in 1995 not to manipulate data to show positive results. Last year, university scientists charged the company with trying to squelch publication of their scientific paper describing a clinical trial that failed. The company said it wanted the paper to include a chart that suggested Remune had some effectiveness, but the lead authors of the paper said the chart was based on spurious analysis.

That trial, on more than 2,500 patients, failed to show that Remune improved survival or lengthened the time before H.I.V. infection progressed to AIDS. But the trial took place just as new AIDS drugs were coming into use that vastly improved survival of patients. That, the company argued, made it nearly impossible for Remune to show a benefit over the placebo.

[Forum]

Falls kein frisches Geld kommt, sieht es wohl finster aus.

Ob das Thema Remune wirklich endgültig vom Tisch ist ???

[Die Stimme]

sieht leider so aus schade heute wieder 800€ verbrannt, gehe endgültig raus und in Kretztechnik rein

[Die Stimme]

hallo weiß jemand was, der wert steigt wieder langsam

[BII-Aktionär]

@die Stimme:

Die stimmung hellt sich langsam wieder auf. Aber von Entwarnung ist noch keine Rede. Die nächsten Tage sind entscheidend. Am Mittwoch/Donnerstag finden Präsentationen der spanien-Studie auf der Welt-Aids-Konferenz in Argentinien statt. Dort wird Remune intensiv auseinandergenommen, d.h. die Details der Studien vorgestellt. Es hängt viel von dieser Präsentation ab.

Das Wichtigste: Trinity (Vertriebspartner für Remune in Thailand) reicht in diesen Tagen den Thailändischen Behörden das Gesuch um Zulassung ein! Wenn diese Zulassung kommt würde endlich Geld fliessen. Ich glaube zwar nicht mehr an eine US und Europa-Zulassung, da wahrscheinlich strengere Kriterien herrschen, aber was solls: dann wirds halt ne 3.-Welt-Medikament.

Falls keine Thailand-Zulassung: Goodbye Remune, Bye-Bye Immune, Traum vorbei, Kursziel 1$ oder weniger.

Ich hoffe, die Thailändischen Behörden stellen sich nicht quer. Könnte aber leider so sein. In so einem Falle würden in Thailand ein paar Milliönchen Thai-Baht Schmiergelder Wunder erwirken! OUUPS! Hab ich das etwa gesagt? Tschuldigung, nur so ein Gedanke :-) Soweit wirds hoffentlich nicht kommen. Wäre ja auch das Ende von Immune.

Viel Spass noch

[Forum]

Das Ende sehe ich keinesfalls, da im Negativfall vermutlich
weitere Gelder beschafft werden können.

[Die Stimme]

danke für die gute info

[Forum]

Sehen die Amis wohl genauso !!

Da ist noch was drin, jedoch nicht mehr das, was ich mir ausgerechnet habe !

[BII-Aktionär]

Trinity Medical Group USA Announces Study Indicating No HIV Mutation Found in Patients Treated With REMUNE(TM) Up to 144 Weeks

RANCHO SANTA MARGARITA, Calif., July 11 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announces the presentation of clinical studies showing that random genotype testing in patients using its immune-based therapy for HIV, REMUNE(TM), did not experience mutation of the virus. After 144 weeks, the study found that the genotyping utilizing nucleic acid sequencing techniques of 1,200 basepairs suggest no mutation of the virus that confers resistance and no evidence of a rapid and significant overgrowth in HIV-1 drug resistant strains. Dr. Wasun Chantratita, a Virologist with the Ramathibodi Hospital at Mahidol University in Bangkok Thailand, had previously found that patients using other antiretroviral drugs developed virus of different genotyping within three to four months of using those treatments. Changes in genotyping indicates mutation of the virus that correlates with build up of resistance to the treatment and can even lead to resistance to other anti-viral drugs.

"In patients using REMUNE as the only therapy, we see no changes in the makeup of the virus after 144 weeks of study," says Dr. Chantratita. He also said, "this is the first treatment we have seen that confers no buildup of resistance to HIV."

The HIV-1 pol gene was chosen for sequence analysis. Sequencing of pol gene region not only enables the determination of the distribution pattern of HIV, but also allows pattern monitoring of resistant mutation to nucleoside reverse transcriptase inhibitors, non nucleoside reverse transcriptase inhibitors and protease inhibitors, according to Dr. Chantratita.

The results of the study were presented today (July 11, 2001) at the First International Aids Society Conference on HIV Pathogenesis and Treatment held in Buenos Aires, Argentina.

Dr. Chantratita`s presentation indicates the method for detecting HIV mutations is in routine use in his unit. He provides recommendations for HIV genotyping for patients undergoing anti-viral therapy.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized

[BII-Aktionär]

so, die Rally kann beginnen...! :-))
Siehe SUPER-NEWS Thread "Schlechte Neuigkeiten für Immune". Ok, ich weiss, falscher Thread aber dieser war mir zu lange... :-)
Heute kaufe ich schon zum 3. Mal nach... Wetten dass?.. :-)

[Marmay200]

hallo bll-aktionär wo finde ich den die SUPER-NEWS Thread "Schlechte Neuigkeiten für Immune"? Für ne schnelle antwort wäre ich doch recht dankbar.
Marmay200

[Heul]

Anbei - mfG

Press Release Issued July 11, 2001 5:14:00 PM ET
New Virological Findings From Phase II Clinical Trial of REMUNE(TM) Presented at the 1st International AIDS Society Conference On HIV Pathogenesis and Treatment

Full text of this press release available at:
http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=no&T…


-----------------------------------

Additional investor information is available at:
http://199.230.26.96/imnr


Thank you for your interest,
Immune Response Corporation

Please Note: The above hyperlink(s) may not retrieve the
web page if the address extends to more than one line.
If this should occur, please copy the full text of the
address and paste it into the address box in your web browser.
Do not reply to this email.

[BII-Aktionär]

ist grad drunter: "Immune Response - Schlechte News" heisst er. von flotsam und jetsam.

Bin froh, dass frankfurt noch nicht reagiert hat! LOL
Habe um 10.00 Uhr 3000 Stück zusätzlich gekauft... :-))))

Hat denn niemand von euch es gelesen?

"differences showing a significant effect of REMUNE
(Hazard Ratio = 0.63, p= 0.036) on time to virologic failure" !!!!!!

Verdammt nochmal (tschuldigung) 0.036!!!! D.h. das Medikament wirkt! und wie!

Jetzt muss nur noch die Finanzfrage geklärt werden. Aber das wird hoffentlich kein Problem darstellen.

Pfizer: Hast du wieder Lust bekommen? LOL
Diesmal wollen wir dich aber nicht... nochmals LOL
Wir gehen diesmal zu Roche oder Novartis. Die Schweizer sind viel lieber als die Amis.
Oder Pfizer: Mit anderen Konditionen (ursprünglich 50:50) z.B. 90 für uns und 10 für dich, können wir noch drüber reden.... :-))))

Ich kann es immer noch nicht verstehen, warum Pfizer abgesprungen ist, kurz vor dem Ziel.... oje...

Grüsse von einem noch nie so Optimistischen BII-Aktionär...

[Lima2000]

Hi BII,
wieder vereint in alter Runde.Hab jetzt auch nochmals
nachgekauft.Schau mer mal!!
Die Ramblas warten!!
Diesmal klappts!!
Lima

[Die Stimme]

mensch da drücken wir mal die daumen für immuni
habe allerdings noch ein fettes minus

[Mr.Latest]

Frage in die Runde:

Welche News müssen eigentich noch kommen, damit IMMUNI endlich wieder zu den alten Ständen zurückkehrt???

Wisst Ihr, was an Tests u.ä. npch aussteht und wann die entsprechenden Ergebnisse bzw. News kommen???

Danke für rasche Antwort!

[ChristlH]

Ich weiss nur, dass bald Q2-Zahlen kommen, die wohl so ziemlich alles entscheiden werden.

[ChristlH]

So wie ich das sehe, ist IMMUNI ein klarer Übernahmekandidat. Wenn nicht ein Wunder geschieht, werden die bis Ende des Jahres aufgekauft oder pleite sein.

Ich hoffe, die Zahlen belehren mich eines besseren, aber glauben tu ich nicht mehr drann.

[Kurumba]

die aktie nervt

[Die Stimme]

leider, aber zuviel verlust zum abstoßen

[Kursfuzzi]

Was ist Börse??
Sepulation?
richtig!!!!
Es nervt? Dann lass die Finger davon.
Leg Dein Geld aufs Sparbuch, das nervt nicht,
höchstens wenn die Börse mal wieder mehr bringt wie das Sparbuch.
Welche Aktie nervt im Moment nicht??
Sicher gibts einige davon, kennst Du die??
hast Du die??
Ja?, dann haste richtig SPEKULIERT!!!
mfg
Fuzzi

[Kurumba]

ja,hab ich, USG und BIOLASE TECHNOLOGY

[Kursfuzzi]

Gratuliere,
Biolase hatte ich auch schon.
Hab nur nicht lange genug gewartet,
bzw. die Geduld verloren. Leider, wie mit Nastech auch,
auch mit kl. Gewinn verkauft.
Richer war gut, nur nicht lange genug gehalten.
Verzockt. Amen
Fuzzi

[Kurumba]

sorry, angeben kann ich nicht, habe schon genug verloren in den letzten Wochen. Kennst du biolabs? Läuft auch gut , die können durch bluttests mammographie machen.

[Die Stimme]

kennt jemand biopulse ?

[Mr.Latest]

Wo laufen wir denn hin??? Ich glaube in Richtung alte Tiefststände. Ich werde morgen 3/4 meiner Immunis verkaufen.

Gruß Latest

[Die Stimme]

schau dir mal die stücke an, ein witz

halten

ich sitz auf minus 47%, und warte auch

[Mr.Latest]

Klar sind die Stückzahlen klein, aber die Richtung ist das Wesentliche. Es nützt uns allen nichts, wenn nur wenige bereit sind, zu so niedrigen Kursen zu verkaufen, wenn es noch weniger gibt, die welche haben wollen.

Ich frage mich wirklich, was da in nächster Zeit noch kommen soll, das dem Kurs hilft. Ohne News fällt der Kurs, mit schlechten sowieso und gute scheinen ihm auch nicht lange zu helfen.

Die Hoffnung stirbt zuletzt... noch hoffe ich!

Gruß Latest

[pungnee]

$ bills are burnable.hier wird von antiaidsvirengequasselt, dabei handelt es sich um (vagabundierende,mutativ veränderte genome).schwierige sache.wer den jackpot knackt,freut sich (so meine ich zu früh),never give up hope.mutative veränderungen unserer dns sind wahrscheinlich beliebte aufgabengebiete unserer defence alliance.ich hoffe mir haut keiner aufs maul.mfg ede

[pungnee]

$ bills are burnable.hier wird von antiaidsvirengequasselt, dabei handelt es sich um (vagabundierende,mutativ veränderte genome).schwierige sache.wer den jackpot knackt,freut sich (so meine ich zu früh),never give up hope.mutative veränderungen unserer dns sind wahrscheinlich beliebte aufgabengebiete unserer defence alliance.ich hoffe mir haut keiner aufs maul.mfg ede

[Geonimo]

Hört sich ja nicht so gut an,

Denke bei 1,5 Dollar wirds wieder interresant!

[Mr.Latest]

Oh Lord ... let money fall from the sky !!!

[pungnee]

irgrnd was neues von immuni?pressekonferenz,thais bestochen oder warum legen die 8% im kurs hin? mfg ede

[biologist]

Weiß jemand zufällig, warum Immune Response heute schon um 12,50 % zugelegt hat? Irgendwelche neuen Infos? Bin gestern wieder bei € 2,40 eingestiegen! Was hat es mit den "Class Action Lawsuits" oder "Class Periods" bzgl. Immune auf sich?
Wäre schön, wenn wir noch einmal zu alten Höhen kämen!

Gruß

biologist

[Mr.Latest]

das war mal wieder der berühmte satz mit X!!!

Scheiße

Gruß Latest

[Nussel]

Wednesday July 25, 7:01 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Intends to Vigorously Defend Lawsuits
CARLSBAD, Calif., July 25 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it will vigorously defend several lawsuits filed in the U.S. District Court for the Southern District of California accusing the Company and certain of its officers of violating securities laws.

The suits allege violations of federal securities laws in connection with disclosures regarding clinical trials of REMUNE(TM) (HIV-1 Immunogen), the Company`s investigational immune-based therapy, during the period from May 31, 1999 to July 6, 2001. The suits seek damages on behalf of an alleged class of investors who purchased publicly traded securities of the Company during that period.

The Company said the suits are without merit and that it will vigorously defend the lawsuits.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: Company information can also be located on the Internet Web site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether clinical trials will be successfully concluded, whether REMUNE will be approved for marketing or be successfully commercialized, and whether or not the Company will be able to successfully defend against these lawsuits. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000 and subsequent Form 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation

[Mr.Latest]

Ich bin zwar des Englischen halbwegs mächtig, aber aus der -meldung werde ich nicht so richtig schlau. Bitte klärt mich auf!

Dank und Gruß Latest

[Die Stimme]

leider kapier ich das auch nicht so richtig, irgendwas mit gerichtsvorlagen gegen angestellte wegen geheimissverletzung ??

der rest ist eigentlich doch alt ??

[bobysmith]

leider bin ich auch nicht in der lage alles zu übersetzen, aber das ist sicherlich nicht auslöser für die kursschwäche. vielleicht könnte aber mal jemand mögliche konsequenzen aus den angekündigten klagen ableiten?

danke

b.s.

[boerseaugsburg]

aus dem raging bull:


Positive News being Presented July 26, in Thailand CONFERENCE PRESENTATIONS


D A T E
CONFERENCE / ABSTRACT TITLE


26 July 2001
HIV Vaccines - An Annual Update 2001
Siam City Hotel, Bangkok, Thailand

Remune Clinical Trials in the USA, Dr. Ronald B. Moss

European (Spain) Study STIR - 2102, Dr. Fernandez-Cruz

Remune Clinical Trials in Thailand, Dr. Vina Churdboonchart

Remune and Genotypic Assay, Dr. Wasun Chantratita

Remune Monotherapy and CD4+ Cells, Dr. Wisut Sukeepaisarncharoen

[biologist]

Interpretation von Beitrag #209:

Einige Anwaltskanzleien streben einen Rechtsstreit gegen führende Mitarbeiter von Immune Response wegen möglicher Verstöße gegen US-Bundesgesetze, sowie Enthüllungen in Bezug der klinischen Remune-Testphasen an.
Dem Kurs der Aktie schadet dieses nicht, da solche Prozesse in den USA in Mengen stattfinden. Genauso wenig tut sich dann was, wenn solche Rechtsstreitereien beigelegt werden.
Immune Response widerspricht diesen Anschuldigen und wird sich energisch gegen diese Vorwürfe verteidigen.

Einen interessanten Beitrag habe ich vor ca. 2 Wochen auf dem Yahoo-Message-Board gefunden. Hier behauptete ein HIV-Patient, der an den Testphasen von Remune beteiligt war, daß die widersprüchlichen Ergebnisse über die Wirksamkeit des Medikamentes aus der Beibehaltung der ursprünglichen Behandlung herrühren. Das soll heißen, daß viele HIV-Patienten offensichtlich nicht bereit sind, ihre bisherige Medikamentierung abzusetzen. Die Person brachte noch einen sehr treffendes Beispiel hierfür: Man stelle sich vor jemand erfinde einen neuartigen Feuerlöscher, wobei gleichzeitig noch ein Eimer voll Wasser vorhanden ist. Jetzt bricht ein Feuerchen aus und statt sofort den neuen Feurlöscher auszuprobieren, wird erst einmal der Eimer Wasser über das Feuer gekippt, der dieses löscht. Danach wird der neue Feuerlöscher eingesetzt. Das Resultat: Keine Wirkung beobachtbar!
Der Autor verwies darauf, daß er seit mehreren Jahren bereits mit Remune behandelt wird und seit dem keine Verschlimmerung seines Zustandes eingetreten, eine Resistenz oder Mutierung seines HIV-Typs zu beobachten ist!

Leider kann ich diesmal, entgegen meiner Gewohnheit, für diesen Beitrag keine Quelle präsentieren, da die Zahl der Beiträge auf diesem Board sehr hoch ist. Ihr müßt also selber mal suchen - Sorry!

Gruß an alle Immune-Fans

Biologist

[Die Stimme]

@biologist

danke für die übersetzung und beurteilung, könntest du bitte mal bei caly vorbeischauen, ich arbeite gerade an einer lösung der finanzprobleme, bin aber aus dem marketing bereich und brauche jemanden mit einer roten liste

[boerseaugsburg]

http://www.bangkokpost.com/today/280701_News15.html

More study needed for HIV vaccine
Available data not enough to judge it


Aphaluck Bhatiasevi


Further research is needed on Remune, the HIV/Aids therapeutic candidate vaccine being tested in Thailand, UNAids vaccine expert Jose Esparza said yesterday.

"Only research will answer the question, not political argument or statistical analysis," said Dr Esparza, adding that available data was not good enough to say "this is it" and not bad enough to say "just drop it." Dr Esparza made the comment after hearing about the HIV-1 Immunogen vaccine marketed as Remune by US-based Immune Response Corporation, at an international conference updating research on HIV vaccines, held in Bangkok.

The data was still marginal and strict protocols were needed to give the answer. Despite an ongoing extended phase-II study on 297 HIV-positive people nationwide, Veena Churdboonchart, of Trinity Medical Group, said her team had proposed going ahead with the phase-III trial, both as a vaccine and as a drug.

The proposal has gone before the ethical sub-committee considering vaccine trials on humans.

The extended phase-II trial of the candidate vaccine, expected to yield results by August 2003, is being held at Vajira Medical College, Phra Mongkutklao hospital, Chiang Mai University hospital, Khon Kaen University hospital and Prince of Songkhla University hospital. The therapeutic vaccine has undergone phase-I safety and phase-II immunogenicity trials in Thailand, but given problems with interpreting results obtained in the second phase, the sub-committee decided to wait for results of the phase-II study before going any further. Most members resigned and the proposal for a further trial is before a new sub-committee chaired by Medical Services Department head Seri Tuchinda. Mrs Veena said her candidate vaccine showed positive results and deserved further research.

Soyeon Kim, a biostatistician from the Harvard School of Public Health who was removed from the team looking at the Remune results, said she was concerned about "selective reporting" in presentation of the candidate vaccine. "It was found that there wasn`t a significant effect." Data needed to be revised. While several Aids scientists raised concerns about the statistical theory used in interpreting results, Mrs Veena insisted that her study had resulted in more people with increased CD4 cell counts than those whose CD4 cells fell. "A significant difference was noted in the changes in CD4 cell counts that favoured the HIV-1 Immunogen-treated group compared to those for the adjuvant-related control group," she said. On average, CD4 cell counts increased by 84 cells by the 40th week, whereas the increase for the control group was 38 cells during the same period, said Mrs Veena. Another matter still undecided was how ethical and appropriate it was to use Remune alone, said Dr Esparza.

He said it would be difficult to see the use of Remune as a monotherapy, just because it was cheap.

"If we have to spend some more years on the trial, we should do so rather than rush into conclusions," he said. Wisut Sukeepaisarncharoen, of Khon Kaen University, who is also the principal investigator of Remune here, accepted at the conference that Remune alone would not cure HIV/Aids. "Remune alone couldn`t cure the disease. If we want to cure the disease, we may have to use other methods like drug combinations," he said.

The trial of the candidate vaccine in Spain also involves the use of anti-retroviral drugs. Dr Esparza said that to confirm that a substance is effective, clear information was needed. "In this case, the information is not clear enough. As a doctor, what worries me is that the decision for treatment depends on statistical analysis. I think decisions can`t be mathematical because we`re talking about human life. We need more data," he said. He said for a disease like HIV/Aids, one has to be patient because sometimes the difference in a person`s health appears only several years on, and then the difference might be modest.

[Die Stimme]

hui das verheißt nichts gutes

[BII-Aktionär]

Die Wahrheit über Pfizer/Remune? Konnte es noch nicht durchlesen aber die Amis sind aus dem Häuschen...

Teil1

* Date: Fri, 6 Jul 2001 17:13:42 EDT
To: [e-mail]
Subject: PFIZER TO ABANDON REMUNE
From David Scondras at [e-mail]
Tel is 617 266 0735 organization: Search For A Cure
See also related New York Times article

I will not be ready to write an article in depth on this issue until I finish researching the Spanish data on their large multiyear time to failure trial of Remune, along with speaking with the staticians who have worked on this data, some of whom feel it is significant and others who feel it is not. I also want to speak with many key researchers across the country who are involved in one or another trial using Remune.
Until then I felt it important to share with you what I know in this less formal fashion.
Although as of this communication no formal statement or press release has been issued by Agouron ( Pfizer ), a series of articles at the Yahoo.com financial site under the code for Pfizer (PEF) indicates that the drug giant will no longer pursue the many trials of Remune which are underway. According to a spokesperson at Agouron, there are "negotiations" going on for an "orderly transition" to whatever future there is for these trials. I believe these " negotiations" are going on with IRC, the Immune Response Corporation that makes Remune.
Conversations are ongoing with key clinical researchers who have trials involving Remune. Among those with such trials are: Bruce Walker of the Massachusetts General Hospital who is conducting an STI trial blinded to Remune to see if the acquisition of HIV specific immune reactions to the antigen increase the amount of time that a person can be off drug and remain below a predetermined viral load, Fred Valentine of New York University who has an ACTG approved trial involving STI`s, and many investigators participating in the large `202` trial with some 450 participants that is presently structured as a time to failure trial.
It is not clear what will happen to those who are presently in these trials. Originally these trials were being funded by the Agouron Corporation. After being acquired by Pfizer, a review of all aspects of Agouron was undertaken. The decision to abandon Remune was made after looking at a series of trials, including the yet to be released data from a Spanish time to failure trial.

[BII-Aktionär]

Teil2

It is not clear what will happen to those who are presently in these trials. Originally these trials were being funded by the Agouron Corporation. After being acquired by Pfizer, a review of all aspects of Agouron was undertaken. The decision to abandon Remune was made after looking at a series of trials, including the yet to be released data from a Spanish time to failure trial.
It is also not clear why the decision to stop was made prior to meetings with community leaders and before data from the Spanish trial was made available. A second round of DSMB meetings about this trial will occur later in the month, and the data from the trial and its analysis will be presented at the International AIDS Society`s meeting in Buenos Aires, Argentina on July 11th. There are clearlly differences of opinion with regard interpretation of the data from this ( and other) trial(s).
I will be speaking with an Agouron statistician ( Glen Andrews) next week regarding the Spanish data. Clearly while nobody wants trials of products that will have no effect on HIV, it is also important to make sure that trials that may establish a proof of concept are not abandoned by companies that have committed themselves to reaching scientific closure on issues critical to the development of therapies for AIDS. In this case, we all need to know in great detail why Pfizer dropped the trials. Unless it is overwhelmingly clear that Remune has no effect, dropping the trials prior to their conclusion is premature, and it is incumbent upon Pfizer to show us that they dropped support for scientific reasons, not for financial reasons.

[BII-Aktionär]

t3:

To the world community, establishing that re establishing HIV specific functioning of cells that are part of the natural immune response against a pathogen is critical, and trials of any product that might be able to show this possibility are important. For this reason, Pfizer needs to present compelling reasons for curtailing these trials, as their action has effects and implications vis a vis the development of similar efforts and products. Merck, for example, is planning to use its DNA vaccine in an STI trial here in Boston. How Pfizer`s decision might affect them will be important to assess.
Finally, the many people who have been participating in these trials need to be able to reach closure. Here in Boston several people I know are in STI trials with Remune. It`s not fair to curtail the funding of these short and relatively inexpensive trials after securing agreements with many clinicians and patients for their participation. We will all be looking carefully at how Pfizer acts with regard to these people.
I will share what information I get from Pfizer as it emerges. If you wish to speak directly with a representative from Agouron ( Pfizer ), I would suggest speaking with Denise Zolg.
* Date: Fri, 6 Jul 2001 18:29:29 EDT
From: [e-mail]
To: [e-mail]
Subject: More on Pfizer and Remune

Disturbing information has come my way regarding how Pfizer is proceeding. Dr. Bruce Walker of Massachusetts General Hospital was told by Pfizer/Agouron to stop enrollment in the controlled trial he is conducting. This trial is to see if vaccinated people after interruptions can control viral load for a longer period of time than non vaccinated people. This would be consistent with data from Pat Bucy at University of Alabama which shows a difference in viral rebound kinetics in people who are vaccinated and with data from Eric Daar of UCLA who shows a significant difference in viral set point when very early seroconverters are vaccinated.

[BII-Aktionär]

t4
The person at Pfizer who provided the "statistical" analysis which is being used to justify curtailment of the ongoing studies of Remune is Glen Andrews. I will speak with him in one week according to Denise Zolg, Corporate Communications at Agouron/Pfizer. Data from a one interruption study of Remune in 46 people will be ready in 30 days according to Agouron. This study did not use more than one interruption and looks at viral kinetics following an interruption of vaccinated vs non vaccinated individuals. When I get this data I will share it.
In addition the Spanish data from the large lengthy time to failure trial will be availble on the 11th and I will circulate that data in its official form.
I told people at Agouron that in my opinion all of the data surrounding Remune and the basis for the decision to stop the trials etc. ought be provided to the community and that a meeting to review all of this data with good statisticians present who are independent of all of the companies involved that we can feel are reasonably independent should be held.
It is a serious thing to stop a series of trials attempting to establish a proof of concept of the most significant possibility of all regarding HIV therapy--can a method of getting the body to control viremia without drugs be found?
It is interesting to note that Pfizer was apparently concerned and upset that Remune would be priced in Thailand far below what they wanted as an asking price.
I believe we need to insist upon one principle: Pfizer needs to demonstrate a rationale for curtailing these trials that is not connected with their efforts to make money off of Remune. It needs to be a scientific rationale. Absent the very data being collected especially in the STI trials, I am personally baffled on how such a rationale can be contructed.
Pfizer cannot take the position that the Immune Response Corporation which is essentially broke undertake continuation of trials which Pfizer can afford with one weeks worth of its CEO`s present salary. What I am saying is that we cannot afford a gray area here--either Pfizer knows that Remune does not work and more importantly that there is NO evidence that would translate as a proof of principle allowing us to improve the immunomodulation that led to the modest but significant result, in which case it is morally bound to show all of us that data, or it does NOT have that information in which case it is morally bound to continue the trials until that data is in hand.
To take any other course of action would be unethical.

[BII-Aktionär]

t5

This is truly appalling - another installment in the mystery of Who Killed Whole-Killed. Pfizer is attempting to squash the only data that can show whether Remune-induced helper T-cell responses can do anything, at exactly the point when results are suggesting that they can indeed help lower the viral load setpoint off drugs (the only appropriate endpoint for therapeutic vaccines, the self-serving opinions of idiotic NIH researcher H. Clifford Lane notwithstanding). If this gets stopped now, it will be another two years before you see similar data from any other therapeutic vaccine and none of the other candidates (although they do better by other criteria) will induce a helper response that`s as broad as that induced by whole-killed. Even for people that will hate Remune forever due to the Berlin conference, the basic questions of immunology that are being addressed here couldn`t be more critical.
Perhaps forming a coalition would be an idea, the way Kiyoshi did the last time this happened.


könnte sein, dass sich Pfizer bös ins eigene fleisch geschnitten hat..

[Mr.Latest]

Hallo zusammen,

wenn ich mir das so durchlese, binn ich froh, dass ich mich von dem Großteil meiner Immunis getrennt habe. Das ewige hin und her geht mir langsam auf den Geist.

Gruß Latest

[BII-Aktionär]

MARILENA: Hast du den Weg in dieses Board gefunden? LOL
Geh mal ins "USXP"-Board, dort findest du eine Ueberraschung. Doppel-LOL

[boerseaugsburg]

Monday July 30, 2:27 pm Eastern Time
Press Release
SOURCE: Trinity Medical Group USA, Inc.
Trinity Medical Group USA Announces Filing of New Drug Application For HIV Treatment, REMUNE(TM), in Thailand
RANCHO SANTA MARGARITA, Calif., July 30 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - news) today announced the filing of a New Drug Application (NDA) with the governing health authorities in Thailand for its HIV-1 Immunogen product, also known as REMUNE(TM). The NDA, which was filed by the Company`s Thai affiliates, has been submitted for the use of REMUNE as a primary treatment for Human Immunodeficiency Virus, or HIV.

The application is a detailed list of requirements that include clinical demonstration of efficacy, safety, and product purity. In addition to requirements of the Ministry of Public Health, requirements of product importation were also submitted to the Thailand Customs authorities.

Some of the application components were supplied by The Immune Response Corporation (Nasdaq: IMNR - news) of Carlsbad, California. The product has been studied for five years in human clinical studies in Thailand. REMUNE was invented by one of IMNR`s founder`s, Dr. Jonas Salk, the inventor of the first effective polio vaccine.

Long term studies conducted with REMUNE in patients with HIV in Thailand have shown it to produce beneficial increases in CD4+ cells, body weight and suppression of viral load in a majority of patients treated.

``This marks another significant milestone in our business plan. Our researchers and affiliates have accomplished a marvelous job in detailing what I believe is a rational treatment for HIV. Thailand has been a world leader in HIV education and prevention efforts for its people and perhaps soon will be the pioneer of a new paradigm of HIV treatment: stimulation of the human body`s own defenses to treat the disease,`` says Dr. James Namnath, CEO of Trinity Medical Group USA.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.

Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is currently listed on the Over the Counter Bulletin Board under the symbol TMGU. The Company`s first product in development is an Immune-Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further study in Thailand. REMUNE is a product licensed from The Immune Response Corporation of Carlsbad, California (Nasdaq: IMNR - news). REMUNE is a trademark of The Immune Response Corporation.

SOURCE: Trinity Medical Group USA, Inc.

[BII-Aktionär]

So, auf das haben wir lange gewartet. leider sind die thailändischen behörden sehr sehr langsam... :-)

Monday July 30, 2:27 pm Eastern Time
Press Release
SOURCE: Trinity Medical Group USA, Inc.
Trinity Medical Group USA Announces Filing of New Drug Application For HIV Treatment, REMUNE(TM), in Thailand
RANCHO SANTA MARGARITA, Calif., July 30 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - news) today announced the filing of a New Drug Application (NDA) with the governing health authorities in Thailand for its HIV-1 Immunogen product, also known as REMUNE(TM). The NDA, which was filed by the Company`s Thai affiliates, has been submitted for the use of REMUNE as a primary treatment for Human Immunodeficiency Virus, or HIV.

The application is a detailed list of requirements that include clinical demonstration of efficacy, safety, and product purity. In addition to requirements of the Ministry of Public Health, requirements of product importation were also submitted to the Thailand Customs authorities.

Some of the application components were supplied by The Immune Response Corporation (Nasdaq: IMNR - news) of Carlsbad, California. The product has been studied for five years in human clinical studies in Thailand. REMUNE was invented by one of IMNR`s founder`s, Dr. Jonas Salk, the inventor of the first effective polio vaccine.

Long term studies conducted with REMUNE in patients with HIV in Thailand have shown it to produce beneficial increases in CD4+ cells, body weight and suppression of viral load in a majority of patients treated.

``This marks another significant milestone in our business plan. Our researchers and affiliates have accomplished a marvelous job in detailing what I believe is a rational treatment for HIV. Thailand has been a world leader in HIV education and prevention efforts for its people and perhaps soon will be the pioneer of a new paradigm of HIV treatment: stimulation of the human body`s own defenses to treat the disease,`` says Dr. James Namnath, CEO of Trinity Medical Group USA.

[Die Stimme]

ich bin heute raus, ich wünsche allen glück

[pungnee]

möchte nur noch mal daran erinnern das dieses hiv genom ein sich ständig mutativ veränderntes genom ist (hiv 1,2..etc).wahrscheinlich der kampf mit dem drachen,dem immer wieder köpfe nachwachsen,ein Teufelszeug ,das die natur in der form nicht so schnell verändern kann.wer macht so was ? das letzte glied der evolution .angst vor der zukunft?

[pungnee]

möchte nur noch mal daran erinnern das dieses hiv genom ein sich ständig mutativ veränderntes genom ist (hiv 1,2..etc).wahrscheinlich der kampf mit dem drachen,dem immer wieder köpfe nachwachsen,ein Teufelszeug ,das die natur in der form nicht so schnell verändern kann.wer macht so was ? das letzte glied der evolution .angst vor der zukunft?

[Donkosak]

@Bll Das hatte ich auch schon gelesen finde aber nicht das das so prickelnd klingt. Bin weiter invest. und werde wenn es nochmal unter die 1,8 geht auch nochmal nachlegen. Sehe die Aktie langfristig auf Kaufen und halte am Kursziel 10,...fest. Wenn ich mir überlege das eine Epimmune in meinem Musterdepot schon über 200% hat und nicht ein Arzneistoff in der klinischen Prüfung also da kann doch was nicht stimmen. Diese IMNR hat mehr als enen Stoff in der kl.Prüfung.Gebt der Aktie Zeit das ist keine schnelle Geldmaschine.

Euer Donkosak-Grischka

[pungnee]

entschuldigt bitte das mein senf öfters 2mal auftaucht(ist unbeabsichtigt,bin wohl etwas daneben).hoffe auch das meine immuni wieder den norden sehen.donksak liegt schon richtig mit den 10€.die übrigen patente von immuni sind am markt,aber forschung kostet geld.pfitzer´s ausstieg kann ich nicht so richtig glauben,ne menge geld war im spiel.man zockt schliesslich zu ende.interner zwist bei immuni ist wohl natur der sache,die jedoch in den usa teuer werden kann.halte die leute dennoch für kompetent und achtbar.mfg ede.ps:kaufe evtl. bei unter 2€ auch nach.

[boerseaugsburg]

30.07. 23:22
Immune Response kurz vor Zulassung?

(©BörseGo - http://www.boerse-go.de)

Die Trinity Medical Group gab heute bekannt, daß man bei der Gesundheitsbehörde in Thailand ein Zulassungsgesuch für das "HIV-1 Immunogen- Product", das auch als "REMUNE(TM)" bekannt ist, eingereicht hat.

Einige Komponenten des Produktes sind von dem US-Biotechunternehmen Immune Response in Kalifornien mitentwickelt worden und in einer fünfjährigen Studie in Thailand erprobt worden. Nun könnte bald die endgültige Zulassung erfolgen.

Die Aktien von Immune Response verloren heute über 7% im Kurs auf 2,1$.

[BII-Aktionär]

"schnelle Zulassung" - LOL
Kennst du die Thailändischen Behörden? na, dann viel spass beim warten. (bin auch investiert)

[FLOTSAM_AND_JETSAM_US]

Thursday August 30, 3:00 am Eastern Time

SOURCE: The Immune Response Corporation
Data Safety Monitoring Board Finds Primary Endpoint Met From Phase II Clinical Trial of REMUNE(R)

CARLSBAD, Calif., Aug. 30 /PRNewswire/ -- As announced by The Immune Response Corporation (Nasdaq: IMNR - news) on July 11, 2001, it was anticipated that the independent Data Safety Monitoring Board (DSMB) would be meeting again to evaluate the results of the Phase II clinical trial (STIR 2102) completed in Spain with REMUNE® (HIV-1 Immunogen), an investigational immune-based therapy to treat HIV infection, in light of data as reported by Dr. Eduardo Fernandez-Cruz, the principal investigator of the trial.

The DSMB met recently to review the final analysis of the STIR 2102 trial as defined by the statistical plan of the trial protocol. The DSMB has advised that the analysis first reported by the DSMB and announced by the Company on June 1, 2001, was insufficient, as it only included the treatment time, but not the complete follow up time of all patients, and did not include the intent-to-treat analysis. In addition, at its recent meeting, the DSMB, among other things, reviewed the reports of the three outside statisticians engaged by the Company, with the DSMB`s concurrence, to independently review the data and noted that these statisticians concurred that the most appropriate primary analysis was the Cox regression model stratified by baseline viral load in an intent-to-treat analysis.

After reviewing the data provided by the STIR 2102 protocol and the reports and views of the protocol statistician and the three outside statisticians, the DSMB expressed its view that REMUNE shows a positive impact on controlling virus and the study had met its primary endpoint (p=0.034).

As previously announced on July 11, 2001, the results of the study were presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment in Buenos Aires, Argentina. The results were analyzed by Dr. Fernandez-Cruz and the protocol statistician, the Company and the three outside statisticians using the intent-to-treat principle. Statistical analyses included the information from patients in both the treatment phase (patients who remained on stable ART [AZT plus ddI] treatment) and the follow-up phase (patients who switched from ART treatment to a three-drug HAART regimen [3TC, D4T, and Indinavir]). Treatment plus follow-up observation times showed a protective effect of REMUNE on time to virologic failure when compared to placebo (Hazard Ratio = 0.66, p= 0.054). Regression analysis (Cox Proportional Hazards Model) which stratified the primary endpoint on baseline viral load (above and below 10,000 copies/ml) and CD4 (above and below 400 cells per cubic mm) increased the differences showing a significant effect of REMUNE (Hazard Ratio = 0.63, p= 0.036) on time to virologic failure; the same analysis, stratified on baseline viral load without CD4, also showed a significant effect of REMUNE on time to virologic failure (Hazard Ratio = 0.63; p = 0.034). As previously reported, the analysis of patients who remained on stable ART (AZT plus ddi) treatment showed no difference in time to virologic failure between treatment and placebo groups (Hazard Ratio = 0.80; p = 0.34); however, because this method of analysis did not include follow-up time of patients who remained on the study on stable HAART therapy, and in light of the aforementioned analyses, the Company believes this analysis is no longer appropriate.

The intent-to-treat principle dictates that data from every patient enrolled in the study, at all timepoints, be included in the analysis. Viral load is the amount of HIV detected in the blood. The hazard ratio is a ratio of the probability of developing an endpoint in the treatment group, compared to the probability of developing an endpoint in the placebo group. Therefore, a hazard ratio that lies between 1 and 0 demonstrates a protective effect of treatment. For example, a hazard ratio of 0.5 denotes the probability of developing an endpoint in the treatment group is one-half of the probability of developing an endpoint in the placebo group.

[Donkosak]

Hallo Remunefans

Habe das heute morgen auch schon im Mailservice gehabt.Wenn mein English gut genug war würde ich sagen Endpunkt erreicht und das mit positiven Ausblick

Kurs aktuell bei 2,75 EURO

Donkosak-Grischka

PS:konnte heute morgen leider nicht mehr nachlegen

[kalabrienfan]

Achtung
IMNR hat 3 Stunden später bekanntgegeben, daß sie nicht
beabsichtigen, die Zulassung weiter zu verfolgen.
Nachzulesen unter lycos. Ich war auch investiert und wollte
heute wieder einsteigen, aber die verar.. uns definitiv.

[kalabrienfan]

Hier die genaue Quellenangabe:
www.finance.lycos.com/home/stocks/quotes.asp?symbols=imnr

[onkelassel]

@kalabrienfreund

da würd ich mir die Mitteilung aber nochmal genau durchlesen und auf jedenfall keine Internet-Übersetzungsmaschine benutzen!

[Heul]

@all
Soweit ich das verstanden habe, hat in der neuesten Pressemitteilung IMNR geschrieben, dass Sie eine zusätziche Studie Nr. 202? nicht weiter verfolgen werden, da die Wirksamkeit Ihres Medikamentes bereits offensichtlich ist.

mfG

[Heul]

Da sind an der Nasdaq geraden (14.47) 500000 Stück zu 2.21 USD gehandelt worden. Nur zur Info.

[GenItalia]

Jungs sammelt mal eure letzten Reserven und übersetzt diesen Satz:
Based on those factors, the company said it was ``highly unlikely`` that Study 202 would be able to achieve its primary goal of determining a treatment effect.
Gen Italia

[RealBlond]

@kalbrianfan:
also, so einfach kannst Du es Dir nicht machen. Es ist keine globale Absage an eine Zulassung von Remune. Es geht da ins Detail. Ich könnte so noch keine definitive Aussage machen.

Wo finde ich das Studienprotokoll für die 202 Studie mit Agouron?

RB

[Andrax]

@ Heul: wo war das denn? bei island sind insgesamt 14.000
stück gehandelt worden

[Heul]

@Andrax
Sieh` mal nach unter Realtime-Kursen bei WO.

[kalabrienfan]

Also so mies ist mein Englisch eigentlich nicht, aber ich
laß mich gerne berichtigen. Ich hab das so verstanden, als
wenn IMNR die Study 2002 Pfizer überläßt, bzw. deren Tochterfirma. Das zeigt mal wieder, daß so kleine Firmen es
unheimlich schwer haben, den Giganten ein Stück vom Kuchen
abzuknabbern. Da ich selbst in der Pharmabranche tätig bin,
kann ich etwas mitreden. Der Kurs könnte kurzfristig trotz-
dem anziehen, aber langfristig sehe ich diese Entwicklung
negativ. Andere Meinungen?

[RealBlond]

@kalabrianfan:
also mein englisch sagt mir, daß nur das Studienprotokoll 202 nicht weiter fortgeführt wird. Dabei wurden initial hochviruslastige HIV-Patienten (bei Diagnosestellung) nach Rückführung in eine niedrige Viruslast durch 3-fach antivirale Therapie anschließend in 2 Gruppen unterteilt, die zusätzlich zu einer Erhaltungstherapie (gleiche Virustatika), die sie alle 3 Monate erhielten, entweder

Remune oder inkomplettes Freundadjuvants erhielten.

Alleine hier zeigte sich kein überzeugender Effekt gegenüber IFA.

Es gibt jedoch noch eine Reihe anderer Studienprotokolle. u.a. eben auch die heute zitierte Studie. Wohl am interessantesten scheint die Thailand-Studie zu sein (2101), wo Remune als Monotherapie bei asymptomatischen Patienten mit noch ausreichender CD4 Zellzahl gegegeben wird.

RB

[kalabrienfan]

@RealBlond
Was du schreibst stimmt schon, aber es handest sich bei der
202 um eine sogenannte key-study, die für die FDA sehr wichtig gewesen wäre. Ich befürchte, die Thailand-Studie
genügt eben gerade aus dem Grund nicht, weil es sich um
asymptomatische Patienten, was nicht einmal 10% ausmacht,
handelt. Und ob denen das Geld langt bis zur Zulassung,
bezweifle ich sehr. Und selbst wenn, es hätten einige BigPlayer was dagegen. Das ist traurig, aber that`s life.
Ich glaube übrigens, die Amis wissen selbst nicht so genau,
was sie mit den News anfangen sollen. Außerdem ist aus IMNR
leider eine Zockeraktie geworden.

[RealBlond]

@kalabrienfan:
Bist Du Dir da sicher, daß die asymptomatischen nur 10% aller HIV-Infizierten ausmachen? Haben die höher virus lastigen automatisch klinische Smptome? Kenne mich da leider nicht so aus.

Sicher kann man auf grund dieser Meldung nicht unbedingt euphorisch werden, aber für mich hat die company auch sonst eine ganze Menge zu bieten. Was ist z.B. mit der Ph III-Studie mit der TCR-Vakzine bei Arthritis Patienten? Außerdem ziemlich fundierte Patentbasis. Es gibt eine ganze Reihe weiterer hoch interessanter präklinischer und klinischer Ph I Projekte. o.k., die Kapitaldecke andererseits ganz schön dünn. Das muß einem natürlich bewußt sein.

RB

[kalabrienfan]

@RealBlond
Es sind nicht mal 10%. Versteh mich nicht falsch. Diese wenigen sind sehr wichtig. Das Problem ist nur, wenn die mit
der Aidsforschung soweit wären, daß der Rest versorgt wäre,
dann wäre mächtig Potential da. Aber man konzentriert sich
noch auf die Masse. Ich bin mehr mit Demenzformen und Alzheimer im Speziellen vertraut und da läuft das ganz ähnlich ab. Pfizer pusht sein Aricept ohne Ende, obwohl es
nur für Alzheimer ist. Andere Firmen haben wesentlich bessere Präparate, die auch bei vaskulären Demenzen helfen,
aber bei vielen ist halt Demenz Alzheimer. Es ist zum Ver-
zweifeln.
IMNR ist gut. Ich war lange dabei und bin mit Minigewinn raus, weil der Cash höchstenfalls noch für 4 Quartale reicht. Aber die sind noch nicht mal in Phase 3. Überleg doch selbst wie lange das noch dauert. Vakzine will zur Zeit
auch niemand, siehe biomira. Kann sich aber schnell ändern.
Es gibt eine Firma, die einen Aids-Test für Urin hat. Sogar
mit FDA-Zulassung. Riesenphantasie, aber verhungert am aus-
gestrecktem Arm, weil die Kohle nicht reicht, um das Ding
zu vermarkten. Rate mal, wer der lachende Dritte ist?
Aber bevor es soweit ist, haben viele Kleinanleger viel
Geld verloren. Ich such mir in letzter Zeit mehr Nebenwerte
die noch genug Reserve haben und bin bis jetzt sehr gut damit gefahren. Wenn Dich Biotech fasziniert, schau mal
unter User Puhvogel. Ich finde, der ist Klasse.
Vor allem der Mauerblümchentread.

[RealBlond]

@kalabrienfan:
danke für Deine detaillierte Antwort! Ich sehe es durchaus nicht unkritisch bei IMNR. Es gibt auch viel zu viele Wettbewerber, die sich in dem Markt tummeln. Und der Immunmodulierungsansatz mit TCR-Vakzinen hat sicher noch nicht den Durchbruch erreicht. Es ist aber vom Ansatz her faszinierend.

Zum Thema Demenz vielleicht noch mal: Was hältst Du denn von Galantamin (Sanochemia/Shire/J&J). Glaubst Du es ist wirksamer, als Donepecil? Es soll ja auch bei vaskulärer Demenz wirken. Was mich bei Sanochemia nur stört, ist das man keine großen Umsätze daraus generieren kann, obwohl das Mittel schon seit 1 Jahr in europa auf demMarkt ist. Liegt es daran, daß man zu viel an die Partner abgeben muß oder wird es noch so wenig verschrieben?

RB

[Donkosak]

Der Tread ist Klasse birgt aber auch ne Menge an Gefahren.Denn Anleger die Ihre alten Kurse wieder sehen steigen aus und dann "aus die maus".Sonst ist der super

Donkosak-Grischka

[kalabrienfan]

@RealBlond
Galantamin ist gut. Aber der Umsatz wird nicht steigen, weil
Akatinol besser ist. Mehr darf ich aus betriebsinternen
Gründen nicht sagen. Alles klar?
Ich hab grad das neueste Update zu IMNR gelesen. Eigentlich
sollte man sofort seine Aktien verkaufen, wenn eine kleine
Firma mit ihrem großen Konkurenten eine Partnerschaft ein-
geht. Klar ist, daß Pfizer denen den Hahn abgedreht hat.
Riesenschweinerei.
Vielleicht äußern sich ja andere auch mal oder sind für Euch
nur die Kurse interessant ( nicht böse gemeint )

[RealBlond]

@kalabrienfan:
danke für den kompetenten Rat! Man hat ja immer Großeltern oder andere Verwandte, die für solch ein Auskunft dankbar sind. Ärzten traue ich diesbezügl. nicht mehr, da sie nur noch an ihr Budget denken und neue innovative Substanzen nicht merh verordnen. Wohin sind wirbloß gekommen in D?

RB

[kalabrienfan]

@ RealBlond
Schau Dir doch bitte mal WKN 856886 und 922351 an.
Lundbeck kriegt die EU-Zulassung für Memantine und vermarktet es europaweit. Weiß nur fast keiner. Ich darf das
sagen, weil meine Firma gottseidank nicht an der Börse ist.
Bei Forest hab ich den Einstieg verpennt und warte und warte, aber es geht einfach nicht runter. Es gibt sie schon
noch, die Bios, die richtig Geld verdienen und bei denen
trotzdem Phantasie drin ist.

[Donkosak]

Hallo an die die noch investiert sind

Frage: Aus den letzten Berichten geht bei Ravax sowie auch bei Remune nicht hervor wann neue Ergebnisse zu erwarten sind.Wäre sehr dankbar wenn mir jemand antwortet wann mit diesen zu rechnen ist.

Bis dann Donkosak

[Nussel]

News:

Friday October 26, 8:00 am Eastern Time
Press Release
SOURCE: Trinity Medical Group USA, Inc.
Trinity Medical Group USA Announces Publication of REMUNE(R) Study Results at 132 Weeks
RANCHO SANTA MARGARITA, Calif., Oct. 26 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - news) today announces the publication of follow-up results of a human clinical study of an Immune-Based Therapy for the treatment of HIV, REMUNE®, at 5 sites in Thailand. The study results, together with previous publications, will be presented to the Thai Governing Health Authorities in connection with the new drug application that has been filed for REMUNE in Thailand.

The publication, entitled ``Long-term Follow-up of HIV-1 Infected Thai Patients Immunized with Remune Monotherapy`` by Sukeepaisarncharoen, et al, appears in the September/October 2001 issue of HIV Clinical Trials journal, the Thomas Land Publishers. An abstract of the publication may be viewed on the Internet at http://www.thomasland.com/_nonsearch/hctissues.htm. The publication is a result of week 132 review of data from 223 asymptomatic, HIV- infected Thai subjects. The study subjects did not receive additional highly active anti-retroviral therapy (HAART). The original study group consisted of 297 HIV positive patients. The results of the study after 40 weeks, which included a placebo control group, were previously announced by the Company in October 2000 and published in the journal Clinical and Diagnostic Laboratory Immunology in September 2000. This two-year follow-up study continued with open label dosing of REMUNE every 12 weeks for the remaining 223 subjects. Changes in CD4+ cells, CD8+ cells and body weight were monitored at each patient visit.

The results of the long-term follow-up study suggest that long-term treatment of HIV-1 infection with REMUNE as a monotherapy is safe and results in a stabilization of CD4 cell counts and increases in CD8 cell counts and body weight. Furthermore, the data shows it is likely that REMUNE treatment may provide more clinical benefit in subjects with higher CD4 cell counts and the therapeutic efficacy of REMUNE continued even longer than the effect observed in other studies and in non-treated HIV+ populations. The treatment guideline published by the U.S. Department of Health and Human Services (http://www.hivatis.org/guidelines/adult/Aug13_01/text/consid… wherein early chronic HIV-1 infection when CD4 cells are still over 350 cells/ul, recommends no highly active anti-retroviral therapy be given. Thus, REMUNE as a monotherapy may be a good alternative for those with CD4 cell counts above 350 cells/ul. The study findings of no annual decline in CD4 cell counts possibly means there is no progression or a slowing in progression to AIDS and possibly reconstitution of the natural immune system.

The recommended U.S. treatment guideline may have important ramifications in countries where access to antiviral drugs is limited and in early chronic HIV-1 infection when CD4 cells are still over 300 cells/ul. Rates of CD4 T cell decline have been determined in similar Thai infected cohorts. In another study of untreated Thai sex workers infected with type E virus, a mean decline in CD4 T cells of 58.8 cells/ul per year was observed. Thus, the stabilization in CD4 cell counts observed in this 132 week study can be considered dissimilar to the natural disease progression observed in similar untreated cohorts.

The results of the long-term study were previously presented at the Eleventh Symposium of HIV Infection, held in Toulon, France (June 15, 2001) and at An International Conference on HIV Vaccines - An Annual Update 2001, in Bangkok, Thailand (July 26, 2001). The long-term follow-up study is in its third year of follow-up and will continue up to Year 4.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.

Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is currently listed on the Over the Counter Bulletin Board under the symbol TMGU. The Company`s first product in development is an Immune-Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further study in Thailand. In July 2001, Trinity USA, through its affiliate Trinity Assets Company Limited, filed a new drug application according to the steps for approval by the Thai Food and Drug Administration to market, distribute and manufacture REMUNE in Thailand. Approval of REMUNE by the Thai FDA is necessary for the marketing, distribution and manufacture of REMUNE. REMUNE is a product licensed from The Immune Response Corporation of Carlsbad, California (Nasdaq: IMNR - news). REMUNE is a registered trademark of The Immune Response Corporation

[Nussel]

Hallo,

Handelsvolumen Amiland heute auch wesentlich größer als
in den letzten Tagen und Wochen.

Gruß

Nussel

[biologist]

Oh, oh! Wer hätte das gedacht? Wieder eine Langzeitstudie, die Remune für effektiv und sicher hält! Könnte zu einem Comeback für IMNR werden. Allerdings: hatten die sich nicht für eine Beendigung des Remune-Programmes entschieden? Was passiert denn wohl jetzt? Ergebnisse und Rechte verkaufen, oder Wiederaufnahme des Programms? Die Zusammenfassung der Ergebnisse findet Ihr im letzten Absatz unter Conclusion.

Hier der Abstract der Studie:

Link: http://www.thomasland.com/_nonsearch/hctissues.htm


HIV Clinical Trials
Volume 2, Number 5, September/October 2001
(return to table of contents) (return to home page) (full text 2540KB)
W. Sukeepaisarncharoen, V. Churdboonchart, S. Kulpradist, B. Isarangkura Na Ayudthya, S. Rugpao, V. Chandeying, W. Sirawaraporn, D. Carlo, and R.B. Moss

Long-Term Follow-Up of HIV-1–Infected Thai Patients Immunized with Remune Monotherapy

Purpose: The purpose of this 2-year follow-up study was to investigate the longterm effect of Remune as monotherapy for HIV-1 infection. Background: Participants previously enrolled in the phase II double-blind, randomized, adjuvantcontrolled study of the HIV-1 Immunogen (Remune) were followed for 2 years. Open-label immunization with Remune monotherapy was given to each participant every 12 weeks. Remune, a gp 120-depleted HIV-1 that was inactivated in betapropiolactone and irradiation, was emulsified with mineral oil (incomplete Freund’s adjuvant). Method: In Study 2101B, the effect of four doses of Remune given every 12 weeks over 40 weeks was compared to placebo in 297 asymptomatic type E HIV-infected patients [Churdboonchart et al., 2000]. A group of 17 volunteers were separated into a subset study and another 57 were excluded from analysis due to discontinuation or addition of other treatments. This 2-year follow-up study continued with open-label dosing of HIV-1 Immunogen every 12 weeks for the remaining 223 patients. Changes in CD4+ cells, CD8+ cells, and body weight were monitored at each patient visit. Results: Overall, immunizations were safe; common adverse events were tolerable injection site reactions. CD4+ T-cell counts remained stable over the 132-week observation period for this cohort with a slight increase of 36.01 cells/µL. CD8+ T-cell counts showed an increase from baseline during the follow-up period (415.21 cells/µL). Furthermore, we also observed an increase in body weight from baseline (1.08 kg) at week 132. In addition, baseline CD4 count appeared to predict CD4 count at week 132 (slope = 0.31, p < .0001).

Conclusion: These results suggest that long-term treatment of HIV-1 infection with Remune monotherapy is safe and results in a stabilization of CD4+ counts. Furthermore, it is likely that HIV-1 therapeutic immunization may show its greatest clinical benefit in participants with higher CD4+ cell counts. Such an approach may have important ramifications in developing countries where access to antiviral drugs is limited and also in early chronic HIV-1 infection when CD4+ cells are still over 300 cells/µL in order to limit the cost and toxicity. Key words: CD4, HIV-1 Immunogen, Remune, Thailand

© 2001 Thomas Land Publishers, Inc. All rights reserved. A Thomas Land ® Publication.


cu biologist

[wolf cub]

Es geht langsam aufwärts
bid 1,52$ ask 1,6$

[det3]

Was ist heute los? Gibt es Neuigkeiten?

[Nussel]

Hallo,

könnte das Immune Response auch auf die Sprünge helfen,
Trinity ist gestern jedenfalls um 33,33% gestiegen:

November 08, 2001

TRINITY MEDICAL GROUP INC (TMGU.OB)
Quarterly Report (SEC form 10QSB)
ITEM 2. MANAGEMENT`S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

FORWARD-LOOKING STATEMENTS.


This report contains certain forward-looking statements which involve substantial risks and uncertainties. These forward-looking statements can generally be identified because the context of the statement includes words such as "may," "will," "expect," "anticipate," "intend," "estimate," "continue," "believe," or other similar words. Similarly, statements that describe our future plans, objectives and goals are also forward-looking statements. Our factual results, performance or achievements could differ materially from those expressed or implied in these forward-looking statements as a result of certain factors, including those listed in this report.


OUR LICENSED TECHNOLOGY.


Trinity Medical Group USA, Inc. was incorporated in the State of Delaware on September 28, 1998 and reincorporated in Nevada in November of 1999 with its principal place of business in California. In December 1999, as the result of a reorganization, we became a Florida corporation. Trinity USA is an affiliate of Trinity Medical Group, Ltd. and Trinity Assets Company Limited. We are a late development stage company with rights to market an HIV-Immunogen also known as REMUNE, a patented therapeutic vaccine treatment, designed to induce specific T cell responses in people infected with the Human Immunodeficiency Virus, or HIV. REMUNE is an immune-based therapy consisting of whole inactivated HIV-1 virus depleted of its gp120 coat protein based on Dr. Jonas Salk`s vaccine technology.

REMUNE is designed to stimulate an HIV-infected individual`s immune system to attack HIV, the virus that causes AIDS. We believe that results from previous clinical trials demonstrate that REMUNE significantly boosts HIV-specific immune responses and may induce a positive virologic effect in HIV-infected individuals. Furthermore, we believe REMUNE stimulates the production of specific antiviral substances that naturally protect components of the immune system from HIV infection. Leading HIV clinical researchers have begun to recognize that in order to effectively stop or slow the progression of HIV to AIDS, therapies must stimulate HIV-specific cell mediated immune responses in infected individuals in addition to reducing viral load through the use of anti-viral drugs. Trinity USA and its affiliates completed Phase II clinical trials in Thailand where REMUNE was used as a sole treatment for individuals infected with HIV.

In July 2001, Trinity USA, through its affiliate Trinity Assets Company Limited, filed a new drug application for approval by the Thai Food and Drug Administration to market, distribute and manufacture REMUNE in Thailand. Approval of REMUNE by the Thai FDA is necessary for the marketing, distribution and manufacture of REMUNE. If the Thai FDA does not approve REMUNE, it cannot be marketed, sold or manufactured in Thailand and Trinity USA will be unable to generate any revenue in Thailand or any other of its licensed countries. If and when the Thai FDA approves our new drug application and we obtain the necessary export license from the U.S. FDA, we are prepared to immediately commence the sale and distribution of REMUNE in Thailand. We can give no assurances, however, that such approval and license will be obtained.

In November 2000, Trinity USA gained approval from two national committees of the Thai government, The Technical Subcommittee on AIDS Vaccine Development and the National Ethical Committee, Ministry of Public Health, to conduct an open label program, known as M903, to treat up to 10,000 individuals. Results of this program were not required by the Thai FDA in their consideration of





REMUNE for full commercialization. Trinity USA has indefinitely postponed the initiation of this program until such time that adequate funding for the program becomes available, if ever.


PLAN OF OPERATION


GENERAL OVERVIEW.

We have minimal operations, nominal assets and no revenues from operations. We have only approximately one year of business history. Our estimates indicate that we will not generate internal cash flows from the sale of REMUNE until 2002. As we do not currently have any external sources of funding, our inability to successfully implement public or private placement offerings and further our business strategy may compromise our ability to achieve our projected revenues.


Our goal is to develop our initial product, REMUNE, so that it may be sold throughout our licensed territory. We intend to support the regulatory approvals in Thailand and then distribute the product first in Thailand. We later intend to engage in sub-license and supply or distribution agreements with parties in our licensed territory countries who will carry out local regulatory requirements related to new drug applications, distribution and product support for REMUNE. In Thailand, we have sub-licensed our rights to REMUNE to Trinity Assets Company Limited.



CAPITAL REQUIREMENTS, CASH FLOW AND OTHER OPERATING CONSIDERATIONS.


Trinity USA requires substantial capital to pursue its operating strategy and currently has limited cash for operations. Until we can obtain revenues sufficient to fund working capital needs, Trinity USA will be dependent upon external sources of financing. To date, we have no internal sources of liquidity and do not expect to generate any internal cash flow until 2002. For the nine month period ended September 30, 2001, we used approximately $617,000 of cash in our operations. This cash was provided by financing activities which included the issuance of convertible promissory notes in the fourth quarter of 2000 and the second quarter of 2001 and officer notes payable in the first and second quarters of 2001. The cash used in operations related primarily to officer salaries and professional fees incurred in connection with the filing of our registration statements on Form SB-2 and our Form 10-KSB for the year ended December 31, 2000. We expect to incur approximately $1,300,000 of research and development expenses during 2001 related to the research and development of our product, REMUNE.

Our current monthly operating overhead is approximately $60,000 which amount will increase if and as we expand our operations. This estimate excludes our average monthly research and development expenses to date of approximately $115,000. Approximately $40,000 of the total $60,000 monthly operating overhead relates to officer salaries and director expenses. When we hire the seven additional employees mentioned in more detail below, we expect it will add approximately $45,000 per month to our operating overhead.

We do not have any other commitments to secure additional capital and there is no assurance that any additional funds needed will be available on favorable terms, if at all. We require substantial working capital to fund our business. We currently anticipate that the net proceeds from other planned private placement offerings, together with our available funds, will be sufficient to meet our anticipated needs for working capital and capital expenditures through at least the next 12 months. However, we may need to raise additional funds prior to the expiration of this period. Moreover, there is no assurance that our estimate of our liquidity needs is accurate or that new business development or other unforeseen events will not occur, resulting in the need to raise additional funds. If we do not raise additional funds to support our operations, our current cash resources will be exhausted by December 31, 2001.



During the next 12 months, Trinity USA expects to pay at least one of the two remaining $5 million payments to The Immune Response Corporation. The two remaining payments must be paid upon 1) the approval of REMUNE in Thailand for commercial sale and 2) receipt of the required factory establishment license or approval from the governing health authority of Thailand to manufacture REMUNE. The amount that Trinity USA expects to pay Trinity Assets Company Limited or Trinity Medical Group, Ltd. for expenses incurred related to clinical studies and the regulatory requirements during 2000 and 2001 could be between $2.2-$2.7 million, of which approximately $669,000 has been paid to Trinity Medical Group, Ltd. from inception through September 30, 2001. The amounts currently or prospectively payable to Trinity Asset Company Limited and Trinity Medical Group, Ltd. are expected to be paid from the cash proceeds to be raised under future public or private placement offerings. The amounts owed to these entities have no definitive repayment terms. All amounts paid or payable to Trinity Asset Company Limited or Trinity Medical Group, Ltd. that relate to research and development expenses have been, or will be, paid under the terms of the applicable sublicense and supply agreement or collaboration and supply agreement. Our obligations to pay for such expenses extend only until full regulatory approval for the sale of REMUNE in Thailand is granted.

The total amounts billed to date by our affiliates in connection with our REMUNE development program in Thailand have been in the proportion of 75% billable research hours and 25% actual, direct expenses. The research personnel have been billed at a rate of $250 per hour for the leading investigator and $125 per hour for associate researchers. The direct expenses that have been billed to date relate primarily to reference laboratory costs associated with quarterly analysis of the test subjects` immune response to the drug therapy, REMUNE. The individuals that continue to receive REMUNE, and whom are subject to this quarterly analysis, are from our Phase II clinical trial. This clinical trial has been approved for an additional two years. We believe that the clinical trial, known as Protocol 2101B, will become one of the longest scientific examinations of Immune-Based Therapy, or IBT, for humans infected with HIV. The approval by two national committees of the Thai government was made with supporting requests from the attending physicians and patients for continued access to REMUNE. With these approvals, patients in the study can continue to receive REMUNE treatment. Results of the study continuation are not required by the Thai FDA in their consideration of REMUNE for commercialization.

In 2001 or 2002, Trinity USA may incur significant expenses, from $1.0 to $2.0 million, in the application of regulatory approvals in other countries. Upon sufficient capitalization, we also intend to directly purchase or lease plant, equipment and secure land leases in late 2001 or early 2002 for a handling and storage facility in Thailand, or lend capital to Trinity Assets Company Limited so they may purchase or lease these facilities and land. The facility will be located close to the Bangkok International Airport and will receive REMUNE shipment in bulk. The facility will be built to U.S. FDA Good Manufacturing Practice standards and provide for climate controlled and secure warehousing. The estimated cost to construct the facility is $12 million and will require six months to one year to construct. The capital for this project would be provided by product revenue and the sale of shares of capital stock, issuance of debt or financing by a banking institution. Until we are able to generate sufficient internal cash flow, raise sufficient capital, or obtain financing to purchase and construct a handling and storage facility, we believe we can rent a facility to meet our first 12 months distribution needs for approximately $500,000.

We intend to increase our employment base in the fourth quarter of 2001 and first quarter of 2002. We intend to add clinical study supervisors, engineering consultants, accounting staff, and additional directors during the fourth quarter of 2001 and first quarter of 2002. From our present level of 3 full-time employees and 1 part-time employee, who is our president, Dr. Vina Churdboonchart, we estimate having about 11 employees and/or contract consultants by the end of the first quarter of 2002. We expect that of the seven additional employees or consultants, 3 will be part-time employees





(accounting, logistics, and sales) and 4 will be full-time employees or contract consultants (Engineering, Public Relations, Regulatory Affairs, and Research and Development).

Dr. Vina Churdboonchart spends approximately 10 hours per week, or approximately 15% of her work week, in her duties as president of Trinity USA. She spends approximately 50 hours per week in her duties with Mahidol University as an associate professor and the Project Coordinator for clinical trails of HIV-1 Immunogen, or REMUNE. Within this project, Dr. Vina oversees and coordinates the REMUNE clinical studies and programs in Thailand.

Meinungen dazu??

Gruß

Nussel

[biologist]

Finanzspritze für Immune Response!

Quelle: http://biz.yahoo.com/prnews/011113/latu053_1.html

Tuesday November 13, 7:01 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Completion of Private Financing
CARLSBAD, Calif., Nov. 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it privately placed a $2,000,000 convertible note and warrant to an accredited investor. Furthermore, the investor and the Company have agreed that, upon the achievement of certain commercial and technical milestones, the Company may sell and the investor may buy additional notes and warrants, subject to certain conditions.

The investor, Kevin Kimberlin Partners, L.P., is controlled by Kevin Kimberlin, a director and major stockholder of the Company.

The note bears interest at a rate of 8% per year. The note, secured by certain of the Company`s intellectual property, matures on November 9, 2004, but is convertible into shares of the Company`s common stock at any time, at the option of the investor, at a discounted conversion price. The warrant, for 1,733,703 shares of the Company`s common stock, is exercisable at a price of $1.44 per share.

Gruß

biologist

[biologist]

Quartalsergebnisse Q3 2001 sind raus! Netto Gewinn $0.04/share! Die positiven Q3 Ergebnisse rühren durch die Zahlung von $7.7 Mio. von Agouron Ph. her, die durch die Beendigung einer Entwicklungsvereinbarung fällig wurden.

Quelle: http://biz.yahoo.com/prnews/011114/law028_1.html

Wednesday November 14, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Third Quarter 2001 Financial Results
CARLSBAD, Calif., Nov. 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced its financial results for the quarter ended September 30, 2001. The net income for the third quarter of 2001 was $1.4 million or $.04 per share, compared to a net loss of $5.2 million or a loss of $.19 per share, reported in the third quarter of 2000. The net income for the third quarter of 2001 resulted from recognition of the deferred revenue of approximately $7.7 million associated with the termination of the development agreement with Agouron Pharmaceuticals, Inc., a Pfizer Inc. company.

For the nine months ended September 30, 2001, the Company reported a net loss of $8.8 million, or $.27 per share, compared to a net loss of $22.0 million, or $.82 per share reported for the nine months ended September 30, 2000. The results for the nine months ended September 30, 2000 reflect the implementation of the Staff Accounting Bulletin No. 101, ``Revenue Recognition in Financial Statements,`` (SAB 101), which the SEC issued in December 1999.

Research related revenue for the quarter ended September 30, 2001 was $7.8 million compared to $1.1 million for the same quarter in 2000. For the nine months ended September 30, 2001 and for the same period of 2000, revenues were $9.9 million and $6.3 million, respectively. The increase in research revenue in 2001 was primarily related to the timing of revenues recognized, per the provisions of SAB 101, under our agreement with Pfizer, entered into in June 1998 and terminated in July 2001.

Gruß

biologist

[biologist]

Kleine Ergänzung:
Analystenerwartung für Q3 2001: $0.01
Somit liegt das Ergebnis +300% über den Erwartungen. Ob die Zahlungen von Agouron jedoch mit eingerechnet wurden entzieht sich meiner Kenntnis!

Quelle: http://biz.yahoo.com/research/earncal/20011114.html?t=imnr

biologist

[biologist]

Immune Response (IMNR) vorbörslich +6,38% (8:35 am)

[BII-Aktionär]

Jungs, es geht wieder was! Die Thai-Behörden haben die fabrik von Immune besichtigt. Bald wird um die Thai-Zulassung entschieden! Ich weiss, was ich nächste woche zu tun hab, da ich meinen Verlust sowieso nicht realisieren möchte. (d.h. K. a. u....) Mehr sag ich ned! :-)

Sagt einfach nicht, ich hätte euch nicht gewarnt! LOL

[Donkosak]

Wo konntest Du denn die Nachricht lesen?
Und was heißt nochmal Du hattest uns gewarnt?????
Ist das nun positiv oder.......

Donkosak

[BII-Aktionär]

don:
diverse amis in den message-boards haben das bestätigt. offiziell liest man nichts davon. und ausserdem: gerüchte mag ich..
natürlich ist es positiv. Die thai-zulassung würde immune zwar nicht reich machen aber es würde wenigstens ein bisschen geld fliessen. Die Produktion von Remune läuft jedenfalls...
ich hatte schon ein paar mal die Hoffnung verloren und meine ehemals 3`500 shares kräfig abgebaut. doch diesmal hab ich noch einen funken hoffnung...

[biologist]

@BII-Aktionär

Dein Posting kann ich bestätigen! Die Meinungen gehen darüber allerdings auseinander. Der eine Teil meint keine Zulassung, der andere sagt ja. Ich persönlich denke, daß es eine Freigabe für die Inbetriebnahme gibt. Hierzu folgendes Posting direkt vom Yahoo-Message-Board:

"TRINITY-!!!!
by: phillyguy666
Long-Term Sentiment: Strong Buy 11/16/01 03:42 pm
Msg: 35527 of 35537

I spoke to Steve today at trinity IR

He said the tour was completed this morning and that the Thai gov`t will give their certification of the plant in the next 7-10 days.At that time they will release a PR.

The next step is for the conditional approval to come in december.

Then the FDA must certify the King Of Prussia plant.(the plant was built to FDA standards,so that should be a formality.)

He said they expect REMUNE to be on sale in Thailand in FEB. of 2002

They have been mass producing REMUNE for months at the facility.

SOUNDS GOOD! "


Für alle, die nicht Englisch können: Zulassungszertifikat der Fabrik in 7-10 Tagen, eine Pressemitteilung folgt. Letztendliche Freigabe im Dezember, Verkaufsstart von Remune in Thailand wird für Februar 2002 erwartet. Aber Achtung: dies ist keine offizielle Quelle!!!!!!

cu biologist

[wolf cub]

Jepp- und sie steigen wieder

[wolf cub]

Immune response geschlossen bei 1,62 $. Im Ask stehen nachbörslich 1,75$ Umsätze im Amiland steigen langsam- hoffe sie brechen bald aus

[frabue3]

na dann mal festhalten. ;-)

[Nussel]

Hallo zusammen,

lange nicht`s mehr von imnr gehört. Was meint ihr wie geht
es weiter, ich überlege vielleicht noch mal ein paar
ins Depot zu legen, die Aktie dümpelt ja seit einiger
Zeit vor sich hin, der nächste Ausbruch kommt dann,
wenn man nicht damit rechnet, wie sieht es eigentlich
mit der Zulassung von Remune in Thailand aus.


Gruß

Nussel

[Donkosak]

Ein Hallo an Alle

@Nussel:Wo das ganze endet ,keine Ahnung.Aber noch weitere reinlegen halte ich für falsch.Wenn die Zulassung für Th. wirklich kommt,kann man nochmal darüber sprechen, weil dann für die anderen Produkte(das sind ne ganze Menge)wieder Geld verfügbar ist.Ich werde meine weiter halten und gehe immernoch von einem Verkauf zwischen 4-8 aus.(evl. auch mehr.

Frohes Fest und alles Gute für Euch

Donkosak-Grischka

[Jacksen]

Ein gutes neues Jahr wünsche ich allen, wer weiß was über Immune Res. habe 3000St bei einen schnitt von 2,60 gekauft hop oder Top

[Nussel]

Hallo,

leider nichts neues zu Immune Response.
Das einzige was sich im Moment bewegt, ist der Kurs, der fällt nämlich von Tag zu Tag, eigentlich wollte ich
nochmal nachkaufen, aber im Moment warte ich lieber mal
ab, der Kursverlauf spricht aber wohl eher dafür, daß es
bei Immune Response wohl nicht so gut läuft, haben die
überhaupt noch Geld zur Entwicklung von Medikamenten??

Nussel

[Donkosak]

Hallo an Alle und auch gleich ein schönes Wochenende

Die letzte News die ich zu IMNR gefunden habe ist die folgende:

Trinity Medical Group USA Announces Certification of REMUNE(R) Manufacturing Facility
TUESDAY, JANUARY 08, 2002 1:59 PM
- PRNewswire


RANCHO SANTA MARGARITA, Calif., Jan 8, 2002 /PRNewswire via COMTEX/ -- Trinity Medical Group USA, Inc. (TMGU) announces that the Thai Food and Drug Administration (FDA) has certified the REMUNE(R) manufacturing facility operated by The Immune Response Corporation in King of Prussia, Pennsylvania as being in compliance with Good Manufacturing Practices (GMP) standards. The Thai FDA GMP standards are based on stringent World Health Organization guidelines. The certification followed an on site inspection by Thai officials in November 2001 that was performed as a requirement of the New Drug Application process originated by the Company and its affiliates, as announced on July 30, 2001. The New Drug Application is a detailed list of requirements that include clinical demonstration of efficacy, safety, and product purity.

As a result of the certification, the Company believes a timely determination can be made by the Thai FDA concerning the commercialization of REMUNE in Thailand.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be needed or successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. There are several government approvals to secure in the near term in order to begin the process of commercialization. The government of Thailand must approve a treatment which has not been approved anywhere else in the world and the U.S. FDA must certify the manufacturing facility and approve the export of the product. Additionally, we require substantial capital to pursue our operating strategy and currently have limited cash for operations.

Ich glaube es wurde auch noch nicht gepostet.

[Nussel]

Hallo,

die Meldung klingt nicht schlecht, die Frage ist nur hilft das auch dem Kurs von Immune Response. Ist IMNR denn
an einen Vertrieb von Remune in Thailand durch Trinity
beteiligt oder würde nur der Kurs von Trinity davon
profitieren.

Tja Fragen über Fragen

Gruß

Nussel

[Donkosak]

Guten Morgen

Wenn das mit dem Kursverlauf so weitergeht können wir bald Brüderschaft mit Gliatech und auch bald mit AVAX trinken.
Scheint wohl niemand mehr mit der Zulassung zu rechnen!

Bis denn Donkosak-Grischka

[ceres]

Hallo,

bin seit fast 2 Jahren bei IMNR drin und habe trotz Höhen und Tiefen bislang nicht die Nerven verloren. Doch in den letzten Monaten tut sich fast gar nichts. Keine positiven Nachrichten; der Kurs geht ständig weiter in den Keller. Ich glaube nicht, dass sich das Blatt zum Positiven wendet. Einfach zuwenig Bewegung. Verkaufen werde ich aber auch nicht. Entweder Tod oder Gold.Es droht Totalverlust. Warten wir es ab.

Gruss von einem entnervten IMNR-Fan.

Ceres

[Nussel]

Hallo,

jetzt ist Zeit zum Nerven verlieren bis jetzt Minus 21%
in Amiland, also wohl doch eher Pleite und Totalverlust,
hab auch lang dran festgehalten, aber da kommen wohl noch
"bad news" hinterher, anders kann ich es mir nicht erklären,
sehr schade.

Nussel

[FockeWulf190De]

Ihr müsst BIOS LANGFRISTIG halten !!!
Denn das Geld für die BIOS liegt doch auf der STRASSE !!

[BII-Aktionär]

Ui,ui,ui..... :-(((
na,ja, ich behalte die Dinger auch.... entweder alles oder nix. studiere sogar übers nachkaufen nach...

[Nussel]

Hallo BII-Aktionär,

ehrlich gesagt kann ich den Kursverlauf auch nicht nach-
vollziehen, gerade weil Trinity wegen der Freigabe zur
Produktion von Remune in Thailand Fortschritte macht,
Trinity(TMGU.OB) wird aber in den letzten Tagen auch
ziemlich verprügelt, vielleicht läuft es mit Remune in
Thailand wohl doch nicht.
Meiner Meinung nach steht und fällt IMNR einzig und
allein mit Remune, auf der Homepage steht zwar, das sie
auch andere Medikamente in der Pipeline haben, aber
Interesse haben die Aktionäre wohl nur an der Entwicklung
von Remune.
Tja ich bin auch ratlos

Nussel

[BII-Aktionär]

Doch, doch. Nachvollziehen kann ich den Kursverlauf. Die Aktionäre warten auf News (Remune-Zulassung und was noch wichtiger ist: Partner! Finanzspritzen!!)

Und solange keine solche News kommen geht der Kurs runter.
Immune Response ist am Anschlag. Das Geld reicht noch etwa für 2 - 3 Monate (im günstigsten Fall). Wenn jetzt keine Partnermeldungen o.ä. kommen sehen wir easy die 50 cents... :-( Im schlimmsten Fall wird die Firma hängengelassen und geht Konkurs. Es geht eben doch nicht ohne Pfizer...schade..

[Donkosak]

Hallo und trotzallem ein schönes Wochenende.

Das mit IMNR sehe ich genauso.Vollgas wer jetzt Verkauft hat praktisch einen ´Totalverlußt.Und warum nicht doch noch.......
Das mit den schlechten Nachrichten könnte jedoch auch möglich sein der Kursverlauf sieht aus als wenn etwas durchgekommen ist.Die Umsätze sind erstaunlich hoch und es geht nur bergab.

Bis denne auf bessere Tage Donkosak-Grischka

[felixleo]

Achtung !
Nasdaq Umsätze 6 mal so hoch wie Vortag und in Deutschland unter 1,4 euro nicht zu bekommen ,was ist da im busch

[Gentil]

Laut Immmune gibt es keine Genehmigung für den HIV-Test

Hat jemand bessere Informationen?

Ein schwer enttäuschter Aktionär

[Gentil]

Laut Immmune gibt es keine Genehmigung für den HIV-Test

Hat jemand bessere Informationen?

Ein schwer enttäuschter Aktionär

[Gentil]

Laut Immmune gibt es keine Genehmigung für den HIV-Test

Hat jemand bessere Informationen?

Ein schwer enttäuschter Aktionär

[Gentil]

Laut Immmune gibt es keine Genehmigung für den HIV-Test

Hat jemand bessere Informationen?

Ein schwer enttäuschter Aktionär

[Gentil]

Entschuldigung, es war eine uralte Mail.
Konkret sieht es besser aus als vermutet.

Lasst Euch überraschen es kursieren GUTE Gerüchte
unter den Maklern!

Bin halt schon so lang Investiert als das ich bei kleinsten negativ reagiere.. SORRY

Alles wird GUT

Viel Spass allen Investierten

Der, der immer vorne bleibt....Gentil

[Donkosak]

Hallo und ein schönes Wochenende

@Gentil Was soll den der Scheiß

Donkosak-Grischka

[Nussel]

SOURCE: The Immune Response Corporation
Animal Study Suggests Intranasal Delivery of HIV-1 Antigen With Adjuvant May Induce Potent Immune Responses Capable of Protection Against Viral Challenge
CARLSBAD, Calif., Feb. 26 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that data presented at the Ninth Conference on Retroviruses and Opportunistic Infections in Seattle on February 25, 2002 suggest that the Company`s envelope depleted killed HIV-1 virus when combined with an adjuvant consisting of immunostimulatory CpG oligodeoxynucleotides (ODN) given intranasally to female mice, does induce potent immune responses in mice capable of protection against intravaginal virus challenge.

Dr. Kenneth L. Rosenthal, principal study investigator and Professor of Pathology at the Centre for Gene Therapeutics at McMaster University Health Sciences Center in Hamilton, Ontario, Canada, presented the data from the study. Female mice immunized intranasally with the Company`s HIV-1 antigen plus CpG ODN immune stimulant had significantly enhanced levels of anti-p24 IgA antibodies in serum and vaginal washes. Productions of IFN-gamma and lymphocyte proliferation were also significantly increased in the same group of animals. Furthermore, Beta-chemokines, which are known to inhibit the use of the CCR5 co-receptor by HIV, were also significantly higher in mice immunized with HIV-1 antigen plus CpG ODN. Most importantly, the intranasal immunization provided protection (93% reduction in virus titer compared to non-immunized animals) against intravaginal challenge with recombinant vaccinia virus expressing HIV-1 gag.

``We are encouraged by this data and believe that further investigation of the use of our envelope depleted whole killed HIV-1 antigen in combination with CpG ODN could pave the way for the development of an easily administered preventative HIV-1 vaccine which may produce protection against HIV infection,`` said Dennis J. Carlo, Ph.D., President & CEO of The Immune Response Corporation.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.

NOTE: Company information can also be located on the Internet Web site: http://www.imnr.com

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether clinical trials will be successfully concluded and whether REMUNE® will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

[merx]

Hey Leute ne schnelle Meldung:

Sunday March 31, 11:30 pm Eastern Time
Press Release
SOURCE: Trinity Medical Group USA, Inc.
Trinity Medical Group USA Announces Study to Broaden Use of REMUNE(R)
RANCHO SANTA MARGARITA, Calif., March 31 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - news) announced today that the Thai National Ethical Committee, Ministry of Public Health, has approved an advanced study of REMUNE®, an Immune-Based Therapy to treat HIV-infected individuals. The study, known as IB3101, is intended to increase the patient base that may ultimately benefit from use of the product. The new study will be conducted concurrently with Study P2101B, which has been ongoing for 224 weeks and has an expected completion date of May 2003. Study IB3101 will be conducted at several Medical Universities and government hospitals in Thailand, with initial results expected after 40 weeks.

This additional study is not a requirement of the New Drug Application currently being processed by the Thai FDA. Study IB3101 will initially involve 60 volunteers and could be expanded at a later date to include additional participants. In previous studies, it was found that response to REMUNE® is best when patients have a stronger immune system as indicated by certain markers, such as higher CD4 cell count and lower viral load. The Company`s previous studies found that up to two-thirds of the patients responded positively to treatment with REMUNE® and that this patient group generally started out with a higher level of CD4 cells. Study IB3101 will select patients with lower CD4 cell counts than those selected for previous Company studies. The patients, however, will be administered REMUNE® at shorter intervals (every 1-2 months instead of every 3 months).

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be needed or successfully concluded and whether REMUNE® will be approved for marketing or be successfully commercialized. There are several government approvals to secure in the near term in order to begin the process of commercialization. The government of Thailand must approve a treatment which has not been approved anywhere else in the world and the U.S. FDA must certify the facility that will manufacture the product and approve the export of the product. Additionally, the Company requires substantial capital to pursue the commercialization strategy in Thailand and currently has limited cash for operations.

Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is currently listed on the Over the Counter Bulletin Board under the symbol TMGU. The Company`s first product in development is an Immune-Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further study in Thailand. In July 2001, Trinity USA, through its affiliate Trinity Assets Company Limited, filed a new drug application according to the steps for approval by the Thai Food and Drug Administration to market and distribute REMUNE® in Thailand. Approval of REMUNE® by the Thai FDA is necessary for the marketing, distribution and manufacture of REMUNE®. REMUNE® is a product licensed from The Immune Response Corporation of Carlsbad, California. REMUNE® is a registered trademark of The Immune Response Corporation.

SOURCE: Trinity Medical Group USA, Inc.

Gruß m e r x

[Nussel]

Hallo,

hier mal wieder News von Immune Response:

The Immune Response Corporation Receives Milestone Payment From Licensee NovaRx Corporation
CARLSBAD, Calif., April 24 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it received a $100,000 milestone payment from NovaRx Corporation, a privately held San Diego company and the exclusive licensee of one of the Company`s issued patents in the field of cancer vaccines. The milestone payment was triggered when NovaRx enrolled the first patient in a Phase II clinical trial using an experimental cancer vaccine in individuals with lung cancer. Under the terms of the License Agreement dated June 4, 1997 between the parties, the Company is also eligible to receive milestone payments for initiation of Phase III trials and product licensure, in addition to a royalty on product sales. The Immune Response Corporation also owns an equity stake in NovaRx, received as partial consideration for the exclusive license.

NovaRx is conducting the Phase II study in collaboration with the Hoag Cancer Center in Newport Beach, California. The cell-based vaccine under study contains established non-small-cell lung cancer cell lines that have been genetically modified to express an antisense DNA molecule which binds to the gene producing Transforming Growth Factor B (TGF-Beta), thus preventing its expression. TGF-Beta is a potent immune suppressive cytokine produced by several types of cancer cells, including lung cancer.

``It is very satisfying to have one of the out-licensed technologies from our cancer vaccine program advance into mid-stage clinical development by one of our corporate partners,`` said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``We are hopeful that under the leadership and direction of Dr. Habib Fakhrai, NovaRx will continue to successfully develop this technology into a viable treatment for patients suffering from lung cancer.``

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection. NOTE: Company information can also be located on the Internet Web site: http://www.imnr.com

[TheRed]

Dies ist ja alles hoch interessant; trotzdem hat IMNR nur noch für wenige Tage Geld, bevor sie zahlungsunfähig sein werden. Da sind diese 100.000 $ gerade ausreichend für < 1 Woche.

Zur Zeit sollte man Meldungen doch bitte nicht mehr unkommentiert in dieses Board stellen, das Risiko , daß jemand dummerweise darauf anspringt ist zu groß (obwohl, wer ohne sich weiter zu informieren, eine Aktie (vor allem Biotech) kauft, ist selber schuld).

Eine Warnung in der ersten Zeile jeder hier veröffentlichten Meldung, daß große finanzielle Probleme vor der Tür stehen, ist wohl angebracht und sinnvoll.

Ich denke, da stimmst du mir doch zu, oder?

Happy trading

The Red

[Nussel]

Hallo The Red,

wie Du sehen kannst habe ich diesen Thread selber eröffnet,
und stelle seitdem die Meldungen immer im Original
herein und eigentlich sollte jeder bevor er irgendwo
Geld in Aktien steckt, sich selbst unabhängig nochmal
über sein Invest informieren, wie Du aber schon selbst
festgestellt hast, gibt es genug, die das nicht machen.
Hier im Board gibt es ja genug Informationen über
Immune Response, um sich ein Bild über die momentane Situation zu machen.

Gruß

Nussel

[TheRed]

Da muß ich dir voll und ganz zustimmen.

Habe mir nur die letzten 20 Postings angeschaut.
Ich fürchte allerdings, daß sich dein Thread bald von selbst erledigen wird.
Ich gebe IMNR weniger als 1 Monat (wohl sehr viel weniger), bis wohl oder übel die Zahlungsunfähigkeit bekanntgegeben werden muß.
Vieleicht schaffen sie ja noch einmal, ausreichend für kurze Zeit, etwas Geld zu sammeln....
Eigendlich schade, hatten eine gute Idee, hat halt nicht so gut funktioniert, wie erhofft.
Wie auch bei Synsorb, etc....

Happy trading

The Red

[thebull 2]

Tuesday April 30, 8:41 am Eastern Time

Immune Response Gets Nasdaq Non-Compliance Notice

CARLSBAD, Calif. -(Dow Jones)- Immune Response Corp. (IMNR) received notification from the Nasdaq National Market
that the company doesn`t comply with listing requirements because its stock has closed below the minimum $1 bid price for the last
30 consecutive trading days.

The company said in a press release Tuesday that in order to regain compliance, the closing bid price for its common stock must be $1 or more for a minimum of 10
consecutive trading days during any period through July 24 .

If Immune Response can`t demonstrate compliance with the rule by July 24 , its securities would be delisted, but it could appeal that decision. Alternatively, the
company could apply before July 24 to transfer its securities to the Nasdaq SmallCap Market, which would extend the period to comply with the minimum bid price
requirement until Oct. 22 .

As reported, the biopharmaceutical company`s board has asked stockholders to approve at the annual meeting on June 11 a 1-for-4 reverse stock split, in order to
raise the share price above the $1 minimum.

The company`s stock closed Monday at 59 cents.

Company Web site: http://www.imnr.com



-Tom Rojas; Dow Jones Newswires; 201-938-5400
(This story was originally published by Dow Jones Newswires)
Copyright (c) 2002 Dow Jones & Company, Inc.
All Rights Reserved

gruss
tb 2

[thebull 2]

Thursday May 30, 7:01 am Eastern Time

Press Release

SOURCE: The Immune Response Corporation

The Immune Response Corporation Releases Results for an AIDS
Preventative Vaccine Candidate

Preliminary Animal Testing Suggests Immune Responses Are Induced In CD4+ and CD8+ T Cells
Aimed Specifically at HIV

CARLSBAD, Calif., May 30 /PRNewswire-FirstCall/ -- Citing an important step in ongoing research in the ability to trigger
immune responses specific to human immunodeficiency virus (HIV), The Immune Response Corporation (Nasdaq: IMNR -
News) announced today preliminary results from a non-human primate study in which CD4+ and CD8+ T cells, the specialized
white blood cells which kill infected cells in the body targeted specifically at HIV, increased in test monkeys after receiving
immunizations of a new combination HIV vaccine.

"Vaccination of rhesus macaques with inactivated gp120-depleted HIV-1, REMUNE®, in the presence of Incomplete Freund`s
Adjuvant and immunostimulatory DNA, ODN 2006, induces robust HIV-specific humoral and cellular responses," said Dr. Peter
Silvera who conducted the tests on behalf of the Southern Research Institute in collaboration with The National Institutes of Health,
The Immune Response Corporation, and the Jonas Salk Foundation.

"This study offers support to our belief that this combination holds promise as a possible preventative vaccine against HIV
infection," said Dr. Dennis Carlo, President and Chief Executive Officer for The Immune Response Corporation. "We believe
strongly in the need for additional testing and study, including clinical human trials, on this combination at a time when there are
limited viable HIV vaccine candidates."

In the test, four rhesus monkeys were given a series of immunizations with REMUNE® plus an adjuvant consisting of sequences of
immunostimulatory DNA (CpG). Four additional monkeys served as a control group, with two monkeys receiving adjuvant alone
and two receiving nothing. HIV specific cell mediated immunity to both HIV proteins and peptides was measured by two different
assays to determine the vaccine`s effectiveness.

According to Dr. Silvera, the results suggested that HIV specific CD4+ and CD8+ T cell responses were present in three of the
four monkeys receiving REMUNE® and the adjuvant, compared to none for the four control animals. CD4+ immune responses
involved primarily T helper cells while CD8+ immune responses were primarily cytotoxic T lymphocytes (CTLs), both of which are
thought to be key components of the immune system`s response to control HIV.

Additionally, antibodies to the HIV core protein p24 were elicited in the monkeys who received REMUNE® plus the CpG
adjuvant.

"With approximately 40 million HIV-infected individuals worldwide, there is an increasing need for an effective HIV preventive vaccine," said Dr. Peter Salk,
Scientific Director of the Jonas Salk Foundation. "The fact that REMUNE®, in combination with CpG, appears to elicit both CD4+ and CD8+ T cell immune
responses, as observed both in this study and in previous animal studies, is encouraging and would appear to position this vaccine approach as a potential candidate
for future testing in humans."

The preliminary results were presented this week by Dr. Silvera at the "Inactivated Retroviral Virions: In Vitro And Vaccine Applications" meeting, sponsored by the
Office of AIDS and Science Applications International Corporation in Annapolis, Maryland. The abstract of the study is available at www.imnr.com .

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing
immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company develops and holds patents on several groundbreaking technologies
that can be applied to any gene in order to increase a gene`s expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of
disorders. Company information is also available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the
uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not
limited to its report on Form 10-K for the year ended December 31, 2001 and subsequent Form 10-Q. The Company undertakes no obligation to publicly release
the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

SOURCE: The Immune Response Corporation


gruss
tb 2

[merx]

noch ne Bestätigung über Reuters

Related Quotes
CYTR
GSK.L
MRK
VXGN 0.85
1455
57.13
7.74 0.00
-35
0.00
0.00
delayed 20 mins - disclaimer
Quote Data provided by Reuters



Thursday May 30, 8:25 am Eastern Time
Reuters Company News
Immune Response HIV vaccine tests well in monkeys




CARLSBAD, Calif., May 30 (Reuters) - Biotech firm Immune
Response Corp. (NasdaqNM:IMNR - News) said on Thursday that its experimental
HIV vaccine increased disease-fighting ability in monkeys and
the company wants to eventually test it on humans.
"This study offers support to our belief that this
combination holds promise as a possible preventative vaccine
against HIV infection," Immune Response President and Chief
Executive Dennis Carlo said in a statement. "We believe
strongly in the need for additional testing and study,
including clinical human trials, on this combination at a time
when there are limited viable HIV vaccine candidates."
In Sept. 2001, Immune Response said it did not intend to
continue a study about whether Remune worked with Roche Holding
Ltd.`s (ROCZg.VX) Viracept and GlaxoSmithKline Plc`s (London:GSK.L - News)
Combivir after the drug fell short of expectations.
Preliminary results for the vaccine, which includes the
company`s product Remune, showed that white blood cells
increased in test monkeys after receiving the HIV vaccine. The
vaccine also includes an inactivated form of HIV with DNA
designed to stimulate the immune system.
Remune has yielded mixed results in various clinical trials
in the past and Pfizer Inc.`s (NYSE:PFE - News) Agouron Pharmaceuticals
unit ended a program to develop the drug last year.
Immune Response said the four monkeys injected with the
vaccine showed a "robust" response.
Shares of Immune Response traded at 43 cents on May 29. The
stock has a 52-week range of 33 cents to $6.60. Much of the
drop to the lower end of the range came after Agouron`s
decision to end the development deal, which also entailed
milestone payments to Immune Response.
GlaxoSmithKline, VaxGen Inc. (NasdaqNM:VXGN - News), and Merck & Co. Inc.
(NYSE:MRK - News) are among the companies currently testing HIV vaccines
in humans.
The Southern Research Institute conducted the study in
collaboration with The National Institutes of Health, Immune
Response and the Jonas Salk Foundation.



Gruß m e r x

[Forum]

Ein Hoffnungsschimmer oder mehr ???

Mit einem neuen Investor geht die Post ab, jedoch ohne .....

[Lima2000]

Na da sag ich doch nur - sauberscht, dolle Performance
Tote leben eben länger , haha

[e.broker]

denke das das heute ein letztes aufbäumen war, gäbe es wirklich noch hoffnung auf einen durchbruch, würden die investoren schlange stehn.

[Forum]

Der gestrige Umsatz in den USA und das High von $ 1,63 ???

Es wird spannend bleiben

[Forum]

Ermutigende Testergebnisse für Immune Response

Das Biotechunternehmen Immune Response (IMNR - WKN 879428)
konnte zuletzt einen Kurssprung von 76 Prozent auf 76 Cents vollziehen
nachdem man ermutigende vorläufige Testergebnisse einer
nichtmenschlichen Primatenstudie eines AIDS-bekämpfenden Wirkstoffes
vorgelegt hatte. Nach Angaben des Unternehmen hätten sich die
weißen Blutkörperchen, welche die befallenden AIDS-Zellen vernichten,
nach Verabreichung des Wirkstoffes deutlich vermehren können.

[thebull 2]

warum werden die denn hier unter amikurs gehandelt
sollten eigendlich bei über0,80€ stehn
gruss
tb 2

[az-maja]

hallo bull

Du auch hier......?

[thebull 2]

naklar
ich hab die news ja gestern als erstes gefunden und dann
muss ich ja gucken was draus wird.
ich versteh beim besten willen nicht warum die hier unter wert
gehandelt werden
gruss
tb 2

[az-maja]

rechne um 14.00 Uhr mit Kursen um 0,85 €

[TheRed]

Ich kann den Kurssprung nicht nachvollziehen.
Dies sind präklinische Daten, es ist nachgewiesen, das auf Gabe der Vaccine eine Immunantwort erfolgt. Also im Prinzip GAR NICHTS. Es ist nicht getestet worden, ob der Körper danach eine Immunantwort auf HIV-Viren durchführt. Soweit waren bisher doch schon alle, die Vaccinen gegen HIV herstellen wollten, bisher sind alle vollständig oder so gut wie vollständig gescheitert, dazu zählen auch die Versuche von IMNR. Dazu kommt, daß dies eine präklinische Studie ist, sie sind also gerade am Anfang; dies löst nicht die aktuellen katastrophalen finanziellen Probleme (und auch nicht die anderen, wie delisting von der NASDAQ (ich bezweifle, daß dieser verhältnismäßig hohe Kurs bestand haben wird), etc.) wenn es ihnen nicht weiterhin gelingt, REGELMÄßIG jeden Monat ein paar Millionen einzusammeln, wird sehr bald Schluß sein. Nächster Termin ist Juni.

Ich würde den aktuellen Kurs zum Glattstellen nutzen, einen besseren Termin wird man meiner Meinung nach nicht mehr bekommen.

Happy trading

The Red

[alexbo]

WKN 931969 Peabodys Coffee

Was ist Peabodys ?

Peabodys ist eine amerikanische Kaffefirma , die versucht einen großen Brocken am globalen Wachstumsmarkt abzubekommen und die Zeichen auf volle Expansion gestellt hat.

Das Kerngeschäft bestand in der Vergangenheit darin , dass man Shops/Cafes in Krankenhäusern, Universitäten usw . unterhalten hat - die zur Zeit vorhandenen Einheiten sollten auf einen geschätzen Jahresumsatz von 4-5 Mio USD kommen (Jahr 2002 -zugrundegelegt die bekannten Zahlen zuzüglich der vorhandenen Wachstumsraten).

In den letzten Jahren hat PBDY ums Überleben gekämpft - hohe Verbindlichkeiten wurden abgebaut, wir haben erstmals eine positive Bilanz im letzten Filing gesehen.

Der Float beträgt insgesamt knapp unter 19 Mio Aktien - reiner Common Stock - keinerlei prefered Shares vorhanden - keine Convertibles.

Das Management besteht aus hochrangigen anerkannten Führungspersönlickeiten - herausragend hier insbesondere zu erwähnen Barry Gibbons der Ex-Ceo von Burgerking , der bei Peabodys die Position des Aufsichtsratsvorsitzenden bekleidet und John Phillips ebenfalls Aufsichtsratsmitglied und eine der großen Persönlichkeiten im Retailbusiness weltweit.

Das erklärte Ziel von Peabodys ist es die Nummer 2 weltweit hinter Starbucks zu werden und die Nummer 1 im Bereich des Kaffees aus biolgischem Anbau.

Um diese Ziele zu verwirklichen strebt man den Vertrieb der eigenen Produkte über die großen Lebensmittleketten an - man ist eine Allianz eingegangen mit Marathonglobal einer Firma , die genau auf diesen Bereich spezialisiert ist und bei der Phillips ebenfalls im Aufsichtsrat sitzt.
Hieraus sind bereits erste Resultate hervorgegangen - man hat einen neuen Brand entwickelt - BlackrhinoCoffee - und Anfang Mai hat man diesen auf der FMI Show in Chicago vorgestellt - der größten Reatailmesse der Welt.

Zusätzlich strebt man den weiteren Ausbau der eigenen Shops an - mit geringem Kapitaleinsatz ist es hier möglich schnell hohe Umsätze und Gewinne zu generieren.

Kaffee ist welweit hinter Erdöl das meiste gehandelte Gut überhaupt - Kaffee ist nach Wasser das verbreiteste Getränk weltweit- wir bewegen uns in einem Milliardenmarkt - die Zuwachsraten der gesamten Branche bewegen sich im zweistelligen Prozentbereich - gerade die Sparte organic Kaffee wächst hierbei noch überdurchschnittlich stärker und verspricht hohe Akzeptanz und Wachstumsraten für die Zukunft.

Durch die hervorragenden Kontakte von John Phillips (er selbst gründete und leitete in der Vergangenheit eine Lebensmittlekette mit über 300Mio USD Umsatz in Arkansas- er saß im Aufsichtsrat bei verschiedenen Big Playern im Retailbusiness u.a. bei Associated Wholesale Grocers http://www.awginc.com/ - er kennst die Branche wie kein zweiter und bringt ein unbezahlbares Know How mit , dass er voll für die Entwicklung , die Vermarktung und den Vertrieb von Blackrhino einbringt.

Ein Webauftritt ist derzeit ebenfalls in Entwicklung - erste Anzeichen kann man schon unter http://www.blackrhinocoffee.com erkennen.


Die Umsatz und Gewinnchancen sind ungeheuer hoch - laut Aussage des Managements kalkuliert man mit Margen von 25 % .

Eine Steigerung des Jahresumsatzes auf nur 30 Mio USD angenommen (das wäre ungeheuer wenig für einen Anbieter in diesem Segment- ein winzig kleiner Bruchteil des Gesamtmarktes von zig Milliarden USD) würde bei diesen Margen beireits einen Gewinn von 7,5 Mio USD zur Folge haben - wenn wir nun sehr vorsichtig kalkulieren und nochmals 1,5 Mio abziehen für den Wasserkopf , weitere Investitionen und Wachstum - verbliebe immer noch ein Gewinn von 6 Mio. USD das entpräche mehr als 50 Cent pro Aktie - ein verschwindend niedriges KGV für einen Wert mit solchen Wachstumsraten von 20 zu grunde gelegt müsste der Kurs schon bei erreichen dieses worth-case Szenarios bei mehr als 8 USD stehen- aktuell stehen wir aber bei 80 Cent in Frankfurt und bei 71 Cent in den USA - eine 1000 % Chance sollte also hier allemal gegeben sein. Wenn man sich die vorhandenen Infos und Meldungen des Unternehmens anschaut , dann kann es normalerweise eigentlich nur eine Frage von sehr kurzer Zeit sein , bis die ersten Aufträge resultierend von der Messe bekanntgegeben werden und der Markt mit entsprechenden Kursgewinnen die zu erwartenden Umsätze einpreist.

[alexbo]

verdammt, sorry, ich hab den Text in den falschen thread kopiert !!!!!!!!

Hatte euren thread gelesen und versehentlich die Antwort in Euren Thread reingesetzt !!!

SORRY !!!!

Alex

[jojobada]

ist doch super kauf ich 5000
danke für die Info

[alexbo]

bitte aber nicht als plumper Push ansehen, ich hab das Posting wirklich versehentlich in den falschen thread gestellt.

Dass du PBDY interessant findest, kann ich wirklich verstehen !!
schaue einfach mal http://blackrhinocoffee.com/ an !

Alex

[merx]

Tuesday June 11, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Publication of Study Results For AIDS Preventive Vaccine Candidate for Developing Countries
Animal Testing Suggests Cell Mediated Responses to HIV Induced After Vaccination
CARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- Following the recent announcement suggesting increased HIV-specific immunity in primates through use of a new HIV combination vaccine, The Immune Response Corporation (Nasdaq: IMNR - News) today announced results of a study published in the journal Vaccine (20, 2002, 2684-92), which suggested a combination of REMUNE® and immuno-stimulatory DNA was able to shift the immune response from an antibody mediated response (Th2) to a cell mediated response (Th1) in mice infected with the parasite Schistosoma.

"The data suggests that REMUNE® in combination with CpG ODN immunostimulatory DNA induces HIV specific immune responses in preclinical studies. Following the recently announced monkey study, conducted in collaboration with the Southern Research Institute, the Jonas Salk Foundation and the National Institutes of Health, this animal study further supports the combination vaccine approach and reinforces our belief in the importance of REMUNE®," said Dr. Dennis Carlo, President and Chief Executive Officer for The Immune Response Corporation. "In light of the devastation AIDS is causing across the developing world, there is a crucial need for additional testing and study, including clinical human trials, in order to determine whether this approach can be useful in countries facing the HIV epidemic."

In the test, mice infected with the parasite Schistosoma were immunized with REMUNE® and CpG ODN immunostimulatory DNA and showed significantly lower levels of Th2 related substances and increased levels of Th1 related substances such as the cytokine gamma interferon.

According to the published findings, the authors examined "the capacity of a synthetic CpG ODN to induce and/or enhance Th1 immune responses to the co-administered whole killed, gp120-depleted HIV-1 antigen (REMUNE®), in Schistosoma mansoni infected mice, with a pre-existent dominant Th2 immune profile. Our results showing that a specific Th1 immune response against HIV-1 can be generated in such schistosoma infected mice, following immunization with REMUNE® combined with CpG ODN has prompted this report."

The authors noted that "The relevance and implication of these findings to the situation in the developing world are obvious and very encouraging, especially in view of the difficulty in eradication of parasitic infections. We suggest that the addition of CpG immunostimulatory sequences to HIV antigens in IFA may optimize HIV specific immune responses, and therefore should be included in future trials of REMUNE® and other candidate HIV-1 vaccines."

"These findings support the concept of testing REMUNE® in the presence of immunostimulating CpG ODN in a human population with a strong pre-existent Th2 immune profile. In other words, individuals with parasitic infections in developing countries could possibly be ideal candidates for immunization with this combination vaccine," said Dr. Ronald B. Moss, co-author of the study and Vice President of Medical and Scientific Affairs for The Immune Response Corporation.

"Currently, many researchers believe that cell mediated responses, rather than antibody mediated responses, are critical to the development of both preventive and therapeutic vaccines for HIV-1," Moss said.

Entitled, "Generation of Th1 immune responses to inactivated gp120- depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory oligonucleotides -- relevance to AIDS vaccines in developing countries," the study was a collaboration with work done by researchers at Hebrew University Hadassah Medical School with vaccine supplied by The Immune Response Corporation. The article can be found at www.elsevier.com/locate/vaccine .

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information also is available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, whether REMUNE® is effective as either a preventive or therapeutic vaccine, whether future trials will be conducted, whether the results of REMUNE® in clinical trials will coincide with the results of REMUNE® in preclinical trials, and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and subsequent Form 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward- looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

Gruß m e r x

[recyceln]

+40% Stuttgart
hmmmm

[merx]

new`s

Restructuring of Equipment Debt Arrangement
Agreement With Transamerica Fixes Default for Equipment Loans
CARLSBAD, Calif., June 19 /PRNewswire-FirstCall/ -- As part of an effort to solidify the Company`s finances, The Immune Response Corporation (Nasdaq: IMNR - News) announced today an agreement with Transamerica Technology Finance Corporation (Transamerica) to restructure its existing equipment loans, in effect curing the existing default under those loans and limiting the circumstances which can serve as the basis for any future default.

"We are pleased at our ability to work with Transamerica in reaching this agreement, thereby fixing this default and continuing our efforts to solidify the Company`s finances," said Dr. Dennis Carlo, President and Chief Executive Officer for The Immune Response Corporation. "It was in both companies` interests to remedy this situation and move on."

The original equipment loan was used primarily to acquire equipment in the Company`s Pennsylvania manufacturing facility and was primarily collateralized by the equipment on premises. The restructured agreement affects $1.5 million of the Company`s outstanding debt.

Pursuant to the agreements signed with Transamerica, the Company is obligated to pay Transamerica milestone payments upon receipt by the Company of proceeds from a certain number of financing activities. The payments would reduce the Company`s existing Transamerica debt. The Company also remains obligated to make its scheduled debt payments to Transamerica until all the debt and interest has been paid in full. Additionally, the Company granted to Transamerica a security interest in the Company`s assets, including its intellectual property, subject to an existing security interest in the intellectual property.

As the Company previously disclosed in its Form 10-Q filed with the Securities and Exchange Commission, Transamerica had delivered the Company a notice of an event of default under its equipment loans.

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information also is available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities, that Transamerica will not in the future declare that the Company is in default of its debt arrangements, accelerate the Company`s debt and seize its assets, whether data generated from previous trials can be replicated in future clinical trials, whether clinical trials will be successfully concluded, whether REMUNE® will be approved for marketing or be successfully commercialized and whether the Company will be able to obtain additional financing. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended March 31, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

gruß m e r x

[merx]

Wednesday June 26, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Bjorn K. Lydersen As Vice President of Manufacturing
CARLSBAD, Calif., June 26 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - News) today announced Bjorn (Ken) Lydersen, Ph.D. has joined the Company as vice president of Manufacturing Operations, a position under which he will oversee all production of products, including REMUNE®, and manufacturing facilities in King of Prussia, Pennsylvania.

"Ken brings over 28 years of experience as a scientist, researcher and medical manufacturing expert. We are fortunate to attract such a talented and knowledgeable professional to oversee our manufacturing efforts," said Dr. Dennis Carlo, president and chief executive officer for The Immune Response Corporation. "We are especially interested in having Ken step in and begin the process of ensuring that production of REMUNE® can move as quickly and efficiently as possible when the opportunity to do so comes."

"This is an exciting opportunity for me. I look forward to being involved in the production of a product such as REMUNE® that may play an important role in the treatment of HIV-1 infection," Lydersen said.

Previously, Dr. Lydersen served as vice president of research and development for Irvine Scientific from 1994-99. Before that, Lydersen was director of in vitro antibody production for Hybritech Inc., a biotechnology company acquired by Eli Lilly & Co. He also served as manager of research and development for KC Biologicals, and a senior research scientist for Corning Glass Works. Most recently he served in several consulting roles for biotechnology firms, medical journals and scientific forums. Dr. Lydersen is the editor of two books that are widely used as teaching tools at various universities, entitled "Large Scale Cell Culture Technology" and "Engineering Handbook of Biotechnology".

Dr. Lydersen received his doctorate in biophysics from Pennsylvania State University, and his master`s degree in industrial management and bachelor`s degree in mechanical engineering from Clarkson College of Technology.

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information also is available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities, that Transamerica will not in the future declare that the Company is in default of its debt arrangements, accelerate the Company`s debt and seize its assets, whether data generated from previous trials can be replicated in future clinical trials, whether clinical trials will be successfully concluded, whether REMUNE® will be approved for marketing or be successfully commercialized and whether the Company will be able to obtain additional financing. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended March 31, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

[Nussel]

Trinity Medical Group USA Announces Amendment of REMUNE(R) Supply Contracts
RANCHO SANTA MARGARITA, Calif., June 28 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU - News) announces that it has amended its REMUNE License and Collaboration contract with The Immune Response Corporation (Nasdaq: IMNR - News). The amended contract provides for an additional $50.00 per unit to be paid to IMNR for the first one million doses of REMUNE purchased by the Company. As consideration for the additional amount to be paid to IMNR, the Company will receive shares of IMNR common stock and a waiver of the final, optional $5 million milestone payment for the technology transfer of REMUNE manufacturing rights in the Company`s licensed territory. The Company will receive four million shares of restricted stock immediately and three million shares when sales milestones occur. Additionally, the Company will receive two million shares (as opposed to 333,333 shares of stock which was specified by our original Stock Purchase Agreement with IMNR) upon Thai Government approval of REMUNE in exchange for a required $5 million milestone payment to IMNR.

The Company plans to allocate two million of the initial four million shares issued by IMNR to its affiliated distributor in Thailand, Trinity Assets Company Limited (TAC), because the Company has revised its supply contract with TAC such that TAC will absorb 50% of the additional $50.00 per unit to be paid to IMNR. The Company also intends to allocate the additional three million sales milestone shares to TAC because TAC has provided a REMUNE purchase commitment to the Company equal to a minimum of one million doses during the first three years of commercial sales in Thailand. The Company plans to utilize its retained portion of the IMNR shares for investment, working capital and other general corporate purposes. The Company has been given registration rights on the stock issued by IMNR and may not sell those shares until the Securities and Exchange Commission declares the applicable registration statement(s) effective.

The previous supply contract with IMNR, dating back to 1995, called for the Company to pay IMNR the unit cost of production plus an agreed upon mark up percentage, which would have resulted in significantly less than the renegotiated profit to IMNR. The terms of the amended license and collaboration contract expire upon the earlier of December 31, 2007 or the purchase of one million units of REMUNE by the Company. The Company`s goal is to have its own production facility in operation by the expiration of the amended agreement.

"We are confident that this new agreement with IMNR will allow our companies to better coordinate efforts in Thailand and will result in a mutually beneficial partnership," says Dr. James Namnath, CEO of Trinity Medical Group USA, Inc.

The Company and its affiliates have completed all scientific studies it feels are needed to support a new drug application in Thailand and, together with its Thai affiliates, have formally requested approval from the regulatory agencies. If approved by Thai authorities, REMUNE would be the first immune-based therapeutic vaccine in use against HIV and the only primary antiviral therapy with no known side effects that also does not accelerate mutation of the virus.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of whether additional clinical trials will be needed or successfully concluded, and those risks set forth from time to time in Trinity Medical Group USA`s SEC filings, including but not limited to its report on Form 10-KSB for the year ended December 31, 2001 and subsequent Form 10-QSB. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is listed on the Over the Counter Bulletin Board under the symbol TMGU. The Company`s first product in development is an Immune-Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further study in Thailand. In July 2001, Trinity USA, through its affiliate Trinity Assets Company Limited, filed a new drug application according to the steps for approval by the Thai Food and Drug Administration to market, distribute and manufacture REMUNE in Thailand. Approval of REMUNE by the Thai FDA is necessary for the marketing, distribution and manufacture of REMUNE. REMUNE is a product licensed from The Immune Response Corporation of Carlsbad, California (Nasdaq: IMNR - News). REMUNE is a registered trademark of The Immune Response Corporation

[thebull 2]

Monday July 8, 7:15 am Eastern Time

Press Release

SOURCE: Immune Response Corporation

The Immune Response Corporation Announces Presentation of Study Results
On REMUNE(R)`s Potential for Treating Chronically Infected HIV-Positive
Patients

Study Presented at XIV International AIDS Conference Examined REMUNE(R)`s Impact on Chronic
HIV-1 Infection in Conjunction With Antiretroviral Drug Therapy

BARCELONA, Spain, July 8 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - News)
announced today the presentation of data at the XIV International AIDS Conference which suggest that REMUNE® induced
helper T-cell immune responses aimed specifically at HIV in chronically infected HIV-positive individuals taking HAART (Highly
Active Antiretroviral Therapy), thereby providing a possible treatment regime for HIV-infected patients. Currently, helper T-cell
responses (cell mediated immunity) are thought to be important in controlling HIV-1 infection.

Dr. Bruce Walker, Director of the AIDS Research Center, Massachusetts General Hospital, presented at a satellite symposium
data from a double blind, adjuvant controlled study involving ten patients with chronic HIV infection. All ten participants in the
study had previously achieved undetectable viral levels through the use of HAART drug therapy. Five patients were treated with
intramuscular injections of REMUNE® once every three months for 52 weeks, while the remaining five patients received injections
of a placebo. Five out of five REMUNE® treated patients showed a significant increase (p = 0.008) in helper T-cell immune
responses against HIV-1. None of the patients receiving placebo exhibited helper T-cell responses. The study and all of the
Lymphocyte Proliferation Assays (LPAs, a measurement of helper T-cell response) were conducted at Massachusetts General
Hospital.

The study was designed to assess the potential for REMUNE® to stimulate HIV specific T helper immune responses in chronically
HIV-1 infected individuals. Previously, Dr. Walker published the results of several studies examining helper T-cell responses in
HIV-positive individuals. One study suggested that HIV patients who receive early treatment retain the ability to mount a helper
T-cell response against the virus. The study suggested that these patients also may be able to maintain control of viral levels during
structured treatment interruptions of HAART. A separate study of long-term nonprogressors (individuals who are infected with
HIV, but do not progress to AIDS) demonstrated that these patients exhibit vigorous helper T-cell responses, indicating their
immune systems were able to recognize and respond to the presence of HIV. Of significant importance is that this ability is lost in
many chronically HIV-infected individuals. The data from this study suggests that REMUNE® may help to stimulate these critical
helper T-cell responses.

"This trial provides further evidence that HIV-1 specific immunity can be stimulated in chronic HIV infection comparable to the
level observed in nonprogressors," Dr. Ronald B. Moss, Immune Response`s vice president of medical and scientific affairs said.

Lymphocyte Proliferation Assays (LPAs) were performed to determine the immune system`s ability to recognize and respond to HIV. LPAs involve testing the
efficiency of the immune system by exposing a blood sample to HIV proteins and monitoring the intensity of the helper T-cell response.

Co-founded by medical pioneer Dr. Jonas Salk and based in Carlsbad, Calif., The Immune Response Corporation is a biopharmaceutical company developing
immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be
applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders.
Company information is available at www.imnr.com. This news release contains forward-looking statements. Actual results could vary materially from those
expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities sufficient to fund
additional trials and development of REMUNE®, whether clinical trials of REMUNE® will be successfully completed, and whether REMUNE® will be approved
for marketing or be successfully commercialized. These and other factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings,
including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended March 31, 2002. The
Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events.

NOTE: REMUNE® is a registered trademark of The Immune Response Corporation.

SOURCE: Immune Response Corporation

gruss
tb 2

[thebull 2]

gehört ja indirekt zum thema

Montag 8. Juli 2002, 13:31 Uhr
98 Prozent der Weltbevölkerung hat keinen Zugang zu lebensrettenden
AIDS-Medikamenten; AHF behauptet, dass PharmakartellAIDS-Konferenz dominiert

March for Life am Sonntag fordert Behandlungsmöglichkeiten für 2 Millionen Menschen
bis zum Jahr 2004

Barcelona, Spanien -

Was: PRESSEKONFERENZ

Wann: Samstag, 6. Juli
Beginnt um 11:00 Uhr

Wer: Konferenzteilnehmer aus den Industrie- und Entwicklungsländern

Wo: Barcelona, Spanien
Vor dem Messegelände in Barcelona, Halle 5

In einer Pressekonferenz soll am Samstag, 6.Juli, um 11:00 Uhr die erdrückende Dominanz der 14. Internationalen
AIDS-Konferenz durch das Pharmakartell, auch Pharmaindustrie genannt, angeprangert werden. Die Pressekonferenz findet
vor dem Messegelände in Barcelona, Halle 5, statt und wird den ganzen Tag auch per Telefon durchgeführt. 98 Prozent der
weltweit an HIV/AIDS Erkrankten haben überhaupt keinen Zugriff auf lebensrettende AIDS-Medikamente. Dennoch
werden die großen Pharmaunternehmen in der nächsten Woche die mehr als 14.000 Konferenzteilnehmer mit schönen
Wörtern einlullen, während sie wenig oder gar nichts dafür tun, lebensrettende Medikamente für den weltweiten Kampf
gegen AIDS zur Verfügung zu stellen.

Was: KUNDGEBUNG & MARCH FOR LIFE-Präsentation
für weltweite AIDS-Behandlung

Wann: Sonntag, 7. Juli

Wo: Barcelona, SPANIEN 16:30 Uhr
In der Nähe der Font Magica de Montjuic,
Messegelände Fira de Barcelona,
Barcelona 08014

AIDS Therapeutic Treatment Now (ATTN) ist eine neue globale Koalition, die sich für die antiretrovirale Behandlung der
weltweit mindestens 2 Millionen HIV-infizierten Armen bis zur nächsten internationalen Konferenz in zwei Jahren in Bangkok
einsetzt. ATTN erwartet für die Demonstration am Sonntag, 7. Juli, ungefähr 10.000 Teilnehmer, die sich in Barcelona um
16:30 Uhr beim Brunnen Font Magica auf dem Messegelände Fira de Barcelona für diesen March for Life einfinden
werden. Weitere Informationen finden Sie unter http://www.attn.info/ oder http://www.aidshealth.org/ .

Ansprechpartner: Ged Kenslea, Communications & Community Relations, Leiter der AIDS Healthcare Foundation,
[phone].

Website: http://www.attn.info/

Website: http://www.aidshealth.org/




gruss
tb 2

[thebull 2]

Monday July 8, 8:00 am Eastern Time

Immune Response Suspends Reverse Stock Split

CARLSBAD, Calif. -(Dow Jones)- Immune Response Corp. (IMNR) doesn`t plan to implement a previously authorized 1-for-4
reverse stock split and will instead submit an application to the Nasdaq Stock Market to move the company`s listing to the
SmallCap Market from the Nasdaq National Market.

In a press release Monday, the company said its application to move its stock listing falls under interim rules adopted on Jan. 2 by Nasdaq.

Such rules allow for a 180-day grace period for companies whose stock price was below the $1 minimum threshold. With the grace period, the company would
have until Oct. 24 to achieve the stock price minimum. If the company`s application is approved and it doesn`t achieve that minimum, it could request an additional
180-day grace period. If granted, the grace period would be extended until April 24 , if Immune Response had either equity of $5 million or a market capitalization
of $50 million....

gruss
tb 2

[merx]

ne neue Nachricht:

Wednesday July 10, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Results of ACTG Clinical Trial Indicating REMUNE(R) Alone Stimulated Stronger Immune Responses Compared With REMUNE(R) Plus IL-2
ACTG 5046 Indicates HIV Specific Immune Responses Stronger in REMUNE(R) Immunized Group on HAART Alone Compared to Immunized Group on HAART Plus IL-2
BARCELONA, Spain, July 10 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - News) announced today that the Adult AIDS Clinical Trials Group of the National Institutes of Health presented new data at the XIV International AIDS Conference from a clinical trial designed to ascertain if the non-specific cytokine, Interleuken two (IL-2) can enhance immune responses after vaccination with REMUNE® and non-HIV immunizations.

The results suggested that more patients receiving REMUNE® while on antiviral drug therapy (HAART) developed stronger immune responses to the HIV (70% vs. 24%, p=0.049) compared to those who received REMUNE® plus IL-2 while on HAART. Similarly, those on HAART alone developed stronger hepatitis A antibodies (88% vs. 36%, p=0.031) after immunization with a hepatitis vaccine compared to patients immunized with hepatitis A vaccine on HAART plus IL-2.

"The results of this trial are significant in demonstrating that REMUNE®`s ability to stimulate a HIV-specific immune response is not improved with the administration of IL-2," said Dr. Ronald Moss, vice president of medical and scientific affairs for The Immune Response Corporation. "Indeed, non-specific stimulation via IL-2 may hinder the immune response to both REMUNE® and non-HIV vaccines."

The study examined 38 HIV-infected patients treated with HAART or HAART plus IL-2 for at least 60 weeks. Patients were immunized with tetanus toxoid, inactivated, gp-120 depleted HIV-1 (REMUNE®), and hepatitis A and B vaccines. The researchers concluded that despite CD4+ cell increases, IL-2 did not enhance immunization responses.

The results were presented today by Dr. Hernan Valdez of the Case Western Reserve Center for AIDS Research in Cleveland, Ohio.

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information also is available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities sufficient to fund additional trials and development of REMUNE®, whether clinical trials of REMUNE® will be successfully completed, and whether REMUNE® will be approved for marketing or be successfully commercialized. These and other factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended March 31, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

[Nussel]

Thursday July 18, 7:08 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Granted Patent For T-Cell Receptor Peptide Vaccine to Treat Psoriasis
Autoimmune Intellectual Property Position Strengthened by Addition of Patent For Psoriasis to Those for Multiple Sclerosis and Rheumatoid Arthritis
CARLSBAD, Calif., July 18 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR - News) announced it was recently granted United States Patent Number 6,413,516 entitled "Peptides and Methods Against Psoriasis." The new patent includes composition and methods claims. The vaccine may suppress the activity of specific T cells that are thought to play a role in the development of psoriasis.

"This U.S. patent for our psoriasis TCR peptide vaccine strengthens our worldwide intellectual property position in therapeutic vaccines for autoimmune diseases," said Dr. Dennis J. Carlo, president and chief executive officer of The Immune Response Corporation. "With the addition of this psoriasis patent, we now have coverage in the major world markets for our TCR peptide vaccine technology for all three of our autoimmune disease targets: rheumatoid arthritis, multiple sclerosis, and now psoriasis."

Approximately 7 million people in the U.S. and 80 million people worldwide suffer from psoriasis, a chronic and often times painful skin disease characterized by scaling and inflammation. The disease occurs after defects in the immune system allow stimulation of specific T cells in the skin that trigger various reactions that culminate in rapid over-production of skin cells, creating inflammation and the flaking characteristic of psoriasis lesions.

"Many autoimmune diseases, including psoriasis, rheumatoid arthritis and multiple sclerosis, are initiated in part by proliferation of auto-reactive pathogenic T cells that incorrectly identify the body`s own cells as foreign and seek to destroy them," said Dr. Richard Bartholomew, executive director of research operations of The Immune Response Corporation. "Our TCR peptide vaccines target these pathogenic T cells to interrupt the chain of events in the immune response that leads to diseases such as psoriasis."

Co-founded by medical pioneer Dr. Jonas Salk and based in Carlsbad, Calif., The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information is available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities sufficient to fund additional trials and development of ZORCELL(TM), the Company`s psoriasis product candidate, whether clinical trials of ZORCELL(TM) will be successfully concluded, whether ZORCELL(TM) will be approved for marketing or be successfully commercialized and whether any issued patents or any patents issued in the future will survive opposition or litigation or provide meaningful proprietary protection. These and other factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended March 31, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: The Immune Response Corporation

[thebull 2]

Thursday August 15, 7:00 am Eastern Time

Press Release

SOURCE: The Immune Response Corporation

The Immune Response Corporation Announces Results From Trial of
REMUNE(R) In Treatment Interruptions for Chronic HIV Infection

Results Indicate Approach Allowed for Extended Periods Off Antiretroviral Therapy

CARLSBAD, Calif., Aug. 15 /PRNewswire-FirstCall/ -- Indicating for the first time in a clinical trial that REMUNE® might give relief for HIV- infected patients
from the adverse side-effects of antiretroviral therapies, The Immune Response Corporation (Nasdaq: IMNR - News) announced today results from an ongoing
study by the Canadian HIV Trials Network (CTN-140 trial), which examined the effects of stopping HAART (Highly Active Antiretroviral Therapy) in adults with
chronic HIV infection.

"With the growing number of studies indicating that HIV-infected patients are developing greater resistance and
significant adverse side-effects to the battery of antiretroviral drugs available today, the results from this study
suggest that treatment strategies using REMUNE® might give their systems the break from drug therapies they
need to recover," said Dr. Emil Toma, principal investigator of the trial and a professor at University of
Montreal and active staff at Hotel-Dieu du Centre Hospitalier de l`Universite de Montreal (CHUM). "With this
study, we can further develop possible therapeutic approaches designed to give patients a break from
antiretrovirals while controlling viral load and boosting the immune system."

The study, conducted over 116 weeks and still ongoing, involved ten adults with a median age of 41 and
ranging from 36 to 51 years of age. All had chronic HIV infection and were on HAART for a median of 2.7
years, with HIV RNA levels (VL) below detection limit (<50 HIV-1 RNA copies/ml) for a median of two
years and median CD4+ T cell count of 385/ml prior to antiretroviral treatment interruption.

After HAART intensification with ddI, GM-CSF, hydroxyurea, and initiation of therapeutic vaccination with
REMUNE®, patients stopped antiretrovirals, but continued to receive REMUNE® every three months. To date, each participant in the study has received nine
doses of REMUNE®.

"In chronically HIV-infected adults, HAART results in significant clinical and immunologic benefits, but even prolonged suppression of HIV replication does not
prevent viral rebound when antiretrovirals are stopped," Dr. Toma said. "We reasoned that intensification of an already optimal HAART (meaning patients with HIV
viral loads below detection limit) with ddI to better fight the HIV in resting cells, hydroxyurea to diminish cell activation and to boost the activity of ddI, GM-CSF to
increase the activity of antiretrovirals in reservoirs such as macrophages, and initiation of a therapeutic HIV vaccine (REMUNE®) prior to stopping antiretrovirals,
might lead to a partial containment of viremia allowing for long periods without recourse to HAART."

Evaluations taken during the study included: clinical, virologic (viral load, HIV genotype, sensitive cultures), immunologic (lymphocyte phenotyping, serum
cytokines/chemokines, Interferon-alpha (IFN-alpha) Elispot, intracellular cytokine staining for IFN-alpha secretion from CD4+ and CD8+ T cells,
lymphoproliferative responses, thymus CT-Scans), health-related quality-of-life, and nutrition.

"One patient has been off therapy for 88 weeks, having not resumed HAART since first stopping and another was off therapy for 44 weeks after the second
interruption," Dr. Toma said. "The other participants stayed off HAART for an average of 16 weeks after the first interruption and for an average of 24 weeks after
the second interruption. It appears that at each subsequent interruption there was a statistically significant decrease in the peak viral load rebound and this was
associated with an increased magnitude and breadth of the HIV specific immune responses.

"Also, with each treatment interruption, the time to attain the peak viral load increased and patients responded more quickly to HAART once it was re- initiated, "
Dr. Toma added. "These chronically infected patients behaved like primary infection patients where partial control of virus is associated with HIV specific immunity.
For the 40 million people around the world currently infected with this deadly disease, this study offers hope for another possible treatment option using
REMUNE®."

The data was presented at the recent 2002 Federation of American Societies for Experimental Biology (FASEB) Meeting on Therapeutic and Preventive AIDS
Vaccines in Tuscon, Arizona.

Participating in the Canadian trial were Hotel-Dieu du CHUM, McGill Research Centre, and Ste-Justine Hospital, all of Montreal, Quebec, and the Canadian HIV
Trials Network (CTN) in Vancouver, B.C.

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing
immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be
applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders.
Company information and a copy of the Canadian trial abstract are also available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether the Company will successfully raise proceeds from financing activities sufficient to fund additional trials and development of REMUNE®, the
uncertainty of successful completion of clinical trials of REMUNE®, whether REMUNE® is effective as either a preventive or therapeutic vaccine, whether future
trials will be conducted, and whether the results of REMUNE® in clinical trials will coincide with the results of REMUNE® in preclinical trials, and whether
REMUNE® will be approved for marketing or be successfully commercialized. These and other risk factors are discussed more thoroughly in The Immune
Response Corporation`s SEC filings, including but not limited to its Report on Form 10-K for the year ended December 31, 2001 and Report on Form 10-Q for the
quarter ended March 31, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which
may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

SOURCE: The Immune Response Corporation

[merx]

und noch ne Meldung,

Thursday August 15, 8:42 am Eastern Time
Dow Jones Business News
Immune Response/Remune-2:May Relieve Adverse Side Effects

CARLSBAD, Calif. -(Dow Jones)- Immune Response Corp. (NasdaqNM:IMNR - News) said results from an ongoing study show the company`s Remune may provide relief for HIV-infected patients from the adverse side-effects of antiretroviral therapies. ADVERTISEMENT




In a press release Thursday, the biopharmaceutical company said the trial, conducted by the Canadian HIV Trials Network, examined the effects of stopping highly active antiretroviral therapy in adults with chronic HIV infection.

The company said there are a growing number of studies indicating that HIV- infected patients are "developing greater resistance and significant adverse side-effects to the battery of antiretroviral drugs available."

Immune Response. which develops immune-based therapies designed to treat HIV, autoimmune diseases and cancer, said the results from this study suggest treatment using Remune might give HIV-infected patients` systems "the break from drug therapies they need to recover."

Company Web site: http://www.imnr.com

-Jason Philyaw; Dow Jones Newswires; 201-938-5400

Gruß

m e r x

[merx]

new`s

Press Release Source: The Immune Response Corporation


The Immune Response Corporation Announces Restructuring and Cost Reductions To Focus Exclusively On REMUNE(R)
Ronald B. Moss M.D. Is Named President
Monday September 9, 7:00 am ET


CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Signaling a move to restructure and reposition the Company for potential product commercialization, The Immune Response Corporation (Nasdaq: IMNR - News) announced today a restructuring program and management changes aimed at reducing costs and refocusing the Company on its most promising core product, REMUNE®, the Company`s therapeutic AIDS vaccine.
ADVERTISEMENT


As part of its exclusive focus on REMUNE®, the Company announced the layoffs of 28 of its 42 employees located at the Company`s headquarters in Carlsbad, California, affecting substantially all non-management employees not working specifically on REMUNE®. In order to ramp up manufacturing capacity, the Company intends to add to its REMUNE® production facilities in King of Prussia, Pennsylvania up to five full-time professionals. The reductions are expected to contribute over time $7.2 million in savings on an annual run rate at $600,000 in cost savings per month.

The management changes announced following a meeting on Friday, September 6th, of the Company`s board of directors include: the elevation of Dr. Ronald B. Moss as new Company president, the launch of a nationwide search for a new chief executive officer and the resignation of Dr. Dennis J. Carlo as president and chief executive officer. Dr. Carlo served as president and chief executive officer of the Company since 1994 and will remain a member of the board of directors. Jed B. Trosper also was named as a new member of the Company`s board of directors.

"REMUNE® has the potential to help those afflicted with HIV and AIDS and is Jonas Salk`s legacy to mankind. It is important for us to take the necessary steps to ensure the continuation of the development of this promising therapeutic vaccine," Dr. Moss said. "I look forward to continuing to work with leaders in the medical and scientific communities, as well as the AIDS activist community, to demonstrate REMUNE®`s utility as a valuable treatment for HIV-1 infection."

"I believe in the promise of REMUNE®and its future potential and eventual regulatory approval," Dr. Carlo said. "As we seek to undertake additional clinical testing of REMUNE®, we will need to strengthen our management team with a chief executive who can help us get REMUNE® approved around the world."

With Dr. Moss` assumption of the management of day-to-day operations, Michael Jeub, vice president of finance and chief financial officer, will continue to manage the day-to-day financial operations, initiate cost control efforts, seek to secure additional financing, and assist Dr. Moss in the administration of the corporate offices.

In a move approved by the Company`s board of directors, Dr. Moss will assume his new responsibilities immediately while the Company initiates its search for a new chief executive officer.

Named vice president, medical and scientific affairs at The Immune Response Corporation in January of 2000, Dr. Moss joined the company as medical director in 1994, and has maintained a clinical affiliation as an assistant clinical professor at the University of California, San Diego School of Medicine. Dr. Moss served two years as senior director of medical and scientific affairs at the Company before being named executive director of medical and scientific affairs in 1998. Dr. Moss is the author of more than 50 manuscripts and 80 abstracts on HIV and immunology, and is the editor in chief of the Journal of Immune Based Therapies and Vaccines.

Jed B. Trosper Added to Board

Jed B. Trosper, chief executive officer of Spencer Trask & Co.`s Corporate Venture Group, also was named to the board of directors.

Trosper is currently responsible for overseeing certain Spencer Trask portfolio companies as they set and meet critical growth, financial and operating milestones. He was most recently president of Home Shopping Network`s international division and former chief operating officer of the Home Shopping Network, Inc.

Co-founded by medical pioneer, Dr. Jonas Salk and based in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies designed to treat HIV, autoimmune diseases and cancer. The Company also develops and holds patents on several technologies that can be applied to genes in order to increase gene expression or effectiveness, making it useful in a wide range of therapeutic applications for a variety of disorders. Company information is also available at www.imnr.com .

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will be successful in its efforts to employ a new chief executive officer, whether the Company will continue as a going concern, whether the Company will successfully raise proceeds from financing activities sufficient to fund operations, the uncertainty of successful completion of clinical trials, whether REMUNE® is effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of REMUNE® in clinical trials will coincide with the results of REMUNE® in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings, including, but not limited, to its Annual Report on Form 10-K for the year ended December 31, 2001, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.




--------------------------------------------------------------------------------
Source: The Immune Response Corporation

[merx]

Press Release Source: The Immune Response Corporation


Extended Spanish Study of Therapeutic HIV Vaccine REMUNE Yields Additional Data
Wednesday February 19, 6:03 am ET
Data Suggests Sustained HIV-Specific Immune Response Among Patients


CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 19, 2003--The Immune Response Corporation (Nasdaq:IMNR - News) today announced that data suggests sustained HIV-specific immune response among patients involved with an extended Spanish Phase II clinical study (STIR-2102) of its therapeutic HIV vaccine REMUNE®.
The results of the study were presented Wednesday, February 12, 2003, at the 10th Conference on Retroviruses and Opportunistic Infections in Boston by Eduardo Fernandez-Cruz, M.D., professor and head of the Department of Immunology at the University General Hospital Gregorio Maranon in Madrid. The university hospital is affiliated with the Spanish Department of Health and Social Services. Dr. Fernandez-Cruz is the principal investigator of the clinical trial of REMUNE in Spain that was initiated in 1997.

The results of this study demonstrated that a cohort of patients who had received REMUNE plus antiretroviral therapy (ART) from the beginning of the study maintained, according to Dr. Fernandez Cruz`s presentation, "strong and long-lasting" HIV-specific cellular immune responses throughout the 60-month extended treatment period. The patients in the control group who received placebo plus ART for 36 months in the original Phase II clinical study did not demonstrate these responses. However, when the control group patients were switched to REMUNE plus ART in the extended study, they developed HIV-specific immune responses similar to the first group that persisted through the end of the 60-month observation period.

"These data lead me to conclude that therapeutic vaccination with REMUNE can be used for immunological reconstitution of patients with chronic HIV infection, which impacts viral load (the amount of circulating HIV in the patient)," said Dr. Fernandez-Cruz.

"We find the results of Dr. Fernandez-Cruz`s study to be extremely encouraging," said Dr. John N. Bonfiglio, chief executive officer of The Immune Response Corporation. "Our mission is to develop REMUNE as quickly as possible for commercialization. Dr. Fernandez-Cruz`s work will be instrumental in helping us design a strategic development program to reach this goal."

Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is dedicated to treating HIV and AIDS through the development of an immune-based therapeutic vaccine. AIDS is one of the leading causes of death worldwide, with over 8,000 deaths per day. Forty-two million people are infected with HIV/AIDS worldwide, 5 million of those infected in 2002 alone.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether the Company will successfully raise proceeds from financing activities sufficient to fund additional trials and development of REMUNE®, whether any such clinical trials will be successful in meeting their primary endpoints and whether the Company will be successful in commercializing REMUNE®, and whether the Company will be able to continue to successfully attract and retain key executives. These and other risk factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2001 and report on Form 10-Q for the quarter ended September 30, 2002. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.



--------------------------------------------------------------------------------
Contact:
The Immune Response Corporation
Kathy Lane, 760/771-2236; Fax: [phone] (Investors)
[e-mail]
or
APCO Worldwide
David Krawitz, 213/893-7300; Fax: [phone] (Media)
[e-mail]



--------------------------------------------------------------------------------
Source: The Immune Response Corporation

[merx]

Press Release Source: The Immune Response Corporation


The Immune Response Corporation Secures $2 Million in Funding
Tuesday April 1, 6:02 am ET
Company to Invest a Portion of the Capital to Further Clinical Development of Therapeutic HIV Vaccine REMUNE(R)


CARLSBAD, Calif.--(BUSINESS WIRE)--April 1, 2003-- The Immune Response Corporation (Nasdaq:IMNR - News) today announced that it has closed a $2 million investment from Cheshire Associates LLC.
Cheshire Associates purchased from the company on March 28, 2003 a short-term convertible promissory note in the amount of $2 million and bearing interest at 8 percent per annum. The note is convertible into either shares of common stock at a price of $1.23 per share (the closing price of common stock on March 27, 2003) or an equal amount of such other securities that the company may offer in the future.

"This financing allows us to finalize the clinical development plan for REMUNE®, our lead product candidate," said John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Through the plan, we are working to address outstanding scientific and regulatory issues pertaining to REMUNE®, clearing the way for us to commercialize a significant treatment option for those afflicted with HIV."

About The Immune Response Corporation

Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is dedicated to treating HIV and AIDS through the development of an immune-based therapeutic vaccine. The scale of the AIDS crisis now outstrips even the worst-case scenarios of a decade ago. Dozens of countries are already in the grip of serious HIV/AIDS epidemics, and many more are on the brink. Around the world, an estimated 5 million people became infected in 2001, 800,000 of them children. Over the next decade, without effective treatment and care, they will join the ranks of the more than 20 million people who have died of AIDS since the first clinical evidence of HIV/AIDS was reported in 1981(a).

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern, whether the Company will successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, the uncertainty of successful completion of any such clinical trials, whether REMUNE® will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE® in preclinical trials. These risks, among things, are set forth in The Immune Response Corporation`s SEC filings, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation.

(a)UNAIDS Report on the Global HIV/AIDS Epidemic 2002

--------------------------------------------------------------------------------
Contact:
The Immune Response Corporation
Kathy Lane,760/771-2236; Fax: [phone] (Investors)
[e-mail]
or
APCO Worldwide
Sara Jones, 213/893-7300; Cell: 818/326-1871 (Media)
[e-mail]



--------------------------------------------------------------------------------
Source: The Immune Response Corporation

[shadow00]

ist noch jemand in imnr investiert, der weiss warum die akte in letzter zeit gestiegen ist. bahnbrechende neuigkeiten hat es meines wissens nach keine gegeben

[Ohiomen]

Immune Response geht seinen Weg ob es eine Zulassung in Thailand bekommt oder nicht. So lange es kein Medikament auf der Welt gegen Aids gibt wird noch viel Geld in die Erforschung von wirksamen Medikamenten gestegt. Und dies ist auch gut so. Tod gesagte leben länger. Wenn andere Bio Techs wieder Oberwasser bekommen ist die Immune wieder dabei!!!

[BaronOppenSAL]

guten abend,
endlich schreibt ihr mal wieder was zu unserer aktie,
ich freue mich,von euch zu hören und ich glaube an unseren wert,schönes wochenende allen.

[shadow00]

Sind euch die Stückzahlen aufgefallen die gegenwärtig gehandelt werden? Da muss es doch eine Nachricht geben. Die Akte kennt ja z. Zt. nur noch eine Richtung- NORDEN.

[BaronOppenSAL]

dann soll sie mal bis 5,50 € laufen!
das wird schon!

[BaronOppenSAL]

fällt heut die 4 $ marke?

[wolf cub]

The Immune Response Corporation Announces Completion of Private Offering of $1.0 Million of Short-Term Notes; Company Takes Further Steps to Reduce Burn Rate


CARLSBAD, Calif., Jun 25, 2003 (BUSINESS WIRE) -- The Immune Response Corporation (Nasdaq:IMNR) today announced the successful completion of a private placement with accredited investors of $1 million of short-term promissory notes. The net proceeds of the offering will be used for general corporate purposes, such as operations, personnel, regulatory expertise and clinical development.

The Immune Response Corporation completed the offering of short-term promissory notes, which bear interest at the rate of 12 percent per annum, on Monday, June 23, 2003. The notes are due on September 30, 2003, or at such time as the company completes a subsequent private placement having net proceeds of more than $1.3 million. The company also issued to the investors 166,666 shares of its common stock and has agreed to register such shares of common stock for resale.

Subject to certain terms and conditions, if the company does not prepay the notes by July 31, 2003, the company is obligated to issue additional shares of its common stock to the purchasers of the notes. Additional shares also are required to be issued by the company to the purchasers of the notes if there is a default by the company under the terms of the notes.

The offering was made to accredited investors only.

The securities have not been registered under the Securities Act of 1933 or any state securities laws and unless so registered may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern, whether the Company will successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), the uncertainty of successful completion of any such clinical trials, whether REMUNE(R) will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R) in preclinical trials. These risks, among things, are set forth in the Company`s SEC filings, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.